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General Introduction  
Causes for and Difficulties in Renal Transplantation 
End-stage renal disease is the final state of an advanced restriction of exocrine-and endocrine 
functions of the kidney and makes survival of critically ill patients without adequate therapy 
impossible. A number of renal replacement therapies are available and include hemodialysis, 
peritoneal dialysis (CCPD and CAPD) and renal transplantation. Dialysis modalities can 
substitute, even in the most favourable case, for only approx. 10% of the exocrine renal 
function and for none of the endocrine functions [1]. In addition, it is time consuming and is a 
significant factor for the increase in health-care costs. More importantly, patients on dialysis 
have a significantly higher mortality rate and a lower quality of life [2-4]. Therefore renal 
transplantation is the best choice for patient with end-stage renal disease.  
The first successful kidney transplantation was carried out in 1954 by Murray with 
monozygotic twins as donor and recipient [5, 6]. Nowadays, as modern immunosuppressive 
drugs have found their way in clinical practice, renal transplantation has become a standard 
therapy for patients with terminal renal failure [7]. Over the past decades, one year allograft 
survival has improved dramatically because of modern immunosuppression and 
improvements in pre-transplantation diagnostics. Yet, the rate of decline in long-term graft 
survival did not significantly change. Hence, chronic allograft loss remains a major hurdle in 
transplantation medicine [8]. Although for deceased donors the importance of HLA matching 
on graft survival has been demonstrated [9], more recently the significance of HLA matching 
has been challenged by the finding that poorly matched kidneys from living donors showed a 
better graft survival than kidneys from well matched deceased donors (3 – year survival rate 
85% and 70% respectively) [10]. This argues against a dominant role for HLA-matching on 
graft survival and indicates that alloantigen-independent factors also must play a significant 
role in transplantation outcome. Living donors and deceased donors differ in two major 
alloantigen-independent factors, i.e. brain death and prolonged cold preservation.  
There exist a multitude of risk-factors that are associated with graft loss. Acute and chronic 
graft rejection, nephrotoxicity due to calcineurin-inhibitors (CNI), cold ischemia time and 
recurrence of focal and segmental glomerulonephritis (FSGN) belong to the most important 
ones [11, 12].  





Graft rejection is a clear example of an alloantigen-dependent factor. It occurs as a 
consequence of immunity against donor antigens (e.g. MHC, blood group antigens, others) 
and is mediated by both humeral and cellular effector mechanisms. There exist three different 
types of rejection. 
 
Hyperacute Rejection 
Hyperacute rejection occurs within minutes after reperfusion, is antibody driven and is caused 
by circulating pre-existing anti-donor antibodies that can bind to blood group - or 
polymorphic MHC antigens on endothelial cells. Binding of these antibodies results in 
complement activation [13, 14], which in turn can activate the coagulation cascade [13]. 
Consequently, formation of intravascular thrombi can lead to vascular occlusion. Pre-existing 
anti-donor antibodies can be caused by blood transfusions, multiple pregnancies or previous 
transplantations. Due to improved pre-transplantation diagnostics, hyperacute rejection has 
become rare [15, 16], nevertheless it might occur in patients with anti-endothelial cell 
antibodies of unknown specificity [17].  
 
Acute Rejection 
There are two types of acute rejection, i.e. acute interstitial - and acute vascular rejection. 
Acute interstitial rejection is mediated by T-cells and is characterized in renal transplantation 
biopsies by tubular infiltration of leucocytes (tubulitis). T-cells, release of cytokines and 
recruitment of other immune-competent cells lead to renal injury within days to weeks. 
Because alloreactive T-cells are directed against foreign MHC molecules, this might explain 
the influence of HLA-matching on graft survival for deceased donors [18]. Although HLA 
identical grafts have a significantly better graft survival [19, 20], acute interstitial rejection 
nevertheless might occur. Serologically matched HLA identical grafts are not necessarily 
genetically identical and therefore small HLA differences could still exist. In addition, apart 
from the MHC loci, other polymorphic proteins may differ between donor and recipient and 
give rise to a cell mediated immune response. Alloantigens are presented to T-cells either by 
donor antigen-presenting cells (direct pathway) or by recipient antigen-presenting cells 
(indirect pathway) [21]. In the latter situation alloantigens must be processed by antigen-
presenting cells of the recipient, and subsequently presented to T-cells as peptides in the 
context of recipient MHC-class-I or class II molecules.  
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The second type of acute rejection is acute vascular rejection. In contrast to the former type, it 
is believed that antibodies directed against endothelial cells are involved [13, 14, 22, 23]. 
Endothelial C4d deposition is an established histological marker for antibody-mediated acute 
vascular rejection [24, 25]. In addition to a humeral immune response acute vascular rejection 
might be mediated by a cellular immune response. The presence of vasculitis, i.e. leucocyte 
infiltration in the vessel wall, is also a hallmark for acute vascular rejection.  
Acute interstitial rejection can be treated effectively by modern immunosuppressive drugs, 
while acute vascular rejection is still a clinical problem and is an important cause for early 
and late graft loss [26, 27].  
 
Chronic Rejection 
Chronic rejection is the leading cause for late graft loss. The aetiology of chronic rejection is 
not clear, but it is believed that inflammatory stimuli, e.g. cytokine release, recruitment of 
monocytes and macrophages are involved in the pathogenesis of this type of rejection [28]. 
Concentric atherosclerotic depositions in the blood vessels, accompanied by glomerular 
sclerosis and tubular atrophy are according to the Banff classification typical histological 
hallmarks for chronic allograft nephropathy [29-31].  
Apart from alloantigen dependent factors, alloantigen independent factors might contribute to 
the development of chronic rejection. In this context preservation injury, donor brain death, 
CNI-toxicity, infection with cytomegaly virus are amongst others important alloantigen-
independent factors [32-34].  
 
Alloantigen-Independent Factors  
Ischemia-Reperfusion Injury and Cold Preservation 
During renal transplantation warm ischemia is unavoidable. The first warm ischemia time 
refers to the time from the beginning of clamping the arteria renalis up to the beginning of 
organ perfusion with cold preservation solution. This is followed by cold ischemia or cold 
storage, i.e. the time that the organ is in transit until the time of organ reperfusion in the 
recipient. The second warm ischemia time is the time required for anastomosis and is usually 
short. 
Organ preservation is a pre-requisite for organ allocation and is mostly performed by cold 
storage. Nevertheless, prolonged cold storage leads to tissue injury due to an increased 
induction of apoptosis and/or necrosis [35-38]. Prolonged cold preservation also impairs the 
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endothelial barrier function resulting in parenchymal edema and hemorrhage [39]. This in 
turn, negatively affects early renal function and long-term graft survival [40].  
Ischemia and subsequent organ reperfusion can result in strong structural changes, which may 
also cause delayed graft function [41]. This type of tissue injury mostly develops because of 
unspecific inflammatory reactions, reinforced leucocyte recruitment, activation of the 
endothelium paralleled by an increased expression of cytokines and adhesion molecules [42, 
43]. An important role in the development of ischemia reperfusion injury is also credited to 
free oxygen radicals. Free oxygen radicals are produced during ischemia and reperfusion by 
an increased degradation of ATP to hypoxanthine [44, 45]. They damage cell membranes and 
macromolecules and can induce the release of inflammatory mediators and proteolytic 
enzymes [46, 47].  
 
Brain death 
Although brain death is well defined from a neurological point of view, less is known about 
the influence of brain death on peripheral inflammation in end-organs in mechanistic terms. In 
the majority of cases brain death is induced by trauma or intracranial bleeding. A rise in 
intracranial pressure with consecutive constriction of the brainstem and compression of 
venous and arterial vessels result in a complete loss of intracranial circulation and finally to 
coma [48]. Cerebral activity, spontaneous respiration and brainstem reflexes pause 
irreversible. Brain death is typically associated with a so called "autonomic storm", i.e. a 
marked increase in blood pressure as a consequence of vasoconstriction, followed by a sharp 
decline in blood pressure. Vasoconstriction is the result of a huge increase in serum 
catecholamine concentration (up to 1000-fold) within minutes [49]. Hemodynamic instability, 
hypothermia, coagulopathy and electrolyte abnormalities can occur consecutively [50]. Also 
other hormonal circuits are impaired. The hypothalamo-pituitary axis is often destroyed by 
brain death entailing the appearance of a central diabetes insipidus [50]. High serum 
catecholamine concentrations and decreased T 3-and cortisol levels result in an increased 
intracellular calcium concentration which entail an increased ATP consumption, subsequently 
leading to an inappropriate cellular energy supply [51]. 
In the past decades experimental evidence has indicated that brain death in organ donors 
enhances graft immunogenicity. This may also explain why long-term graft survival is better 
when renal grafts are retrieved from living donors as opposed to grafts from brain-dead 
donors, despite poor HLA-matching of the former [10]. A number of proinflammatory 
cytokines, e.g. IL-6 or TNF-α are increased in serum of brain-dead animals [52-54]. Also 
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gene expression studies of renal tissue from brain-dead animals showed a higher expression of 
cytokines, chemokines, selectins and fibrinogen, especially in hemodynamic instable animals 
[55]. Concomitantly to the increased expression of inflammatory molecules an increase in 
mononuclear cell infiltration have been reported [56, 57]. The group of Tilney [58] could 
show in an animal model that brain death induced infiltration of leucocytes, most likely via 
upregulation of adhesion molecules like ICAM-1, E-and P-selectins. They also found that the 
production of complement, interleukin-1beta and other proinflammatory chemokines and 
cytokines was increased in grafts of brain dead animals. Other studies have shown that brain 
death enhances ischemia-reperfusion injury and accelerates acute and chronic rejection in 
transplanted grafts [59, 60]. 
 
Strategies for graft protection 
Demographic changes, an increased incidence of end-stage organ failure and a relative stable 
supply of donors are leading to an increasing gap between demand and supply of donor 
organs. In 2007 approximately 11.000 patients were waiting for kidney transplantation in 
Europe, but only around 3900 kidneys from deceased donors were available and only around 
3400 transplantations were performed (Eurotransplant, annual report 2007). The increasing 
gap between demand and supply has forced transplant physicians not only to use organs 
obtained from optimal donors, but also organs from so-called “marginal donors”. These 
donors fulfil the extended criteria for organ donation, are in general older and might have 
previous diseases such as diabetes. Appropriate donor management is also of utmost 
importance in this context, as it may reduce the number of donor organs that are not accepted 
for transplantation because of organ damage.   
The importance of donor pre-treatment is to maintain organ quality before implantation. 
Because organ quality is a risk factor for chronic organ loss, donor pre-treatment could 
positively affect the donor-recipient balance by increasing graft survival time. The use of 
organs from so called "marginal donors" can also effectively increase the potential donor 
pool.  
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Impairment of physiological control circuits in brain-dead organ donors 
Hormonal resuscitation 
In the acute phase of traumatic brain injury marked changes in the hypothalamo-pituitary axis 
have been documented [61-63]. As a consequence gonadotropin deficiency, growth hormone 
deficiency and corticotrophin deficiency could occur. Furthermore patients could show an 
evidence of thyroid hormone imbalances and inappropriate antidiuretic hormone secretion 
leading to diabetes insipidus or the syndrome of inappropriate anti-diuresis [64, 65]. 
Therefore fluid resuscitation, methylprednisolone bolus, liberal use of thyroid hormone and 
early use of vasopressors in hemodynamic unstable brain-dead donors is frequently applied at 
many intensive care units. Appropriate donor management increases the pool for organ 
donation and is associated with significant increases in organs transplanted per donor [66-68]. 
 
The Inflammatory Reflex  
The question, why brain death negatively affects peripheral organs, can be answered only 
partially. Do organs sense the state of brain death, and if so, how this is accomplished, 
remains to be answered. Clearly changes in microcirculation and hormonal abnormalities 
could lead to damage in end-organs. This damage might give rise to an inflammatory process. 
There is unambiguous evidence that the parasympathetic nervous system can modulate innate 
immunity [69], [70, 71]. The vagus nerve innervates a variety of visceral organs and might be 
considered as the interface between the central nervous system and the immune system. In the 
cholinergic anti-inflammatory pathway, also referred as inflammatory reflex, the vagus nerve 
is of eminent importance [72]. Paraganglia cells located in the parasympathetic paraganglia 
express IL-1 receptors [73], which allows to signal the presence of peripheral inflammation to 
the brain. Subsequently, acetylcholine is released from the efferent nerve fibres as a negative 
feedback for control of excessive inflammation [71] (Figure 1). Acetylcholine, the principle 
neurotransmitter of the vagus nerve, controls immune cell functions via the alpha7 nicotinic 
acetylcholine receptor [74]. This results in inhibition of NF-κB activation and thereby 
controlling the production of proinflammatory cytokines [75, 76]. 
  




inflammatory pathway by which 
the brain modulates a systemic 
inflammatory responses was first 
described by Borovikova et al in a 
sepsis model [77]. Acetylcholine 
significantly attenuated the release 
of TNFα and prevented the 
development of septic shock. In in 
vitro and in vivo models 
cholinergic agonists also revealed 
an inhibitory effect on TNFα 
induced endothelial cell activation. 
This was reflected by  an inhibition 
in the expression of endothelial 
cell adhesion molecules in vitro 
and blockade of leukocyte 
migration in vivo in an air pouch 
model [78]. Vagus nerve stimulation in rats modulates the inflammatory response during 
acute hypovolemic hemorrhagic shock resulting in an improved survival [79]. Moreover, 
vagus nerve stimulation significantly attenuates TNF synthesis and shock during reperfusion 
injury in a standard model of aortic occlusion [80]. A number of studies already have shown a 
correlation between brain injury and autonomic neurologic dysfunction measured by heart 
rate variability in humans [81, 82]. Although there is no experimental evidence that brain 
death impairs the inflammatory reflex, it is conceivable that vagus nerve activity ceases in the 
course of brain death and this might therefore account for brain death induced inflammation. 
This will be discussed in chapter 2 of my thesis.  
 
Preconditioning of organ donors in renal transplantation 
The concept of donor pre-treatment is based on minimising peri-operative organ damage by 
induction of cytoprotective mechanisms or by modulation of graft immunogenicity. 
 
It has been shown that peri-operative treatment of brain-dead donor animals with steroids can 
significantly improve graft survival by inhibiting the expression of proinflammatory cytokines 
 
Fig. 1 The cholinergic anti-inflammatory pathway  
(Tracey et al, Nature 2002) 
Efferent activity in the vagus nerve leads to acetylcholine (ACh)  
release in organs of the reticuloendothelial system, including  
the liver, heart, spleen and gastrointestinal tract. Acetylcholine 
interacts with a-bungarotoxin-sensitive nicotinicreceptors  
(ACh receptor) on tissue macrophages,which inhibit the release  
of TNF, IL-1, HMGB1 and other cytokines 
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[83]. Similarly, inhibition of P-selectin-mediated leucocyte adhesion by the use of soluble P-
selectin-glycoprotein-ligand (sPSGL) can improve long term graft survival [83] 
 
Dopamine in Transplantation Medicine  
From 1999 on we have focused on dopamine as a potential drug for preconditioning of 
deceased donors. Our interest started from the clinical observation that donor catecholamine 
use reduces acute allograft rejection and improves graft survival after cadaveric renal 
transplantation. Subsequent retrospective clinical studies also demonstrated the impact of 
donor dopamine usage on immediate graft function after kidney transplantation [3, 84, 85]. 
For long time dopamine has been considered as “first line” vasopressor and was frequently 
used at the intensive care unit (ICU) to improve organ perfusion. Acute renal failure (ARF) is 
common in critically ill patients and is associated with a high mortality rate. Because animal 
models use ischemia to induce experimental ARF, there is the widespread belief that lack of 
blood flow is responsible for ARF. Low-dose dopamine (LDD) has been shown to increase 
renal blood flow in animal and in human volunteers. Thus, it has been administered to humans 
for almost 3 decades in the belief that it would lead to renal arterial vasodilation and increase 
renal blood flow (RBF). However, 2 meta-analyses and a large double-blind, prospective, 
multiple-center, randomized controlled trial have failed to demonstrate that dopamine protects 
the kidney in critically ill patients with ARF [86, 87]. Currently, there is insufficient evidence 
to support the use of renal-dose dopamine in the intensive care unit. Nevertheless, it must be 
emphasized that the meta-analysis studies were unable to detect increasing adverse effects of 
LDD at the level of statistical significance. 
 
Fig. 2 Chemical structure of dopamine  
Dopamine, an alpha and beta-
sympathomimetic drug is an endogenous 
catecholamine that stimulates the release of 
adrenalin. It acts via binding to alpha and beta1 
receptors as well as dopaminergic receptors.  
The benefit of donor catecholamine usage is controversially discussed in transplantation 
literature. Some studies have suggested the use of catecholamines at least in hemodynamic 
unstable donors [88, 89], while other studies showed that donor dopamine usages was 
associated with a poor transplantation outcome [90] or were not able to show any effect [91]. 
A positive influence of donor dopamine usage could be related to improved organ perfusion 
[92]. Chammoro et al suggested for heart transplantation that catecholamines should be used 
in donors without limitation to improve coronary blood circulation and because of possible 
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immunomodulatory effects [93]. It is generally believed that activation of the immune system 
depends on the presence of so called danger signals [94]. These signals activate the innate 
immune system which in turn leads to inflammation. In the absence of alloantigens the 
inflammatory response is self-limiting, but in the presence of foreign antigens it leads to 
acquired immunity, perpetuation of the inflammatory response and tissue destruction [94]. As 
suggested from studies in brain dead animal models, it is most likely that brain death results in 
activation of the innate immune system [58, 95, 96]. Also ischemia and subsequent 
reperfusion are conditions in which danger signals may lead to tissue inflammation [41-43]. 
Ischemia results in an increased expression of MHC class II molecules in the kidney [97, 98] 
and in necrosis and apoptosis of renal tubular cells [36] [35, 36, 99, 100]. Because we could 
show that dopamine treatment of brain dead donors have a beneficial effect on delayed-graft 
function and long-term renal allograft survival [3, 84], it is conceivable to think that donor 
dopamine treatment might reduce danger signals. 
Indeed, dopamine is able to induce the expression of the protective gene heme oxygenase 1 
(HO-1) in endothelial cells [101], to delay the expression of adhesion molecules after TNFα 
stimulation, to inhibit the production of chemokines in renal tubular epithelial and endothelial 
cells [102] and to protect endothelial cells against cold preservation injury [103, 104]. In an 
animal model we could observe that pre-treatment of donor rats with dopamine improves 
early graft function, protects endothelial cells against cold preservation injury and improves 
renal function after warm ischemia [105, 106]. Moreover, treatment of brain-dead rats with 
dopamine reduces monocyte infiltration and improves renal perfusion in donor kidneys [107].  
 
Heme oxygenase-1 
In animal models it has already been shown that an up-regulation of the antioxidative enzyme 
hemoxigenase-1 (HO-1) in the donor improves long-term graft survival [108-110]. HO-1 
exerts anti-inflammatory effects and seems to be protective in transplantation medicine [108-
110].  
The HO system comprises several iso-enzymes [111, 112], of which the inducible HO-1 iso-
enzyme seems to be particularly important as anti-inflammatory mediator [113-116]. Heme 
oxygenases are the rate-limiting enzymes in degradation of heme into carbon monoxide (CO), 
Fe2+ and biliverdin, the latter being subsequently converted to bilirubin [117, 118]. In addition 
to its unambiguous role in oxidant induced injury [119-121], unequivocal evidence 
demonstrates that the heme oxygenase system (HO) also takes part in control of inflammatory 
processes [113-115, 122]. A possible mediator by which HO-1 exerts its beneficial effect is 
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carbon monoxide (CO). As CO itself up-regulates HO-1 expression, perpetuation of the anti-
inflammatory effect could be expected [123].  
Otterbein et al and Sethi et al clearly demonstrated the anti-inflammatory potential of CO in 
macrophages and monocytes [113] as well as in endothelial cells [124, 125]. The salutary 
effect of CO has also been shown for organ transplantation and ischemia reperfusion injury in 
animal models [126, 127]. Recently a new class of molecules, termed CO-releasing molecules 
(CORM), has been described that are composed of transition metals carbonyls and have the 
ability to liberate CO under appropriate conditions [128]. In particular, CORM-3 
(tricarbonylchloro(glyconato)ruthenium(II)) and CORM-A1 (sodium boranocarbonate), both 
of which are fully water soluble, rapidly liberate CO when dissolved in physiological 
solutions. These molecules might therefore be of therapeutically interest to modulate ongoing 
inflammatory reactions by delivering CO in a controllable fashion [129]. 
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Aims of the study  
Brain death and cold preservation are both alloantigen-independent factors that are involved 
in pre-transplantation injury and consequently negatively affects transplantation outcome [32-
34]. The aim of this studies was to investigate how these factors influence graft quality and 
how appropriate intervention in the donor, or in the allograft during cold preservation, can 
influence organ function after transplantation. 
For this purpose it is important to investigate the progressive changes during brain death in 
more detail. Previous studies could already show a correlation between brain injury and 
autonomic neurologic dysfunction measured by heart rate variability in humans [81, 82]. 
There is however no evidence available demonstrating that impairment of the parasympathetic 
nervous system occurs in the course of brain death and that this might contribute to 
inflammation in end-organs. This has been studied in chapter 2.  
Static cold storage is the most commonly used preservation method in organ transplantation. 
Yet prolonged cold preservation is associated with a poor transplantation out-come. In 
chapter 3 we addressed if cold preservation and brain death are synergistic with respect to 
pre- and post-transplantation injury. 
To reduce pre-transplantation injury, new strategies in donor management and/or organ 
procurement are warranted. In two retrospective clinical studies our group could already show 
that catecholamine donor pre-treatment results in a lower incidence of acute rejection 
episodes and a substantially better graft survival [3, 84, 85]. Although the precise mechanisms 
by which DA may improve the transplantation outcome after renal transplantation are not 
entirely known thus far, several mechanisms have been suggested. In chapter 4 we tested the 
hypothesis that the anti-inflammatory effect of DA is independent of blood pressure 
stabilization. In a subsequent study that we conducted, we addressed if dopamine treatment of 
brain-dead donor rats can influence early renal function and renal inflammation after 
transplantation. The results of this study are described in chapter 5. Since in the latter study 
cold preservation was not applied, we addressed in chapter 6 the question if donor dopamine 
treatment is protective when grafts are subjected to 24 hrs of cold preservation.  
Because the anti-inflammatory potential and cytoprotective properties of CO already have 
been shown [113, 124, 125], we tested in chapter 7 if addition of CO-releasing molecules to 
the preservation solution can prevent endothelial damage and thereby maintaining vascular 
function. Since it is generally believed that vascular damage can give rise to intima 
hyperplasia, we also tested if the protective effect of CO-releasing molecules was translated 
into reduction of intima hyperplasia, in aortic grafts harvested 2 months after transplantation.  
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Backround Brain death is associated with inflammation in end-organs. Because the vagus 
nerve is implicated in control of inflammation, we tested in the present study the hypothesis 
that brain death causes impairment of the parasympathetic nervous system, hence contributing 
to inflammation. Stimulation of the vagus nerve would therefore reduce the expression of 
inflammatory mediators during brain death.  
Methods Brain death (BD) was induced in F344 rats. Heart rate variability (HRV) was 
assessed in BD and ventilated rats by ECG. In the intervention group the vagus nerve of BD 
rats was electrically stimulated (BD+STIM). Intestine, kidney, heart and liver were harvested 
after 6h and processed for further analysis. Affymetrix chip- analysis was performed on 
intestinal RNA. Quantitative PCR was performed to confirm differences in gene expression. 
Serum was collected to investigate TNFα release and complement consumption. Syngeneic 
renal transplantations were performed to address the influence of vagus nerve stimulation on 
renal function.  
Results HRV was significantly lower in the BD group compared the ventilated NBD group, 
suggesting a change in parasympathetic activity. Vagus nerve stimulation inhibited the 
increase in serum TNFα concentrations and complement consumption. Affymetrix analysis, 
using RNA isolated from the small intestine, revealed that vagus stimulation resulted in 
down-regulation in a number of pro-inflammatory genes including cytokines, adhesion 
molecules and signalling molecules. This was confirmed in independent experiments by 
qPCR. In renal tissue vagus stimulation significantly decreased the expression of E-selectin 
and IL1 beta. In liver/heart IL-6 and VCAM-1/ TNF-α and E-selectin expression was higher 
in the BD group but this was not influenced by vagus stimulation. Renal transplantation 
revealed a significantly better renal function in recipients and a tendency for reduced renal 
inflammation.  
Conclusions Our study demonstrates impairment of the parasympathetic nervous system 
during BD. Stimulation of the vagus nerve reduces the expression of pro-inflammatory genes. 
Although this was more pronounced in small intestine, down regulation of E-selectin and IL1 
was also observed in the kidney. Renal function was significantly improved after 
transplantation when vagus nerve stimulation was performed in BD donors. Hence, vagus 
nerve stimulation might be a new approach in donor management to avoid inflammation in 
the course of brain death. 




There is unambiguous evidence that the parasympathetic nervous system can modulate innate 
immunity [1, 2]. The vagus nerve meanders through the abdomen and thorax and can be 
considered as a primitive extension of the central nervous system (CNS), innervating a variety 
of visceral organs. In the cholinergic anti-inflammatory pathway, also referred as anti-
inflammatory reflex, the vagus nerve is of eminent importance [3]. Paraganglia cells located 
in the parasympathetic paraganglia express IL-1 receptors [4], which allows to signal the 
presence of peripheral inflammation to the brain. Subsequently, acetylcholine is released from 
the efferent nerve fibres as a negative feedback for control of excessive inflammation [2]. 
Acetylcholine, the primary parasympathetic neurotransmitter, can bind to both nicotinic and 
muscarinic cholinergic receptors. The main nicotinic cholinergic receptor found on 
macrophages is the α7 subunit [5]. Activation of this receptor leads to inhibition of NF-κB 
and hence to down regulation in the production of pro-inflammatory cytokines [5]. Apart 
from its effect on NF-κB activation, acetylcholine also can dampen inflammatory responses 
through the inhibition of high mobility group box 1 (HMGB1) release by activated 
macrophages [6]. The pro-inflammatory role of HMGB1 has undisputedly been shown in 
sepsis models [7, 8].  
Over the past years experimental evidence has accumulated, suggesting that the anti-
inflammatory reflex may represent a genuine therapeutic target for undesired inflammatory 
responses. The beneficial effect of vagus nerve stimulation has been reported in models of 
inflammatory bowel disease [9-11] ischemia reperfusion injury [12] and sepsis [13]. It is 
believed that this effect is mediated through the α7 receptor, resulting in inhibition of 
leucocyte recruitment to endothelial cells by suppression of VCAM-1 expression [14]. 
Traumatic brain injury is a leading cause of death and disability. Early after traumatic brain 
injury, organ damage can be caused by the immune system during a systemic inflammatory 
response, which seems to be dependent on MyD88 [15]. In due course however, these patients 
become more susceptible for sepsis as a consequence of host defence failure, also called 
immune paralysis [16]. Although immune paralysis is poorly understood, Kox et al [17] have 
suggested that an increased vagal tone might account for this phenomenon. Activation of the 
cholinergic anti-inflammatory pathway inhibits innate immunity, while at the same time 
activation of the innate immune system is required to combat infections.  
Brain death is considered to be an important cause of pre-transplantation injury [18]. It is 
associated with hemodynamic instability, hypotension, hypothermia, coagulopathies and 
electrolyte abnormalities [18]. In addition, a number of immunological alterations occur, e.g. 
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cytokine release and upregulation of adhesion molecules eventually leading to inflammation 
in end-organs [19-22]. To our knowledge the role of the anti-inflammatory reflex in brain 
death associated inflammation has not been studied. In the present study we hypothesize that 
during brain death the anti-inflammatory reflex is impaired. As a consequence, inflammation, 
possibly triggered by hypoperfusion, ischemia or tissue injury, can not be controlled. Vagus 
nerve activation during brain death would therefore have a beneficial effect on the 
inflammatory response in end-organs.  
  





Inbred male Fisher (F344, RT11vr) and Lewis (LEW, RT11) rats weighing 200 to 250 g were 
obtained from Charles River (Sulzfeld, Germany). Animals were kept under standard 
conditions and fed standard rodent chow and water ad libitum. All procedures were performed 
according to the Guide for the Care and Use of Laboratory Animals published by the National 
Academy of Sciences and were approved by the local authorities (RP Karlsruhe, AZ 35–
9185.81/113/07). 
 
Experimental Protocol  
Brain death and vagus nerve stimulation 
Before induction of brain death, Fisher rats were anesthetized with ketamine (Ketanest, 
Pfizer, Karlsruhe, Germany, 100 mg/kg intraperitoneally) and xylazine (Rompun, BayerVital, 
Leverkusen, Germany, 6 mg/kg intraperitoneally) and placed on a heating table to keep their 
body temperature constant. A 3F Fogarty catheter was inserted epidural in an occipital burr 
hole and gradually inflated during 10 minutes with 500 µL of saline. The state of brain death 
(BD) was verified by the occurrence of autonomic storm, the absence of corneal reflexes and 
by an apnoea test. All animals were mechanically ventilated by a tracheostoma with a rodent 
ventilator (Ugo Basile, Comerio, Italy). Systemic blood pressure (mean arterial pressure 
[MAP], mm HG) was continuously measured (6 hrs) in the donors by a femoral arterial 
catheter (Statham pressure transducer P23Db and a Gould pressure processor, FMI, Ober-
Beerbach, Germany). Every animal was treated with NaCl 0.9%. In one group of animals, 
electrical stimulation of the vagus nerve was performed by placing bipolar electrodes 
connected to a stimulation module (digi 3000, Promed GmbH, Farchant, Germany) on the 
cervical vagus nerve trunk. A constant voltage stimulus (5 V, 2 ms, 1 Hz) was applied during 
the whole brain death period, starting 15 min before brain death induction. Electrocardiogram 
was recorded for frequency-domain analysis of RR intervals (PFM2, Michael Nowak 
Elektronische Anlagen, Berlin, Germany). Anesthetized, non brain-dead ventilated (6 hrs) 
animals served as controls. After 6 hours the small intestine, the kidneys, the heart and the 
liver were harvested and frozen in liquid nitrogen for further analysis. Serum was collected 
before and six hours after brain death. Each group consisted of a minimum of six animals. 
Animals were divided into 3 groups: 
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BD: Brain-dead control 
BD+STIM: Brain-dead with vagal stimulation 
NBD: Non brain-dead ventilated control 
 
Renal Transplantation 
In separate experiments brain death was induced in Lewis rats, similarly as described above. 
In one group of animals vagus stimulation was performed. The left kidney was transplanted 
directly after brain death into Lewis recipients. Recipients were anesthetized with enflurane 
(Ethrane; Aca Mueller/Adag Pharma, Gottmadingen, Germany). Animals were divided into 2 
groups, i.e. BD-Tx (Brain-dead Lewis donor grafts transplanted into Lewis recipients) and 
BD+STIM-TX (Brain-dead vagal stimulated Lewis donor grafts transplanted into Lewis 
recipients). Each group consisted of a minimum of eight animals. Renal function was assessed 
in recipients by serum creatinine measurements on days 0, 1, 3, 5 and 7 after transplantation. 
Kidneys were harvested 7 days after transplantation. The upper poles were frozen in liquid 
nitrogen, and the remaining part was fixed in 10% buffered formalin solution. 
 
RNA isolation, cRNA and array hybridization 
Sample preparation and processing was performed according to the Affymetrix GeneChip 
Expression Analysis Manual (http://www.Affymetrix.com). Briefly, the small intestine of BD 
animals was harvested 6 hours after brain death induction or 6 hours after ventilation in NBD 
animals. Total RNA was isolated from the tissue using Trizol®-Reagent (Invitrogen, 
Carlsbad, CA). Hereafter DNase treatment was carried out, using RNase free DNase I 
(Ambion, Woodward, Austin, TX, USA). RNA concentration and quality were assessed by 
RNA 6000 nano assays on a Bioanalyser 2100 system (Agilent, Waldbronn, Germany). Five 
µg of RNA was converted into cDNA using T7-(dT) 24 primers and the SuperScript Choice 
system for cDNA synthesis (Life Technologies, Inc., Rockville, MD, USA). Biotinlabelled 
cRNA was prepared by in vitro transcription using the BioArray high yield RNA transcript 
labelling kit (Enzo Diagnostics, Farmingdale, NY, USA). The resulting cRNA was purified, 
fragmented and hybridized to rat genome 230 2.0 array gene chips (Affymetrix, Santa Clara, 
CA, USA). After hybridization the chips were stained with streptavidin–phycoerythrin 
(MoBiTec, Goettingen, Germany) and analysed on a Gene-Array scanner (Hewlett Packard 
Corporation, Palo Alto, CA, USA). 
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Microarry processing and statistical analysis 
Gene expression profiling was performed using arrays of rat genome 230 2.0 -type from 
Affymetrix. A Custom CDF Version 11 with Entrez based gene definitions was used to 
annotate the arrays. The Raw fluorescence intensity values were normalized applying quantile 
normalization. Differential gene expression was analysed based on loglinear mixed model 
ANOVA [23], using a commercial software package SAS JMP7 Genomics, version 3.1, from 
SAS (SAS Institute, Cary, NC, USA). A false positive rate of a=0.05 with Holm correction 
was taken as the level of significance. The overrepresentation analysis (ORA) is a microarray 
data analysis that uses predefined gene sets to identify a significant overrepresentation of 
genes in data sets (Subramanian et al, 2005; Manoli et al, 2006). Pathways belonging to 
various cell functions such as cell cycle or apoptosis were obtained from public external 
databases (KEGG, http://www.genome.jp/kegg/). A Fisher's exact test was performed to 
detect the significantly regulated pathways.  
 
PCR-Analysis 
Quantitative PCR analysis was performed using RNA isolated from small intestine, kidneys, 
heart and liver of brain-dead and non brain-dead animals. Snap-frozen tissue samples were 
homogenized using a Polytron homogenizer (IKA Labortechnik/Fischer Scientific, Schwerte, 
Germany). 500 ng of total RNA was reversed transcribed into cDNA according to the 
manufacturer’s instructions, using the 1st Strand cDNA Synthesis Kit. cDNA was diluted in 
20 µl DEPC-treated water and stored at -80°C until use. Specific DNA standards were 
generated by PCR amplification of cDNA, purification of the amplified products, and 
quantification by spectrophotometry. Light cycler PCR of cDNA specimen and DNA 
standards were conducted in a total volume of 25 µl, containing 2 µl FastStart DNA Master 
SYBR GreenI, 10 pMol of forward and reverse primers and 2mMgCl2. Primer sequences 
were as follows: TNFα (Applied Biosystems (AB), Foster City, CA, USA; material number 
Rn99999017_m1), IL6 (AB; material number Rn99999011_m1), IL1α (AB; material number 
Rn00566700_m1), IL1 ß (AB; material number Rn00676330_m1), E-selectin (AB; material 
number Rn00594072_m1), ICAM 1 (AB; material number Rn00564227_m1),VCAM 1 (AB; 
material number Rn00563627_m1), MyD88 (AB; material number Rn01640049_m1), C1R 
(AB; material number Rn01492538_m1), CXCL12 (AB; material number Rn00573260_m1), 
CXCR4 (AB; material number Rn01483207_m1) and ITGA6 (AB; material number 
Rn01512704_m1). 
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The amplification profile consisted of 2 minutes at 50°C and 5 minutes at 95°C followed by 
45 cycles of amplification, each cycle consisting of denaturation at 95°C for 15 seconds, 
annealing for 20 seconds at 55°C and extension for 30 seconds at 72°C. Standard curves were 
generated in all experiments. PCR efficiency was assessed from the slopes of the standard 
curves and was found to be between 90% and 100%. Linearity of the assay could be 
demonstrated by serial dilution of all standards and cDNA. All samples were normalized for 
an equal expression of GAPDH. PCR were performed on a taqman platform. 
 
Systemic changes in serum TNFα and complement consumption  
Serum was collected from all animals before and 6 hrs after BD or ventilation in the NBD 
group. ELISA was performed for TNFα using a commercial kit (R&D, Wiesbaden, 
Germany). AP50 and CH50 were performed by standard methods as described (Martens HA 
et al, Analysis of C1q polymorphisms suggests association with SLE, serum C1q and CH50 
levels and disease severity. Ann Rheum Dis. 2008 May 26). according to as in donor animals 
before and 6 hrs after brain death induction. 
 
Histology  
Paraffin embedding of harvested grafts was performed using routine procedures. Paraffin 
sections (4 µm) were fixed in 10% neutral buffered formalin. For histology the sections were 
stained with hematoxylin-eosin, periodic acid-Schiff, and trichrome. A minimum of 20 
microscopic fields were assessed for each graft. Histologic grading was performed according 
to the Banff ’97 classification [24], reporting on renal transplant biopsies. Sections were 
evaluated in a blinded fashion and graded by a renal pathologist (R.W.). Histologic evaluation 
and grading included transplant glomerulopathy, tubulointerstitial fibrosis, tubular atrophy, 
and vasculopathy. The histologic grading scale was from 0 to 3 (0=not present, 1=mild 
alteration, 2=moderate alteration, and 3=severe alteration). 
 
Statistical Analysis 
Numerical data are expressed as mean ±SEM. For renal function, PCR-analysis and ELISA 
statistical analysis was performed using the Kruskal-Wallis test with option for multiple 
comparisons (StatsDirect 2.2.8, Aswell, UK). For analysis of light microscopy, Fisher’s exact 
test was applied. A P- value of less than 0.05 was considered as significant.  
 
 




Heart rate variability (HRV) 
To assess if there was a change in parasympathetic and sympathetic activity in the course of 
BD, HRV was determined in BD and NBD animals. As depicted in figure 1, HRV, expressed 
as standard deviation of the RR intervals, was significantly lower in the BD group, suggesting 
a change in parasympathetic activity. HRV could not be measured in the BD + STIM group 
































p = 0.0049                      6,45814286
3,6625
 
Fig. 1 HRV in BD and ventilated NBD donors. HRV was measured as described in materials 
and methods and expressed as standard deviation of the RR intervals. ECG was performed on 
a total of 6 animals/group. 
 
 
Genome wide gene expression profiling 
Because the small intestine is strongly innervated by the vagus nerve, and previous reports 
have shown that brain death induces the expression of pro-inflammatory genes in the small 
intestine [25], we first investigated if vagus stimulation resulted in global changes in gene 
expression profiles in the small intestine of BD animals. Principle component analysis (PCA) 
revealed that with exception of the NBD group, gene expression profiles in the BD and BD + 
STIM groups were more heterogeneous. All groups however could be distinguished in 
separate clusters on the basis of their gene expression profile. While in the NDB group all 
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animals fell in one cluster, two distinct clusters were identified in the BD group, each 
consisting of 2 animals. In the BD + STIM group, three out of 4 animals were within one 






Fig. 2 Principle component anaysis of BD 
(green dots), BD +STIM (red dots) and 
NBD (blue dots) animals. Each dot 




All genes were grouped according to the pathways in which they are involved. We focussed 
on 4 pathways, i.e. leukocyte transendothelial migration (Table 1), cytokine cytokine-receptor 
interaction (Table 2), focal adhesion (Table 3) and Toll like receptor (Table 4), and assessed 
by pair wise comparisons the effect of BD (BD vs NBD) and vagus nerve stimulation 
(BD+STIM vs BD). We also compared BD+STIM vs NBD to assess if significant changes 
were due to vagus stimulation per se and to identify changes during BD that were not 
influenced by vagus stimulation. In general, three types of patterns could be identified. 
Firstly, genes that were significantly increased during BD (BD vs NBD) but were decreased 
by vagus stimulation (BD+STIM vs BD). No significant change was observed for these genes 
when comparing the BD+STIM vs NBD groups, suggesting that the changes in gene 
expression occurring during BD were normalized by vagus stimulation. Genes belonging to 
this group included chemokines and their receptors (CCL2, CCL7, CCL11 CCL21B, CCL22, 
CxCL1, CxCL10, CxCl16), cytokines (IL-1α an β), adhesion molecules and junctional 
proteins (VCAM-1, ICAM-1, JAM-2), extracellular matrix molecules (COL1A1, COL3A1, 
COL5A1, COL5A2) and signalling molecules (Cav2, Fyn, MyD88, CD14, PTK2, SIP1A) 
(Table 1 to 4). The second type of pattern identified were genes that were significantly 
changed by vagus stimulation, irrespective of BD (significance for BD+STIM vs BD and for 
BD+STIM vs NBD but not for BD vs NBD). This type of pattern included chemokines 
(CXCL4, CXCL12, CCL3, CCL5, CCL6), junctional proteins (JAM3, CLDN4), cytokines 
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and receptors (TGFB3, CSF1R, CCR1), signalling molecules (ILK, GNAI2, PTK2B, ZYX, 
NFKBIA), extracellular matrix molecules (COL6A2, FN, LAMC1) and others (MMP2, 
CYBB) (Table 1 to 4). In the last type of pattern significance was found for the BD+STIM vs 
NBD and for the BD vs NBD but not for the BD+STIM vs BD comparisons, indicating BD 
induced changes which were not influenced by vagus stimulation (Table 1-4). The following 
genes belong to this type, chemokines (CXCL11, CX3CL1), signalling molecules (PIK3R1, 
GNAI3, MAPK8, MAPK13, MAP2K1, ARHGAP5, NFKB1), and others (BMPR2, 
TNFRSF1B, ITGA6, FADD).   
 BD+STIM vs. BD BD+STIM vs. NBD BD vs. NBD 
 P-Log(10) change P-Log(10) change P-Log(10) change 
Chemokines and receptors     
CXCL12 8,84 D 7,28 D 0,07  
CXCL4 3,90 D 3,12 D 0,09  
CXCL16 8,06 D 1,29  11,20 I 
CXCR4 5,17 D 0,14  5,21 I 
       
adhesion molecules      
VCAM1 3,89 D 0,40  2,27 I 
ICAM1 5,37 D 0,27  5,84 I 
       
junctional adhesion molecules, claudins    
JAM3 2,66 D 6,16 D 1,72  
JAM2 8,73 D 2,00  2,57 I 
CLDN4 4,41 D 3,32 D 0,15  
       
Signaling molecules      
PIK3R1 0,28  4,42 D 5,43 D 
GNAI3 0,18  3,38 D 2,74 D 
GNAI2 6,05 D 3,00 D 0,83  
PTK2B 2,64 D 2,28 D 0,01  
PTK2 8,03 I 0,79  4,5 D 
MAPK13 0,10  7,24 D 7,74 D 
SIPA1 2,27 D 0,05  2,18 I 
ARHGAP5 1,77  2,20 D 5,70 D 
       
Others       
MMP2 4,05 D 2,67 D 0,27  
CYBB 5,27 D 3,47741914 D 0,35  
 
Table 1: significant differences in the leukocyte transendothelial migration pathway. The cut 
off for significance was defined as P-Log(10)>2. When significance was reached P-values are 
displayed in red cells. Change: D (decrease), I (increase). 





BD+STIM vs. BD BD+STIM vs. NBD BD vs. NBD 
 
P-Log(10) change P-Log(10) change P-Log(10) change 
Chemokines       
CCL22 3,92 D 0,81  5,97 I 
CXCL10 4,14 D 0,16  3,04 I 
CCL2 7,88 D (-1,10) 2,42 I (0,56) 12,76 I (1,66) 
CXCL12 8,84 D 7,28 D 0,07  
CCL3 5,52 D 2,32 D 1,05  
CCL7 3,08 D 0,30  3,70 I 
CCL6 2,36 D 3,59 D 0,55  
CCL11 10,02 D 1,35  5,11 I 
CCL21B 2,31 D 0,74  3,93 I 
CXCL11 0,68  6,08 D 8,31 D 
CXCL4 3,90 D 3,12 D 0,09  
CXCL16 8,06 D 1,29  11,20 I 
CXCL1 4,07 D 0,04  3,42 I 
CCL5 2,62 D 4,32 D 0,77  
CX3CL1 0,91  6,61 I 4,11 I 
       
Cytokines       
IL1A 2,87 D 0,03  2,66 I 
IL1B 15,49 D 0,06  14,31 I 
TNF 0,56  2,56 I 4,14 I 
TGFB3 5,62 D 2,80 D 0,77  
       
Receptors       
BMPR2 0,11  2,31 D 2,65 D 
TNFRSF1B 0,72  3,81 D 5,86 D 
CSF1R 6,32 D 4,47 D 0,28  
CCR1 4,59 D 5,77 D 0,49  
CXCR4 5,17 D 0,14  5,21 I 
 
Table 2: significant differences in the cytokine cytokine-receptor interaction pathway. The cut 
off for significance was defined as P-Log(10)>2. When significance was reached P-values are 
displayed in red cells. Change: D (decrease), I (increase). 




 BD+STIM vs. BD BD+STIM vs. NBD BD vs. NBD 
 P-Log(10) change P-Log(10) change P-Log(10) change 
Adhesion molecules      
ITGA6 0,53  3,72 D 5,26 D 
       
Extracellular matrix      
COL1A1 2,38 D 0,18  2,72 I 
COL3A1 6,64 D 0,68  3,75 I 
COL5A1 4,92 D 1,05  2,19 I 
COL5A2 10,69 D 3,19 D 3,22 I 
COL6A2 4,59 D 2,41 D 0,57  
FN1 2,24 D 2,19 D 0,06  
LAMB3 0,29  3,89 D 4,88 D 
LAMC1 5,04 D 7,43 D 0,87  
       
Signaling molecules      
MAPK8 1,26  19,76 D 14,53 D 
MAP2K1 1,01  7,92 D 5,00 D 
ILK 3,24 D 2,20 D 0,21  
CAV2 4,76 D 0,68  2,22 I 
FYN 6,43 D 0,37  4,33 I 
ZYX 5,31 D 4,63 D 0,01  
 
Table 3: significant differences in the Focal adhesion pathway. The Cut off for significance 
was defined as P-Log(10)>2. When significance was reached P-values are displayed in red 
cells. Change: D (decrease), I (increase). 




 BD+STIM vs. BD BD+STIM vs. NBD BD vs. NBD 
 P-Log(10) change P-Log(10) change P-Log(10) change 
Cytokines and chemokines     
IL1B 15,49 D 0,06  14,31 I 
TNF 0,56  2,56 I 4,14 I 
CCL3 5,52 D 2,32 D 1,05  
CCL5 2,62 D 4,32 D 0,77  
CXCL10 4,14 D 0,16  3,04656755 I 
CXCL11 0,68  6,0834588 D 8,31 D 
       
Receptors       
CD14 5,41 D 0,23  3,90 I 
       
Signaling molecules      
NFKB1 0,30  9,27 I 10,595589 I 
NFKBIA 2,30 D 6,07 D 2,03  
PIK3R1 0,28  4,42 D 5,43 D 
MYD88 6,35 D 3,24 I 12,85 I 
JUN 2,36 D (-0,24) 14,11 D (-0,74) 7,11 D (-0,50) 
MAPK8 1,26  19,76 D 14,53 D 
MAPK13 0,10  7,24 D 7,74 D 
       
Apoptosis       
FADD 0,61  6,72 I 4,71 I 
 
Table 4: significant differences in the Toll like receptor pathway. The Cut off for significance 
was defined as P-Log(10)>2. When significance was reached P-values are displayed in red 
cells. Change: D (decrease), I (increase). 
 
 
qPCR and anylsis of changes in other organs  
A number of genes were subsequently selected for qPCR to confirm the results obtained by 
affymetrix analysis (Table 5). From the set of genes that were selected, only down-regulation 
of ITGA6 during BD could not be confirmed in independent experiments on intestinal RNA, 
while for all other genes qPCR and affymetrix analysis were in concordance. We next 
assessed if similar changes were also observed in other organs. In renal grafts IL-1α, E-
selectin, ICAM-1 and ITGA6 were significantly upregulated during BD. Vagus stimulation 
significantly decreased the expression of E-selectin but not of ICAM-1 and ITGA6, while for 
IL-1α there was a trend for a decreased expression (P=0.08). The expression of IL-1β was not 
influenced during BD, but in the BD + STIM group the expression hereof was significantly 
decreased compared to BD (Table 5). 




  INTESTINE KIDNEY 
BD 4.2±0.6 5.4±0.8 
BD+STIM 2.1±0.4 ** 4.6±1.0 
 
TNFα 
NBD 1.7±0.2 ** 3.4±0.3 
BD 3.5±0.8 93.8±17.9 
BD+STIM 2.1±0.8 55.0±12.7 
 
IL-6 
NBD 0.8±0.5 * 63.4±20.9 
BD 0.7±0.1 7.10±2.6 
BD+STIM 0.2±0.02 ** 2.04±0.3 
 
IL-1α 
NBD 0.2±0.03 ** 1.05±0.2** 
BD 2.1±0.2 3.41±0.7 
BD+STIM 0.5±0.08 ** 1.76±0.15* 
 
IL-1β 
NBD 0.7±0.06 ** 3.22±0.4 
BD 8.4±3.1 30.0±7.3 
BD+STIM 2.0±0.3 * 13.0±2.2 * 
 
E-selectin 
 NBD 3.1±1.6 * 6.6±2.1 * 
BD 1.4±0.1 2.8±0.5 
BD+STIM 0.9±0.2 * 1.8±0.4 
 
VCAM-1 
NBD 0.7±0.1 * 2.1±0.3 
BD 1.7±0.2  6.84±2.57 
BD+STIM 0.7±0.2 ** 5.8±1.61 
 
ICAM-1 
NBD 0.7±0.1 ** 3.63±0.87* 
BD 1.2±0.1 1.46±0.08 
BD+STIM 0.9±0.03 * 1.64±0.13 
MyD88 
NBD 0.7±0.04 ** 1.32±0.05 
BD 0.7±0.06 1.44±0.3 
BD+STIM 0.3±0.1 ** 0.61±0.12 
C1R 
NBD 0.5±0.02 * 1.9±0.34 
BD 0.5±0.03  1.06±0.3 
BD+STIM 0.25±0.1 * 0.66±0.07 
CXCL 12 
NBD 0.34±0.02 0.87±0.13 
BD 1.9±0.1 0.71±0.1 
BD+STIM 0.5±0.2 ** 0.75±0.1 
CXCR4 
NBD 0.8±0.1 ** 1.26±0.2 
BD 0.6±0.06 0.88±0.1 
BD+STIM 0.7±0.08 0.65±0.01* 
ITGA 6 
NBD 0.8±0.08 0.82±0.06 
 
Table 5: *: P<0.05, vs. BD; **:P<0.01, vs. BD. 
 
 
Heart and liver grafts were only tested for TNFα, VCAM-1, E-selectin and IL-6 expression. 
In liver IL-6 and VCAM-1 expression was higher in the BD group but this was not influenced 
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by vagus stimulation. Similarly in heart, the expression of TNF-α and E-selectin was 
increased during BD, but not influenced by vagus stimulation (Table 6).  
 LIVER HEART 
 BD BD+STIM NBD BD BD+STIM NBD 
TNFα 22.1±3.4 18.0±3.1 11.9±4.7 2.7±0.3 1.9±0.3 1.3±0.3 * 
IL-6 51.3±13.9 63.7±35.0 37.5±26 * 9.1±2.2 6.6±2.0 8.2±2.7 
E-Selectin 20.2±6.9 7.1±1.5 3.5±1.3 4.6±1.3 3.3±0.5 1.3±0.2 ** 
VCAM-1 6.5±1.3 5.2±0.4 3.0±0.5 * 2.5±0.5 2.5±0.3 3.8±0.9 
 




To assess if vagus stimulation results in systemic changes, serum TNFα concentrations and 
complement consumption were measured. Although serum TNFα concentration were in 
generally low in all groups (range 5-26 pg/ml), there was a significant increase over time 
observed during BD. This did not occur in the NBD group and was completely inhibited by 
vagus stimulation (Fig. 3). In contrast, complement consumption was clearly observed in the 




Fig. 3 Serum TNFα concentration in BD-, BD+STIM - and NBD animals. Serum was 
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animals (grey bars) and assessed for TNFα production. The results are expressed as mean 
increase in TNFα concentration ± SEM at time point 6 hrs relative to time point 0 hrs. For 
each group a total of 6 animals were included.  
 
 
Vagus nerve stimulation improves renal function in the recipient 
Previously we have demonstrated that renal function is significantly better after 
transplantation when renal allografts are retrieved from NBD compared to BD donors [26]. 
Therefore we tested if vagus nerve stimulation during BD can improve renal function after 
transplantation in the recipient. One day after transplantation serum creatinin and urea were 
clearly lower in recipients that received a renal graft from a BD + STIM donor, compared to 





















Fig.4 Renal function in recipients receiving a graft from a BD or BD + STIM donor. Renal 
function was assessed as described in materials and methods and was expressed as mean 
serum urea concentration (A) or as mean creatinin concentration (B) ± SD. For each group a 
total of 8 animals were included.  
 


























Histological analysis of these grafts by Banff-Classification revealed that there was a 
tendency to a lower interstitial inflammation and tubulitis score in the BD + STIM group, but 
this did not reach statistical significance (Table 7). 
 
BANFF BD BD+STIM 
i0 6 (50) 6 (60) 
i1 6 (50) 4 (40) 
i2 0 (0) 0 (0) 
i3 0 (0) 0 (0) 
t0 6 (50) 6 (60) 
t1 6 (50) 4 (40) 
t2 0 (0) 0 (0) 
t3 0 (0) 0 (0) 
v0 12 (100) 10 (100) 
v1 0 (0) 0 (0) 
v2 0 (0) 0 (0) 
v3 0 (0) 0 (0) 
 
Table 7: *: severity of interstitial 
inflammation (i), tubulitis (t) and intimal 
arteritis (v) is indicated by the grading scale 
(0=not present, 1=mild alteration, 
2=moderate alteration, and 3=severe 
alteration). **: numbers in parenthesis 
represents the % of animals with a given 
score. A tendency for less interstitial 
inflammation and tubulitis could be observed 
in The BD-STIM group, but it did not reach 
statistical significance. 
 




The present study was conducted to test the hypothesis that during brain death vagus nerve 
activity is decreased resulting in impairment of the anti-inflammatory reflex. The main 
findings of this study are the following. Firstly, HRV is significantly lower in BD - compared 
to ventilated NBD animals, suggesting a decreased parasympathetic activity. Secondly, vagus 
nerve stimulation results in down-regulation of pro-inflammatory genes in different organs, 
hence normalising gene expression for a number of genes which were increased in BD 
animals. Also, some genes that were not influenced by BD were down-regulated by vagus 
nerve stimulation. Changes in gene expression occurring during BD and BD + STIM were 
more pronounced in the small intestine but were also observed in other organs. Thirdly, vagus 
nerve stimulation resulted in a decrease in serum TNFα concentrations and to lower 
complement consumption. Fourthly, Vagus nerve stimulation of BD donors improved renal 
function in the recipient after transplantation. 
 
The relationship between HRV and parasympathetic effect has been shown by Bloomfield et 
al [27] and Hayano et al [28]. According to Goldberger et al [29] this relation can be 
described as a parabolic function in which HRV increases as parasympathetic activity 
increases until it reaches a plateau level. If parasympathetic activity further increases, HRV 
decreases again. A decreased HRV therefore not necessarily reflects low parasympathetic 
activity. Nevertheless Chuen-Wang et al [30] have shown that HRV decreases after vagal 
denervation, hence our data are suggesting that in the course of brain death vagus nerve 
activity decreases. Furthermore medicamentous blockade of vagus nerve through 
methylatropine decreases HRV nearly to zero [31]. We are aware that anaesthetic medication 
can modulate HRV [32]. Because the ventilated NBD animals received anaesthesia, while the 
BD animals did not, this could have biased the results. Anaesthesia however reduces HRV 
[32-34], hence our data would rather underestimate than overestimate the effect of BD on 
HRV.  
 
Since the initial report that vagus nerve stimulation attenuates the systemic inflammatory 
response to endotoxin [35], a number of studies have reported a beneficial effect of vagus 
nerve stimulation in a variety of inflammation models [10-12, 36, 37]. It is generally accepted 
that brain death induces inflammation in end organs [19-21, 38, 39], yet, the involvement of 
the vagus nerve in this respect has never been studied. Although our data suggest that 
impairment of the anti-inflammatory reflex during brain death might account for 
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inflammation, this study does not allow assuming a direct causal relation. Nevertheless our 
study clearly demonstrates the anti-inflammatory potential of vagus nerve stimulation in the 
setting of brain death. Pathways that were the most significant affected were the leukocyte-
transendothelial migration pathway, the cytokine-cytokine receptor pathway, the focal 
adhesion pathway and the Toll like receptor pathway. In particular cytokines, chemokines, 
adhesion molecules, extracellular matrix components and signalling molecules were 
decreased by vagus nerve stimulation. Further immuno-histological analyses are currently in 
progress to assess if these changes in gene expression are of functional relevance in terms of 
mononuclear cell infiltration.   
 
In comparison to the small intestine, changes in gene expression were much less in the kidney 
of BD and BD + STIM animals. It must be emphasized however that we only looked in the 
kidney on a selected set of genes. The genes that were up-regulated within this selected set 
included IL-1α, E-selectin and ICAM-1. Up-regulation of E-selectin in the kidney during BD 
also have been demonstrated by others [40]. In contrast to the small intestine only E-selectin 
was significantly down regulated in the kidney by vagus nerve stimulation. The differences 
between small intestine and kidney might be explained by differences in vagus nerve 
innervation.  
 
In the course of BD serum TNFα concentrations only increased in donors that did not receive 
vagus nerve stimulation. In addition, complement consumption, which occurs as a consequent 
of inflammation, was decreased in the BD + STIM group. A relation between decreased 
TNFα production and vagus nerve stimulation has also been demonstrated by Rosas-Ballina 
et al [37] in a model of endotoxemia. It is therefore possible that the anti-inflammatory effect 
of vagus nerve stimulation in our brain death model could be related to inhibition of TNFα 
production. The finding that vagus nerve stimulation does not significantly reduce ICAM-1 
expression in the kidney however argues against this assumption.  
 
Recently, Yeboah et al [12] has demonstrated that cholinergic agonists attenuate renal 
ischemia-reperfusion injury in rats and that alpha7nAChR plays an important role in the 
pathophysiology of renal I/R injury. This is in line with our observation that vagus nerve 
stimulation of BD donors improves renal function in the recipient after transplantation. 
Moreover our data suggest that stimulation of the anti-inflammatory pathway in BD donors 
might be an effective way to improve I/R mediated acute renal failure in renal transplantation. 
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Whether vagus nerve stimulation is still effective in allo-transplantation or when the graft is 
subjected to cold ischemia remains to be elucidated. 
 
In conclusion our study demonstrates impairment of the parasympathetic nervous system 
during BD. Stimulation of the vagus nerve reduces the expression of a variety of pro-
inflammatory genes in different organs. Renal function was significantly improved after 
transplantation when vagus nerve stimulation was performed in BD donors. Hence, vagus 
nerve stimulation might be a new approach in donor management to avoid inflammation in 
the course of brain death and to improve renal function in the recipient after transplantation.   
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Backround Brain death and cold preservation are major alloantigen-independent risk factors 
for transplantation outcome. The present study was conducted to assess the influence of these 
factors on transplantation associated injury independently or in combination.  
Methods Brain death (BD) was induced in F344 rats. Renal grafts were harvested after 6 hrs 
and either directly transplanted in unilateral nephrectomized Lewis recipient or subjected to 
24 hrs of cold preservation in UW solution before implantation. Allografts obtained from 
living donor (LD) rats were also subjected to cold preservation or not. DNA damage was 
assessed before implantation by TUNEL staining. Ten days after transplantation renal 
histology was performed according to Banff 97 classification. The expression of cytokines 
and adhesion molecules were analysed by quantitative PCR. 
Results Cold preservation significantly increased the number of TUNEL positive cells in 
renal allografts. Ten days after transplantation histology revealed a higher degree of tubulitis 
and vasculitis scores when the grafts were subjected to cold storage. Vasculitis was 
aggravated when the graft was obtained from BD donors. BD, but not cold preservation alone, 
was associated with papillary necrosis. This was more frequently observed after cold 
preservation. Immunohistology showed an increase of MHC class II+ cells after cold 
preservation. The combination of BD and cold preservation revealed a higher degree of 
VEGF and IL-10 expression. 
Conclusions Our Study emphasizes that cold ischemia time should be limited when renal 
allografts from brain-dead donors are transplanted. 
 




Kidney transplantation is the treatment of choice for the majority of patients with end-stage 
renal disease. In the face of the increasing shortage of donor organs, the number of renal 
transplantations using allografts form living donors has increased substantially over the past 
decade. Nevertheless, the majority of renal allografts are still retrieved from deceased donors. 
Yet, transplantation outcome is poor compared to that of renal allografts obtained from living 
donors [1, 2].  
It has been well established that in the sequel of brain death, perturbation of organ function 
and structure develops, possibly as a consequence of hemodynamic instability, hypotension, 
hypothermia, and increased inflammation [3] [4-8]. Clearly, this will influence organ quality 
and hence affect long-term graft survival. Evidence has culminated in various experimental 
brain death models, that organs derived from such animals are prone to accelerated rejection 
after heart or renal transplantation [9-11]. Because brain death is a potential risk factor for 
transplantation outcome, there is an increasing urge to improve organ quality of deceased 
donors by means of donor treatment. The use of steroids [12], soluble P-selectin glycoprotein 
ligand (sPSGL) [12] or dopamine [13-16] are only a few examples that have shown a 
beneficial effect in this context.  
Apart from brain death, organs from deceased donors are further injured by prolonged cold 
preservation, another alloantigen-independent factor which may in turn lead to functional 
deterioration [17, 18]. Prolonged cold storage is associated with poor graft outcome [17, 18] 
as it significantly affects organ quality by increasing tissue necrosis or apoptosis during organ 
preservation and reperfusion [19-22]. Hypothermia also impairs the endothelial barrier 
function, thus resulting in parenchymal oedema and haemorrhage [23]. Aside from donor age, 
brain death and cold ischemia time have such a profound influence on graft outcome, they are 
likely the most important donor variables that might explain the difference in long-term graft 
survival between allografts from living versus deceased donors.  
Although a number of studies already have documented the single influence of cold ischemia 
time or brain death on transplantation outcome, only in a few of these, have a combination of 
brain death and cold ischemia been investigated [24, 25]. Therefore, in the present study we 
addressed to what extent brain death and cold ischemia, have a synergistic effect on organ 
damage, tissue inflammation and graft histology after renal transplantation.  





Inbred male Lewis (LEW, RT11) and Fisher (F344, RT11vr) rats weighing 200 to 250 g were 
obtained from Charles River (Sulzfeld, Germany). Animals were kept under standard 
conditions and fed standard rodent chow and water ad libitum. All procedures were performed 
according to the Guide for the Care and Use of Laboratory Animals published by the National 
Academy of Sciences and were approved by the local authorities (RP Karlsruhe, AZ 35–
9185.81/27/04). 
 
Experimental Protocol  
Before induction of brain death, donor animals were anesthetized with ketamine (Ketanest, 
Pfizer, Karlsruhe, Germany, 100 mg/kg intraperitoneally) and xylazine (Rompun, BayerVital, 
Leverkusen, Germany, 6 mg/kg intraperitoneally) and placed on a heating table to keep their 
body temperature constant. A 3F Fogarty catheter was inserted epidural in an occipital burr 
hole and gradually inflated during 1 minute with 200 µL of saline. The state of brain death 
was verified by the occurrence of autonomic storm, the absence of corneal reflexes and by an 
apnoea test. All animals were mechanically ventilated by a tracheostoma with a rodent 
ventilator (Ugo Basile, Comerio, Italy). Systemic blood pressure (mean arterial pressure 
[MAP], mm HG) was continuously measured (6 hrs) in the donors by a femoral arterial 
catheter (Statham pressure transducer P23Db and a Gould pressure processor, FMI, Ober-
Beerbach, Germany). Six hours post brain death, the left kidneys were harvested and either 
persevered for 24 hours in UW-solution or transplanted directly into recipients. Anesthetized 
living donor animals served as controls. Recipients were anesthetized with enflurane 
(Ethrane; Aca Mueller/Adag Pharma, Gottmadingen, Germany). Experiments were performed 
in the allogeneic Fisher-Lewis rat model. Animals were divided into 4 groups.  
 
Group 1: LD-Cp, grafts from living Fisher donors (LD) directly transplanted (-Cp) in 
unilaterally nephrectomized Lewis recipients 
Group 2: LD+Cp, grafts from living Fisher donors (LD) subjected to 24 hours of cold 
preservation (+Cp) before transplantation in unilaterally nephrectomized Lewis recipients 
Group 3: BD-Cp, grafts from brain death Fisher donors (BD) directly transplanted (-Cp) in 
unilaterally nephrectomized Lewis recipients  
Group 4: BD+Cp, grafts from brain death Fisher donors (BD) subjected to 24 hours of cold 
preservation (+Cp) before transplantation in unilaterally nephrectomized Lewis recipients. 
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No immunosuppression was administered. Each group consisted of a minimum of six 
animals. Kidneys were harvested 10 days after transplantation. The upper poles were frozen in 
liquid nitrogen, and the remaining part was fixed in 10% buffered formalin solution. 
 
TUNEL-Staining 
TUNEL staining was performed according to the manufacturer’s instructions (Roche 
Diagnostics, Mannheim, Germany). In brief, tissue sections were washed twice with 
phosphate-buffered saline after fixation and incubated for 15 min at 70°C in permeabilization 
solution (0.1 mM sodium citrate). Hereafter the sections were extensively washed and 
incubated for 30 min at 37°C with 50 µL of reaction mixture in humid chambers. In each 
experiment and for each staining a negative control was included by omitting dUTP 
transferase from the reaction mixture. TUNEL positive cells were detected by 
immunofluorescence microscopy using a fluorescein isothiocyanate filter. 
 
Histology and Immunohistochemistry 
Paraffin embedding of harvested grafts was performed using routine procedures. Paraffin 
sections (4 µm) were fixed in 10% neutral buffered formalin. For histology the sections were 
stained with hematoxylin-eosin, periodic acid-Schiff, and trichrome. A minimum of 20 
microscopic fields were assessed for each graft. Histologic grading was performed according 
to the Banff ’97 classification [26], reporting on renal transplant biopsies. Sections were 
evaluated in a blinded fashion and graded by a renal pathologist (R.W.). Histologic evaluation 
and grading included transplant glomerulopathy, tubulointerstitial fibrosis, tubular atrophy, 
and vasculopathy. The histologic grading scale was from 0 to 3 (0=not present, 1=mild 
alteration, 2=moderate alteration, and 3=severe alteration). 
For immunohistochemical staining the sections were first rinsed in phosphate-buffered saline 
followed by blocking of endogenous peroxidase (3% hydrogen peroxide) and biotin (Avidin 
blocking kit, Vector, Burlingame, CA, USA). The sections were incubated for 1 hr with ED1 
monoclonal antibody for detection of monocytes and macrophages or with F-17–23–2 
monoclonal antibody directed against major histocompatibility complex (MHC II) or with 
anti-CD3 monoclonal antibody for detection of T-cells (all from Linaris GmbH, Wertheim, 
Germany). Hereafter the sections were incubated with species-specific secondary antibodies 
for 1 hr. Sections incubated with murine or rabbit IgG were used as negative controls. 
Standard avidin-biotin complex staining was performed according to the manufacturer’s 
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instructions (ABC kit, Vector Burlingame, CA, USA). After addition of the 3,3' 
diaminobenzidine substrate the sections were counterstained with hematoxylin, dehydrated in 
graded ethanol and xylene and mounted in Permount. ED1, MHC II and CD3 positive cells 
were counted in a blinded fashion under the microscope using a 400× magnification. A 
histological grading scale was used for quantification (0=no positive cells present, 1=less than 
25 positive cells/microscopic field, 2=25 to 50 positive cell/microscopic field, and 3= more 
than 50 positive cells/ microscopic field). At least seven or eight animals per group and 20 
microscopic fields were evaluated.  
 
Quantitative PCR 
Snap-frozen tissue samples were homogenized using a Polytron homogenizer (IKA 
Labortechnik/Fischer Scientific, Schwerte, Germany). 500 ng of total RNA was reversed 
transcribed into cDNA according to the manufacturer’s instructions, using the 1st Strand 
cDNA Synthesis Kit. cDNA was diluted in 20 µl DEPC-treated water and stored at -80°C 
until use. Specific DNA standards were generated by PCR amplification of cDNA, 
purification of the amplified products, and quantification by spectrophotometry. Light cycler 
PCR of cDNA specimen and DNA standards were conducted in a total volume of 25 µl, 
containing 2 µl FastStart DNA Master SYBR GreenI, 10 pMol of VEGF, IL10, VCAM, 
ICAM-1, E-selectin, IL-6 and TNFα forward and reverse primers and 2mMgCl2. Primer 
sequences were as follows: VEGF (forward 5’ TTC ATC ATT GCA GCA GCC C 3’, 
reverse: 5’ CAG CTA TTG CCG TCC AAT TGA 3’), IL10 (forward: 5`TAC CTG GTA 
GAA GTG ATG CCC C 3`, reverse: 5`AAT CGA TGA CAG CGT CGC A 3`), VCAM 1 
(Applied Biosystems (AB), Foster City, CA, USA; material number Rn00563627_m1), 
ICAM-1 (AB; material number Rn00564227_m1), E-selectin (AB; material number 
Rn00594072_m1), IL6 (AB; material number Rn99999011_m1) and TNFα (AB; material 
number Rn99999017_m1). The amplification profile consisted of 2 minutes at 50°C and 5 
minutes at 95°C followed by 45 cycles of amplification, each cycle consisting of denaturation 
at 95°C for 15 seconds, annealing for 20 seconds at 55°C and extension for 30 seconds at 
72°C. Standard curves were generated in all experiments. PCR efficiency was assessed from 
the slopes of the standard curves and was found to be between 90% and 100%. Linearity of 
the assay could be demonstrated by serial dilution of all standards and cDNA. All samples 
were normalized for an equal expression of GAPDH. IL-10 and VEGF PCR were performed 
by light cycler, all other PCR were performed on a taqman platform. 




Numerical data are expressed as mean ± standard deviation. For immunohistological 
parameters statistical analysis was performed using Fisher`s exact test (StatsDirect 2.2.8, 
Aswell, UK). For analysis of light microscopy, Fisher’s exact test was applied. For PCR-
analysis Kruskal-Wallis test with option for multiple comparisons was applied. A P- value of 
less than 0.05 was considered as significant. 





To study if BD and or cold ischemia affected organ quality before implantation, we assessed 
DNA damage in renal allografts by means of TUNEL staining. In renal allografts from LD 
only a few TUNEL positive cells were detected (1±3). This was slightly increased in allograft 
from BD donors (3±4). When renal allografts were subjected to cold preservation the number 
of TUNEL positive cells increased significantly both in LD (12±6) and BD (32±10) donors, 
compared to allografts that were not subjected to cold preservation (LD-Cp vs. LD+Cp: 
P<0.05; BD-Cp vs. BD+Cp: P<0.01). Significantly more TUNEL positive cells were found in 
BD donors compared to LD (Fig 1).   
 
Fig. 1 TUNEL positive cells in renal allograft directly before transplantation. Note that BD 
alone does significantly affect apoptosis, although it clearly aggravates apoptosis when the 
grafts were subjected to cold preservation. Original magnification: 400x.  
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Cold ischemia enhances renal infiltration after transplantation 
We next assessed severity of inflammation response 10 days after transplantation in renal 
allografts obtained from all groups. When the allografts were not subjected to cold 
preservation (Cp), there was a tendency for an increased number of infiltrated ED1+ cells in 
grafts obtained from brain dead (BD) donors compared to grafts from living donors (LD) 
(Table 1A, LD-Cp vs BD-Cp P=NS). Prolonged cold preservation (24 hrs in UW solution) 
increased the inflammatory response, in both LD and BD, although in the former this was not 













0 0 (0**) 0 (0) 0 (0) 0 (0) 
1 0 (0) 0 (0) 0 (0) 0 (0) 
2 5 (71.4) 2 (28.6) 4 (57.1) 0 (0) 
3 2 (28.6) 5 (71,4) 3 (42.9) 8 (100) 
 
Table 1A: Immunohistological analysis for ED1 positive cells. 
*: histological grading was assessed as described in the materials and methods section (0= 
no positive cells present, 1= less than 10 positive cells/microscopic field, 2=10 to 25 positive 
cells / microscopic field, and 3= more than 25 positive cells/ microscopic field). At least six 
animals per group and 20 microscopic fields were evaluated. **: numbers in parenthesis 
represents the % of animals with a given score.  
 
 
The number of MHC class II positive cells in the grafts obtained from BD or LD donors was 
also increased after prolonged cold preservation. However, no significant difference was 
observed in the number of MHC class II positive cells between BD and LD when the grafts 
were not subjected to cold preservation (Table 1B, BD-Cp vs BD+Cp P<0.001; LD-Cp vs 
LD+Cp P<0.05; LD+Cp vs BD+Cp P<0.05, LD-Cp vs BD-Cp P=NS). The number of 
infiltrating T-cells was not different amongst the groups (Data not shown). 
 
 














0 0 (0**) 0 (0) 0 (0) 0 (0) 
1 2 (28.6) 0 (0) 4 (57.1) 0 (0) 
2 5 (71.4) 4 (57.1) 2 (28.6) 0 (0) 
3 0 (0) 3 (42.9) 1 (14.3) 8 (100) 
 
Table 1B: Immunohistological analysis for MHCII positive cells. 
*: histological grading was assessed as described in the materials and methods section (0= 
no positive cells present, 1= less than 10 positive cells/microscopic field, 2=10 to 25 positive 
cells / microscopic field, and 3= more than 25 positive cells/ microscopic field). At least six 
animals per group and 20 microscopic fields were evaluated. **: numbers in parenthesis 
represents the % of animals with a given score.  
 
Fig 2: Representive immunohistological staining for ED1+ cells in renal allografts collected 
10 days after transplantation. ED1 expression in allografts from LD-Cp, LD+Cp, BD-Cp and 
BD+Cp is depicted. Original magnification: 400x. 
 
 




Histologic scores according to the Banff 97 classification also revealed that the inflammatory 
response was significantly increased in both LD and BD donors when the grafts were 
subjected to cold preservation (Table 2). This was reflected by a higher tubilitis (t) and 
vasculitis (v) score (t: BD-Cp vs BD+Cp: P< 0.0001; v: BD-Cp vs BD+Cp: P<0.0001, t: LD-
Cp vs LD+Cp: P<0.05; v: LD-Cp vs LD+Cp: P=0.05). No difference in the degree of 
interstitial (i) infiltration between the groups was found. BD seems to aggravate cold 
preservation damage particularly in vessels as higher vasuclitis scores were observed in these 
grafts, while tubulitis scores were not significantly different (v: LD+Cp vs BD+Cp: P<0.01, t: 
LD+Cp vs BD+Cp: P=NS) (Table 2; Fig. 3A). In light microscopy we could also demonstrate 
the occurrence of papillary necrosis. This was observed in 20% and 25% of the animals in the 
BD-Cp and BD+Cp group respectively, but was not found in the LD groups (Fig. 3B). 
Papillary necrosis occurred after transplantation, since it was not observed directly after BD 










i 0 0 (0**) 0 (0) 0 (0) 0 (0) 
i 1 0 (0) 0 (0) 0 (0) 0 (0) 
i 2 0 (0) 0 (0) 0 (0) 0 (0) 
i 3 8 (100) 7 (100) 7 (100) 8 (100) 
t 0 0 (0) 0 (0) 0 (0) 0 (0) 
t 1 0 (0) 0 (0) 0 (0) 0 (0) 
t 2 6 ( 75) 1 (14.3) 7 (100) 0 (0) 
t 3 2 ( 25) 6 (85.7) 0 (0) 8 (100) 
v 0 0 (0) 0 (0) 0 (0) 0 (0) 
v 1 4 (50) 0 (0) 7 (100) 0 (0) 
v 2 4 (50) 7 (100) 0 (0) 1 (12.5) 
v 3 0 (0) 0 (0) 0 (0) 7 (87.5) 
 
Table 2: Histologic scores according to the Banff`97 classification.  
*: severity of interstitial inflammation (i), tubulitis (t) and intimal arteritis (v) is indicated by 
the grading scale (0=not present, 1=mild alteration, 2=moderate alteration, and 3=severe 
alteration). **: numbers in parenthesis represents the % of animals with a given score. Cold 
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preservation resulted in significantly more severe tubuitis in both donor types (-Cp vs +Cp, 
P<0.05). The combination of BD and cold preservation resulted in significantly more severe 
vasculitis (LD+Cp vs BD+CP, P<0.01). 
 
Fig 3A: Representive hematoxylin-eosin staining of renal allografts collected 10 days after 
transplantation. Note that cold preservation results in more severe tubulitis in both types of 
donors (panels to the left). Cold preservation also resulted in more severe vasculitis, 
particularly in the BD group (panels to the right). Original magnification: 400x. 




Fig. 3B: Overview of a renal papilla in LD (panels to the left) and BD (panels to the right) 
donors. While in LD papilla necrosis was not observed, in 20 % of the BD animals this 
occurred after renal transplantation. An example of papilla necrosis is depected (panel to the 
right). Original magnification: 20x upper panels, 100x lower panels.  
 
Cytokine expression 
To assess if the cytokine profile was different amongst the groups, we performed quantitative 
PCR for VCAM-1, ICAM-1, E-selectin, TNFα, IL6, VEGF and IL-10. To this end total RNA 
was isolated from renal allografts 10 days after transplantation. No difference in the mRNA 
expression of VCAM-1, ICAM-1 was found between the groups. Although the mRNA 
expression of E-selectin was significantly higher in the BD-Cp group compared with the LD-
Cp or LD+Cp groups, this was not found in the BD+Cp group (Table 3). Similar findings 
were observed for IL-6. There was a tendency for an increased TNFα mRNA expression 
when the grafts were subjected to cold preservation, but this did not reach statistical 
significance. Both VEGF and IL-10 mRNA expression were significantly increased in the BD 
compared to the LD groups. This was more pronounced after prolonged cold preservation 
(Table 3). 
  




Gene*  LD-Cp  LD+Cp BD-Cp BD+Cp 
ICAM-1 2.38±0.34 2.50±0.32 2.7±0.45 2.74±0.59 
VCAM-1 4.78±0.26 4.78±0.16 4.86±1.23 5.74±1.11 
E-selectin 2.52±0.87 2.22±0.61 4.28±0.79** 2.56±1.07 
TNFα 11.17±2.74 14.11±6.05 10.41±4.62 15.06±1.63 
IL-6 0.52±0.09 0.57±0.18 1.51±1.11 0.64±0.11 
IL-10 28±5 37±4 116±25** 216±118*** 
VEGF 307±94 274±107 790±157** 1649±883*** 
 
Table 3: Quantitative PCR-Analysis for the expression of adhesion molecules and cytokines 
*: The results are expressed as mean gene of interest/GAPDH ratio ± SD. In each group 
kidneys from 4 animals were analysed. **: P<0.05, LD-CP or LD+Cp vs BD-Cp 
***:P<0.01, LD-Cp or LD+Cp vs BD+Cp.  




Many studies have clearly shown that brain death is a donor associated risk factor that 
negatively affects transplantation outcome [27-30]. There is also general consensus that 
prolonged cold preservation time significantly contributes to pre-transplantation injury as it 
results in tubular and vascular damage [17-19]. Although based on these findings, it can be 
anticipated that the combination of BD and cold preservation will lead to culmination of 
organ damage. There are, however, only a few studies that have investigated the combination 
of brain death and cold preservation on tissue damage after transplantation. Therefore we 
assessed to what extent BD, cold preservation or the combination of both affects post-
transplant injury after renal transplantation.  
 
The main findings of our study are that cold preservation, but not BD alone, increases DNA 
damage in renal tissue before implantation. BD augmented DNA damage when grafts were 
subsequently subjected to prolonged cold preservation. After transplantation renal 
inflammation was significantly higher in grafts that were subjected to cold preservation. BD 
aggravated inflammation as indicated by a higher score for MHC class II positive cells in 
these grafts. In particular, vasculitis but not tubulitis was significantly more severe in the 
BD+Cp compared to the LD+Cp group. BD, but not cold preservation alone, was associated 
with papillary necrosis. Papillary necrosis occurred after transplantation as it was not found 
directly after BD.  
Prolonged cold preservation severely affects the vasculature and might impair the endothelial 
barrier function [31]. Endothelial barrier dysfunction is generally associated with edema 
formation, which might subsequently lead to vascular occlusion and secondary tissue 
ischemia. Although we did not investigate endothelial barriere dysfunction in the present 
study, we recently have shown in an isolated ventilated and perfused rat lung model that cold 
preservation severely affects the endothelial barriere resulting in profound edema formation 
upon lung perfusion, accompanied by an increase in mononuclear cell infiltration [32, 33]. 
We are aware that these results may not be entirely extrapolated to renal grafts, but they do 
indicate the vulnerability of the micro-vasculature towards cold preservation. We did not 
specifically address if DNA damage occurred in endothelial cells during cold preservation. 
However, based on the localisation of TUNEL positive cells, our data suggest that damage of 
peritubular capillaries might have occurred. Interestingly, BD alone did not affect DNA 
damage in renal tissue, but clearly augmented the number of TUNEL positive cells when 
these grafts were subjected to cold preservation. Due to hemodynamic imbalances 
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hypoperfusion of the kidney could occur [13]. Reduced perfusion could in turn make the renal 
tissue more prone to cold ischemic damage.  
 
Interstitial inflammation was not different amongst the groups. In contrast, vasculitis, a 
hallmark for acute vascular rejection [26], was more severe in the BD+Cp group. This was 
not found for tubulitis, as the tubilitis scores between the BD+Cp and LD+Cp groups were not 
significantly different. BD alone also did not affect severity of vasculitis (LD-Cp vs BD-Cp, 
P=NS). In a retrospective study of Sanchez-Fructuoso [34], BD was found to be a risk factor 
for acute vascular rejection. It must be stressed that in the study of Sanchez-Fructuoso all 
renal grafts were subjected to hypothermic preservation. Therefore BD alone might not be a 
risk factor for vasculitis but only in combination with cold ischemia, as our data suggest.  
Recently, Mikhalski et al [35] showed that cold ischemia time is a risk factor for acute 
interstitial rejection when renal allografts were obtained from deceased donors. Cold ischemia 
time was not found to be a risk factor for acute interstitial rejection when grafts were obtained 
from living donor in the study of Simpkins et al [36]. These findings are not in agreement 
with the data from our model as for both living and BD donors cold preservation increased 
severity of tubulitis. It must be noted however, that in the study by Simpkins et al cold 
ischemia time was not more than 8 hrs, while in our study 24 hrs of cold preservation was 
applied. This might explain the conflicting results found in both studies. 
 
Although Banff classification and immunohistology scores revealed a significant difference 
between the groups, this was not reflected by quantitative PCR analysis when mRNA 
expression of inflammatory genes was assessed. This might be explained by the fact that only 
a minority of infiltrated mononuclear cells were present in the vessel wall or tubuli resulting 
in different Banff vasculitis and tubulitis scores respectively. The majority of infiltrating cells 
were present in the interstitium and no differences in Banff interstitial infiltration scores were 
detected between the groups. Nevertheless, immunohistology showed that significant more 
ED1 and MHC class II positive cells were present in the grafts obtained from the BD+Cp 
group. Given that interstitial infiltration scores where not different between the groups, our 
data suggest enrichment of monocytes in the BD+Cp group. Because the inflammatory genes 
that were studied are not specific for monocytes, the results obtained from the quantitative 
PCR and immunohistology might differ.   
A comparative immunohistochemical analysis of pretransplant donor biopsies from deceased 
and living related donors (LRD) have revealed high expression levels of E-selectin, HLA-DR 
Chapter 3 –Effects of Cold Preservation and Brain Death in Renal Transplantation 
 
 65
antigens, ICAM-1 and VCAM-1 in biopsies from cadaveric kidneys, as opposed to that was 
found in biopsies from LRD kidneys [37]. Upregulation of inflammatory genes during BD 
have also been demonstrated by others using animal models [4, 7, 8]. This is compatible with 
our previous findings that BD increases the number of inflammatory cells in the kidney [13, 
14]. Nevertheless, our present study revealed that 10 days after transplantation no large 
differences between the groups were found for the inflammatory genes that were tested. 
While VCAM-1 and ICAM-1 mRNA expression was similar in the BD and LD groups, there 
was an increased E-selectin mRNA expression in the BD-Cp but not in the BD+Cp group. 
Although it remains to be elucidated why this was not found in the latter group, endothelial 
damage as a consequence of vasculitis might underly this phenomenon.  
With exception of VEGF and IL-10 no significant differences in mRNA expression for 
cytokines or growth factors were found between the groups. VEGF was strongly up-regulated 
in grafts from BD animals compared to grafts from LD donors. This was not influenced by 
cold preservation and did not correlate with the severity of vasculitis. VEGF is up-regulated 
by hypoxia in a variety of organs [38-40]. Hence the increased expression could be related to 
tissue ischemia. It has also been demonstrated, that acute brain trauma with consecutive 
sympathetic activation increases IL10 plasma levels [41, 42]. Ten days after transplantation 
IL10 expression was still increased in grafts from brain dead donor rats, probably as a 
response to renal inflammation.  
 
Renal papillary necrosis can occur as a consequence of an ischemic process in the renal 
papilla [43, 44]. Interstitial inflammation may lead to compression of the medullary 
vasculature and thus predispose the vessels to ischemic damage. Also vasculitis compromises 
perfusion and hence can contribute to papillary necrosis. Since severity of vasculitis was 
higher in the BD+Cp group this might explain the higher incidence of papillary necrosis in 
this group. It remains to be addressed why papillary necrosis was only observed in grafts 
obtained from BD animals, even when the grafts were not subjected to cold preservation. One 
possible explanation might be related to hypoperfusion of the renal tissue during the state of 
BD, thereby predisposing the renal papillae to ischemic damage. 
 
In conclusion, our study demonstrates that BD amplifies tissue damage before and after 
transplantation when renal allografts are subjected to prolonged cold ischemia. Because our 
study once more stresses the importance of minimizing cold ischemia time in grafts from 
deceased donors, strategies in donor management and/or organ procurement aimed to 
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minimize pre-transplant injury are warranted. This could be feasible by donor pre-
conditioning that limits brain death and cold preservation injury [15, 16, 45]. Alternatively, 
changing organ allocation, e.g. local organ donors for local recipients, would significantly 
reduce the time for cold preservation. While the later might be more difficult to implement for 
reasons of matching, multi-organ donation and logistics, donor pre-conditioning seems to be a 
more practical approach to overcome this problem.  
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Backround Brain death (BD) is associated with profound inflammation in end-organs. 
Dopamine (DA) treatment reduces this inflammatory response, but the underlying 
mechanisms remain thus far largely unknown. In the present study we investigated if the anti-
inflammatory effect of DA was related to hemodynamic stabilization and by which receptors 
it was mediated.   
Methods BD was induced in F344 donor rats. DA was given either before BD for 24 hrs or 
after brain death induction during a definite time. Adrenergic or D-receptor blockers were 
administered to inhibit the receptor stimulation mediated by DA. Hemodynamic changes were 
recorded and kidneys were harvested after 6 hrs of BD. 
Results Mean arterial pressure (MAP) was completely normalized by DA treatment. DA pre-
treatment before BD induction and treatment during BD both significantly inhibited monocyte 
infiltration. The anti-inflammatory as well as its blood-pressure stabilizing effect was 
abrogated by concomitant application of adrenergic receptor blockers. In contrast, 
concomitant application of D-receptor blockers only abrogated the anti-inflammatory effect 
but did not affect blood pressure stabilization. In contrast, pergolide and adrenergic receptor 
blockers completely normalized blood pressure but did not affect renal inflammation. 
Conclusions Hence, DA might reduce BD induced monocyte infiltration possibly by 
hemodynamic stabilization, D-receptor activation or a combination of both.  




The majority of renal allografts are still retrieved from deceased donors. Brain death is 
considered to be an important cause of pre-transplantation injury. It is associated with 
hemodynamic instability, hypotension, hypothermia, coagulopathies and electrolyte 
abnormalities [1]. In addition a number of immunological alterations occur, e.g. cytokine 
release and upregulation of adhesion molecules that eventually lead to inflammation in end-
organs [2-4]. It is believed, that the release of endogenous catecholamines plays a pivotal role 
in this process. During brain death serum catecholamine concentrations increase rapidly, 
resulting in profound vasoconstriction. As brain death ensues, serum catecholamine 
concentrations drop again. The process of vasoconstriction and subsequent vasodilatation 
dramatically influences blood pressure and defines the so-called “autonomic storm” [5, 6]. 
Catecholamines are frequently used in intensive care medicine to stabilize blood pressure in 
critically ill patients and in patients with irreversible brain injury [7-9]. There are conflicting 
data in the literature regarding the mode of action and effects of dopamine in clinical kidney 
transplantation [10-13]. In two retrospective clinical studies however, Schnuelle et al. [14, 15] 
demonstrated that dopamine treatment of  brain-dead donors have a beneficial effect on 
delayed-graft function and long-term renal allograft survival. Although the precise 
mechanisms by which dopamine may improve transplantation outcome after renal 
transplantation are not known so far, several mechanisms have been suggested. Dopamine is 
able to induce the expression of the heme oxygenase 1 (HO-1) in endothelial cells [16], delays 
the expression of adhesion molecules after TNFα stimulation, inhibits the production of 
chemokines in renal tubular epithelial and endothelial cells [17], and protects endothelial cells 
against cold preservation injury [18]. Moreover, treatment of brain-dead rats with dopamine 
reduces monocyte infiltration and MHC class II expression in donor kidneys [19].  
Since dopamine treatment also improves hemodynamic instability in BD donors it is unclear 
to what extent the beneficial effect of donor dopamine treatment on transplantation outcome is 
primarily mediated by blood pressure stabilisation. In the present study we therefore tested the 
hypothesis that the anti-inflammatory effect of dopamine is independent of blood pressure 
stabilisation. We investigated the involvement of α- and β-adrenergic- as well as 









Inbred male Fisher (F344, RT11vr) rats weighing 200 to 250 g were obtained from Harlan-
Winkelmann (Borchen, Germany). Animals were kept under standard conditions and fed 
standard rodent chow and water ad libitum. All procedures were performed according to the 
Guide for the Care and Use of Laboratory Animals published by the National Academy of 
Sciences and were approved by the local authorities (RP Karlsruhe, AZ 35–9185.81/27/04). 
Experimental Protocol  
Before induction of brain death, donor animals were anesthetized with ketamine (Ketanest, 
Pfizer, Karlsruhe, Germany, 100 mg/kg intraperitoneally) and xylazine (Rompun, BayerVital, 
Leverkusen, Germany, 6 mg/kg intraperitoneally) and placed on a heating table to keep their 
body temperature constant. A 3F Fogarty catheter was inserted epidural in an occipital burr 
hole and gradually inflated during 1 minute with 200 µL of saline. The state of brain death 
was verified by the occurrence of autonomic storm, the absence of corneal reflexes and by an 
apnoea test. All animals were mechanically ventilated by a tracheostoma with a rodent 
ventilator (Ugo Basile, Comerio, Italy). Systemic blood pressure (mean arterial pressure 
[MAP], mm HG) was continuously measured during the whole experiment (6 hrs) by a 
femoral arterial catheter (Statham pressure transducer P23Db and a Gould pressure processor, 
FMI, Ober-Beerbach, Germany). Anesthetized, non brain-dead ventilated donor animals 
without inserted Fogarty catheter served as controls. The animals were divided into 10 groups. 
Donor animals were treated intravenously by microinjection pumps (CMA/100, CMA/ 
Microdialysis, Sweden) according to the following scheme (Fig. 1): 
  
Group 1: Vehicle not brain death (VEH-NBD), Fisher rats non brain death ventilated plus 
NaCl 0.9%. 
Group 2: Vehicle brain death (VEH-BD), Fisher rats brain death plus NaCl 0.9%. 
Group 3: Dopamine brain death (DA), Fisher rats brain death plus dopamine 10 µg/min/kg 
[19, 20] during the first three hours of brain death.  
Duration of DA infusion was based on a time-response-analysis, in which 3 hours of DA 
infusion from the onset of BD on appeared to be the shortest period for effectively inhibiting 
monocyte infiltration in renal tissue.  
Group 4: Dopamine + adrenergic Receptor-antagonists (DA+ADR.BLOCK), Fisher rats 
brain death plus dopamine 10 µg/min/kg and propranolol/doxazosin (Sigma-Aldrich 
Deisenhofen, Germany/Pfizer GmbH, Karlsruhe, Germany; 10/5mg/kg body weight/d p.o. 
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day -1,0 prae op) during the first 3 hours of brain death [21]. 
Group 5: Dopamine + dopaminergic Receptor-antagonists (DA+D-BLOCK), Fisher rats 
brain death plus dopamine 10 µg/min/kg and SCH-23390 (10µg/kg body weight/min, Sigma-
Aldrich Deisenhofen, Germany ) and domperidone (10mg/kg body weight p.o. day -1,0 prae 
op, Sigma-Aldrich Deisenhofen, Germany) during the first 3 hours of brain death [22, 23]. 
Group 6: Dopaminergic Receptor-agonist pergolide (D-Agonist), Fisher rats brain death plus 
pergolide (0.5 mg/kg body weight i.p., Sigma-Aldrich Deisenhofen, Germany) during the 
whole duration of the experiment [24].  
Group 7: Pergolide + adrenergic Receptor-antagonists (D-Agonist+ADR.BLOCK), Fisher 
rats brain death plus pergolide (0.5 mg/kg body weight i.p., Sigma-Aldrich Deisenhofen, 
Germany) and propranolol/doxazosin during the whole duration of the experiment.  
 
To investigate if dopamine could already evolve its protective effects before brain death 
occur, separate groups of animals were pre-treated with dopamine for 24h with osmotic 
minipumps (Alzet 2ML1) implanted subcutaneously in the animal’s back. A catheter attached 
to the pump was placed in the left femoral vein and the pre-treatment solution was 
administered with a mean pumping rate of 10 µL/hr. After implantation of the osmotic 
minipump, animals were kept in single cages and had free access to water and chow. After 
24-hours pre-treatment, dopamine infusion was discontinued and brain death was induced. 
Animals were divided into 3 groups according to the following scheme: 
 
Group 8: Vehicle not brain death 24 hours pre-treatment with saline (VEH-NBD 24), Fisher 
rats non brain death ventilated pre-treated intravenously for 24 hrs before anaesthesia with 
saline. 
Group 9: Vehicle brain death 24 hours pre-treatment with saline (VEH-BD 24), Fisher rats 
brain death pre-treated intravenously for 24 hrs before brain death induction with saline. 
Group 10: Dopamine pre-treatment for 24 hours (DA24), Fisher rats plus dopamine 10 
µg/min/kg [20] pre-treated intravenously for 24 hrs before brain death induction with 
dopamine. 
 
In all groups the kidneys were collected after 6 hours for immunohistochemical stainings and 
PCR analysis. Each group consisted of a minimum of six animals. 




Fig 1: Schematic representation of all intervention studies. BD was induced in groups (II-VII, 
IX+X) at timepoint t = 0, and routine data monitoring was performed for 6h thereafter 
(kidney explantation t = 6). Drugs were applied to the BD rats at various time frames as 




Serial paraffin sections (4 µm) were fixed in 10% neutral buffered formalin for 
immunohistochemical staining. After phosphate-buffered saline rinsing and blockade of 
endogenous peroxidase (3% hydrogen peroxide) and endogenous biotin (Avidin blocking kit, 
Vector, Burlingame, CA), sections were incubated for 1 hr with primary antibody for 
monocytes and macrophages ED1 (monoclonal mouse anti-rat, (Linaris Biologische Produkte 
GmbH, Germany), major histocompatibility complex (MHC II) (F-17–23–2, monoclonal 
mouse anti-rat, Linaris), T-cells (CD3) (monoclonal mouse anti-rat, Linaris) followed by 
incubation with species-specific secondary antibodies for 1 hr. Irrelevant murine or rabbit 
control antibody or omission of the primary antibody served as controls. Standard avidin-
biotin complex staining was performed according to the manufacturer’s instructions (ABC kit, 
Vector); 3,3' diaminobenzidine substrate was applied, and the sections were counterstained 
with hematoxylin. After dehydration in graded ethanol and xylene, slides were mounted in 
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Permount for evaluation. ED1 and MHC II positive cells were counted in a blinded fashion 
under the microscope at 400× enlargement. At least six animals per group and 20 fields or 
more per view per sample were evaluated in a blinded fashion. Analysis was performed using 
a magnification of 400x. 
 
Light cycler polymerase chain reaction 
Kidneys from naive-, ventilated non BD-, NaCl treated and dopamine treated BD rats were 
investigated. Snap-frozen tissue samples were homogenized using a Polytron homogenizer 
(IKA Labortechnik/Fischer Scientific). 500 ng of total RNA was reversed transcribed into 
cDNA according to the manufacturer’s instructions, using the 1st Strand cDNA Synthesis Kit. 
cDNA was diluted in 20 µl DEPC-treated water and stored at -80°C until use. Specific DNA 
standards were generated by PCR amplification of cDNA, purification of the amplified 
products, and quantification by spectrophotometry. Light cycler PCR of cDNA specimen and 
DNA standards were conducted in a total volume of 25 µl, containing 2 µl FastStart DNA 
Master SYBR GreenI, 10 pMol of HO-1 forward and reverse primers and 2mMgCl2. The 
amplification profile for each sample was as follows: 2 minutes at 50°C, 5 minutes at 95°C 
followed by 45 cycles of amplification each cycle consisting of denaturation at 95°C for 15 
seconds, annealing for 20 seconds at 55°C and extension for 30 seconds at 72°C. Standard 
curves were generated in all experiments. PCR efficiency was assessed from the slopes of the 
standard curves and was found to be between 90% and 100%. Linearity of the assay could be 
demonstrated by serial dilution of all standards and cDNA. Primer sequences were as follows: 
HO-1, forward: ATG TCC CAG GAT TTG TCC GA; reverse: TAA AGC CTT CCC TGG 
ACA CCT). S16, forward: CAC CTA ACC ATA CGC CTT GCT T; reverse: TGG ATC 
ATA GGA GCC CAA CTG). All samples were normalized for an equal expression of S16. 
Each experiment was repeated 3 times with similar results. 




Peripheral blood was drawn through a femoral arterial catheter before and 6 hours after brain 
death induction. The animals were either treated with NaCl or dopamine (N=3 in both groups) 
as described earlier. Peripheral Blood Mononuclear Cells (PBMC) were isolated by Ficoll 
density gradient and stained with directly conjugated monoclonal antibodies (ED1 FITC; 
MHCII RPE; CD 11a FITC; CD18, FITC; CD62L FITC, all from BD Biosciences, 
Heidelberg, Germany). After incubation with monoclonal antibodies (30 minutes at 4°C) the 
samples were extensively washed and analysed on a FACScalibur flow cytometer (BD 
Biosciences, Heidelberg, Germany). 
 
Statistical Analysis 
Numerical data are expressed as mean ± standard deviation. For immunohistological 
parameters and PCR-analysis statistical analysis was performed using the Kruskal-Wallis test 
with option for multiple comparisons (StatsDirect 2.2.8, Aswell, UK). For analysis of the 
blood pressure data two-way ANOVA was applied. A P- value of less than 0.05 was 
considered as significant. 




MAP and inflammatory response in brain dead rats after dopamine intervention 
In untreated Fisher rats mean arterial pressure (MAP) was approximately 110±13 mm Hg. 
Two minutes after inflation of the fogarty-catheter MAP decreased slightly (82±5 mm Hg), 
followed by a sharp increase (161±5 mmHg) in the next two minutes. Within 20 min after 
induction of brain death, MAP decreased to 70±5 mmHg and remained unchanged thereafter 
in untreated animals. In ventilated, non brain-dead animals, MAP was stable during the first 3 
hours but gradually declined during the last 3 hrs (Fig. 2 A). When dopamine was applied 
during the first three hours after brain death, the hypotensive period was completely abrogated 
when compared to untreated brain-dead controls. Hypotension reoccurred upon cessation of 
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Fig. 2: Hemodynamic changes in BD rats. MAP was recorded as described in the method 
section in VEH-BD (closed circles) and VEH-NBD (open circles) rats (Fig. 2 A). Significant 
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differences in MAP between both groups were observed from the onset of BD on until 3 hrs 
after BD (P<0.05 VEH-BD vs VEH-NBD). No differences in MAP were found before 
induction of BD. Dopamine treatment during BD (grey squares) significantly improved MAP 
compared to NaCl treated BD (closed circles) rats (P<0.05, DA vs VEH-BD) (Fig. 2 B). After 
cessation of dopamine treatment MAP was not different from the NaCl treated BD (closed 
circles) rats. The results are expressed as MAP (mmHg) of at least 4 animals in each group.  
 
 
In kidneys of untreated brain-dead rats infiltration of ED1+ and MHC class II+ cells was 
significantly higher compared to kidneys from ventilated non-brain-dead rats (30±6 vs 22±3 
for ED1+ cells; P<0.005 and 101±15 vs 68±20 for MHC class II+ cells; P<0.005). Three 
hours of dopamine treatment from the onset of BD on significantly diminished the infiltration 
of these cells (22±5 vs 30±6; P<0.005, for ED1+ cells Fig. 3 A, B and 56±23 vs 101±15; 
P<0.005, for MHC class II+ cells Fig. 3 C). BD also significantly increased the number of 
CD3 positive T-cells in renal tissue compared to ventilated non-brain-dead animals (13±5 vs 
8±2, P<0.05). Although dopamine treatment showed a tendency to reduce CD3 infiltration, 
this did not reach statistical significance (13±5 vs 11±2; P=NS; 8±2 vs 11±2; P=NS; Data not 
shown).  
 
Fig 3A: Analysis of ED-1 positive cells in the kidneys of ventilated non-brain-dead rats, 
brain-dead rats and brain-dead rats treated with dopamine (Fig. 3 A, B). BD rats were 
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treated with dopamine for 3 hrs from the onset of BD on (DA). NaCl treated BD (VEH-BD) 
and non BD (VEH-NBD) rats served as controls (VEH-NBD vs VEH-BD, VEH-BD vs DA, #: 
P<0.01). The results are expressed as mean number of positive cells per 10 fields of view ± 
standard deviation. At least 120 fields of view were analysed comprising 6 to 8 animals per 
group. Analysis was performed using a magnification of 400x. 
 
Fig 3B Immunohistological staining of ED-1 positive cells 
 




Fig 3C: Analysis of MHC class II positive cells was assessed in Fig. 3 C. The animals were 
treated similar as in A (VEH-NBD vs VEH-BD, *: P<0.05; VEH-BD vs DA #: P<0.01). The 
results are expressed as mean number of positive cells per 10 fields of view ± standard 
deviation. At least 120 fields of view were analysed comprising 6 to 8 animals per group. 
Analysis was performed using a magnification of 400x. 
 
 
Association of inflammatory response with MAP 
To investigate in more detail if the anti-inflammatory effect of dopamine was related to an 
improved MAP, we performed additional experiments using dopamine together with 
alpha/beta-receptor-antagonists (i.e. doxazosin/propranolol). Application of alpha/beta-
receptor-antagonists together with dopamine resulted in a significantly reduced MAP 
comparable to untreated brain-dead controls (Fig. 4 A). Propranolol/doxazosin completely 
abrogated the beneficial effect of dopamine on monocyte infiltration (35±8 vs 22±5 for ED1+ 
cells and 87±10 vs 56±23 for MHC class II+ cells; DA+ADR.BLOCK vs DA, P<0.001 for 
both ED1 and MHC class II, Fig. 4 B). 
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Fig. 4A: Influence of adrenergic and dopaminergic receptor antagonists on hemodynamic 
changes and monocyte infiltration in dopamine treated BD rats. Adrenergic receptor 
antagonists (grey triangle) completely abrogated blood pressure stabilisation by dopamine 
during BD (Fig. 4 A). Additional MAP curves represent NaCl treated VEH-BD (closed 




Fig. 4B: Adrenergic receptor antagonists also abrogated the effect of dopamine on monocyte 
infiltration (VEH-NBD and DA vs DA +ADR.BLOCK, #: P<0.01, Fig. 4 B). 





An additional group received dopamine simultaneous with D1/D2-receptor-antagonists 
(SCH23390/ domperidone). In this group (DA+D-BLOCK) MAP was not significantly 
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VEH-BD DA + D-Block
Fig. 4C: D1/D2 receptor antagonists (white squares) did not affect blood pressure 
stabilisation by dopamine (Fig. 4 C). Additional MAP curve represent NaCl treated BD 
(closed circles) rats. For reasons of clarity the MAP curve of dopamine treated rats is not 
depicted, but was similar as in Fig. 2 B. 
 
 
However, monocyte infiltration was significantly stronger when D1/D2-receptor-antagonists 
were applied (42±8 vs 22±5 for ED1+ cells and 97±15 vs 56±23 for MHC class II+ cells; 
DA+D-BLOCK vs DA; P<0.0001 for both ED1 and MHC class II, Fig. 4 D).  




Fig. 4 D Although D1/2-receptor-antagonists did not influence dopamine mediated blood 
pressure stabilisation during BD, they completely abrogated the anti-inflammatory effect of 
dopamine as assessed by immunohistochemistry for ED-1 positive cells (VEH-NBD and DA 
vs DA + D-BLOCK, #: P<0.01, Fig. 4 D). 
 
 
In addition, the D-receptor Agonist pergolide reduced monocyte infiltration to a similar extent 
as dopamine (23±3 vs 30±6 for ED1 positive cells, D-Agonist vs VEH-BD) but did not 
stabilise MAP (Fig. 4 E, F).  
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Fig. 4 E 
 
Fig. 4 E+F: The D-receptor agonist pergolide had no blood pressure stabilizing properties 
(grey circles) (Fig. 4 E). Nevertheless it inhibited monocyte infiltration (VEH-BD vs D-
Agonist, *: P<0.05 and DA vs D-Agonist, P=NS, Fig. 4 F). 
 
Fig. 4 F 
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Pergolide did not reduce monocyte infiltration when used in combination with 
propranolol/doxazosin although hemodynamic destabilisation during BD did not occur under 
this condition ( Fig. 4 G, H).  
 
Fig 4 G 
 
Fig. 4 H+G: The influence of pergolide together with adrenergic receptor blockers on 
hemodynamic changes and monocyte infiltration is depicted in Fig 4 G and H respectively. In 
Fig 4 H, the group of dopamine plus adrenergic blockers (DA+ADR.BLOCK) is also depicted 
for comparison (D-Agonist vs D-Agonist+ADR.BLOCK, *: P<0.05 and DA+ADR.BLOCK vs 
D-Agonist+ADR.BLOCK, P=NS). For hemodynamic changes the results are expressed as 
MAP (mmHg) of at least 4 animals in each group. For immunohistochemical analysis at least 
120 fields of view were analysed comprising 6 to 8 animals per group. Analysis was 
performed using a magnification of 400x. 
 
 









































Fig. 4 H 
 
 
Influence of dopamine pretreatment on MAP and renal inflammation 
To study if dopamine was also effective before induction of brain death we pretreated animals 
for 24 hrs with dopamine. The animals did not receive dopamine during the 6 hours brain-
death period. Hemodynamic changes during brain death were not affected by dopamine pre-
treatment (Fig. 5 A). In contrast, dopamine pre-treatment markedly reduced monocyte 
infiltration in the kidneys (44±7 vs 37±5 for ED1+ cells, untreated vs DA pre-treatment brain 
dead rats, P<0.05; 63±17 vs 43±16 for MHC class II + cells, untreated vs DA pre-treatment 
brain dead rats, P<0.01, Fig. 5 B), indicating that inhibition of monocyte infiltration per se is 
not mediated by restoring MAP.  
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Fig. 5A  
 
Fig. 5: Influence of dopamine treatment before BD induction on hemodynamics and monocyte 
infiltration. Rats were treated for 24 hrs with dopamine using an osmotic mini-pump (DA 24). 
Control groups (VEH-NBD 24, VEH-BD 24) were treated with saline for the same time. 
Dopamine was not applied during the period of BD. MAP was not affected by dopamine pre-
treatment (grey triangle, Fig. 5 A). ED-1 (shaded bars) and MHC class II (black bars) 
positive cells were assessed as described (VEH-BD 24 vs DA 24, *: P<0.05, Fig. 5 B). For 
hemodynamic changes the results are expressed as MAP (mmHg) of at least 4 animals in each 
group. For immunohistochemical analysis at least 120 fields of view were analysed 
comprising 6 to 8 animals per group. Analysis was performed using a magnification of 400x. 
 




Fig. 5 B 
 
 
Influence of dopamine on HO-1 gene expression 
In renal tissue of ventilated non brain-dead rats HO-1 gene expression was slightly but 
significantly increased compared to naive controls (P<0.05). Brain death led to a profound 
upregulation of HO-1 gene expression (naive vs. brain death: P<0.0001), which was 
completely abrogated by dopamine treatment (VEH-BD vs DA: P<0.05). Similarly, HO-1 
expression was significantly lower when pergolide was applied to the BD donors (VEH-BD 
vs D-agonist: P<0.05). Application of pergolide in the presence of propranolol/doxazosin 
restored HO-1 expression to that observed in untreated BD animals (Fig. 6)  




Fig. 6: Quantitative PCR-Analysis for HO-1 gene expression in kidneys of naive (NAIVE), 
ventilated non BD (VEH-NBD), NaCl treated brain death (VEH-BD) dopamine treated brain 
death (DA), pergolide treated brain death (D-Agonist) and pergolide + 
propranolol/doxazosin treated brain death rats (D-Agonist+ADR.Block). The results are 
expressed as mean HO-1/S16 ratio ± SD. In each group kidneys from 4 animals were 
analysed (NAIVE vs VEH-BD, #: P<0.01; VEH-NBD vs VEH-BD, *: P<0.05; VEH-BD vs 





To investigate if BD influences the expression of adhesion molecules on circulating 
peripheral blood leucocytes we performed FACS-Analysis using anti-CD11a, CD18, and 
CD62L monoclonal antibody. No significant changes in the expression of these molecules 
were observed during BD. The expression of adhesion molecules on circulating leucocytes 
was also not affected in animals receiving dopamine during the BD period (data not shown).




The present study demonstrates that dopamine in a clinically relevant dosage reduces 
monocyte infiltration in renal tissue of brain death donors irrespective if the treatment started 
before or after brain death induction. This protective effect is partly mediated by improving 
MAP during BD. In addition dopamine seems to have a direct anti-inflammatory effect 
mediated via D-receptor stimulation.  
 
Brain death is considered to be an important alloantigen-independent risk factor in 
transplantation [25-27], as it is associated with a rapid up-regulation of inflammatory 
mediators and consequently with mononuclear cell infiltration in end-organs [28, 29] [30, 31]. 
It thus seems that allografts obtained from brain-dead donors are more immunogenic 
compared to grafts obtained from living donors [32].  
A major problem during brain death is the occurrence of hypotension. This in turn leads to 
hypoperfusion of organs, tissue ischemia and consequently  to generation of reactive oxygen 
species (ROS) [27, 33]. Blood pressure stabilization to physiological values seems therefore 
to be auspicious in preventing tissue injury in BD donors before organ procurement. We have 
recently demonstrated in an animal model, that dopamine treatment during brain death 
improves renal perfusion [19]. A correlation between hemodynamic stabilization and reduced 
renal inflammation has also been demonstrated by other groups [2, 27, 30, 34]. The finding 
that the beneficial effects of dopamine on MAP and monocyte infiltration were abrogated 
when blood pressure lowering substances were applied to brain death rats, are in line with 
these studies. It is therefore tempting to postulate that the anti-inflammatory effect of 
dopamine is largely mediated by improving hemodynamics. There are however, several 
arguments against this assumption. Firstly, dopamine pretreatment reduced monocyte 
infiltration although MAP was not influenced during brain death. Secondly, D-receptor 
antagonists abrogate the anti-inflammatory effect of dopamine without changing its blood 
pressure stabilising properties. Thirdly, application of a D-receptor agonist reduced monocyte 
infiltration, but it did not improve MAP during BD.   
 
Our results indicate that dopaminergic/adrenergic receptor-antagonists inhibit the anti-
inflammatory response mediated by dopamine in kidneys of brain-dead donors. While 
adrenergic receptors most likely exert a beneficial effect on hemodynamic stabilization, 
D1/D2 receptors inhibit monocyte infiltration independent of hemodynamic effects. D1/D2-
antagonists do not influence renal perfusion as demonstrated by Asico et al. [22]. It must be 
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stressed however that D1/D2 receptor stimulation itself not necessarily results in an anti-
inflammatory effect, since application of pergolide in the face of adrenergic receptor blockade 
did not affect BD induced monocyte infiltration. Thus, pergolide and dopamine do not display 
completely similar effects in this regard. Although it is unclear from our data what the 
underlying mechanism for this discrepancy might be, additional anti-inflammatory effects 
mediated by dopamine and not by pergolide must be considered. Inhibition of IL-8 production 
by dopamine [17] is a plausible explanation and needs to be investigated in future studies. 
It also needs to be discussed if the anti-inflammatory effect of dopamine is due to changes in 
renal tissue or if it is due to changes in monocyte behaviour. Previously, we already have 
shown that the expression of adhesion molecules in kidneys of BD rats is inhibited by 
dopamine treatment [19]. In the present study we show that neither BD nor dopamine 
treatment during BD changes the expression of CD11a/CD18 and CD62L on circulating 
mononuclear cells. Nevertheless, we can not rule out that dopamine treatment also influences 
the inflammatory properties of monocytes. Several studies indeed indicate that 
catecholamines have the propensity to inhibit TNFα and NO production in monocytes [35-40] 
[41] [42]. 
An increasing number of studies have suggested the involvement of heme oxygenase 1 (HO-
1) in the regulation of inflammation [43-46]. This is largely mediated by carbon monoxide 
(CO), a by-product of heme catabolism [44]. In BD animals renal HO-1 was significantly 
upregulated. These findings were unexpected since in these animals monocyte infiltration was 
much higher than in ventilated non BD rats. Similar to dopamine, pergolide also abrogated the 
upregulation of HO-1. HO-1 expression was comparable in pergolide and adrenergic receptor 
blocker treated rats as in untreated BD animals.  
 
The findings on HO-1 seem to be in conflict with previous data reported by our group, 
showing that HO-1 expression was upregulated by dopamine [16]. It must be stressed 
however that in vitro induction of HO-1 was strictly dependent on the pro-oxidative effects of 
dopamine. Moreover, dopamine mediated HO-1 mRNA and protein expression required a 
longer period of time than the 3 hrs of dopamine infusion used in the present study. Since 
HO-1 expression is upregulated during cellular stress, e.g. ischemia, it is conceivable, that 
upregulation of HO-1 during BD was related to the hemodynamic instability of the donor rats. 
This is in line with the finding that upregulation of HO-1 was abrogated in dopamine treated 
BD rats. However, also in pergolide treated rats hemodynamic instability occurred during BD 
and this was not reflected by an increased HO-1 mRNA expression. In addition, pergolide 
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treatment together with adrenergic receptor blockers, increased HO-1 expression to the extent 
of that observed in untreated BD rats. Thus, neither the involvement of D-receptor stimulation 
nor the effects of hemodynamic destabilisation on HO-1 expression can unambiguously be 
demonstrated in this study.  Nevertheless, or results imply that the anti-inflammatory effect of 
dopamine is not mediated by HO-1.  
 
In conclusion, we demonstrate that although hemodynamic stabilisation is beneficial to limit 
BD induced inflammation, the anti-inflammatory effect of dopamine involves more than just 
blood pressure stabilisation. Activation of D1/D2 receptors and even non-receptor mediated 
effects of dopamine might collectively contribute to the anti-inflammatory effect of dopamine 
in BD donors.  
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Backround Brain death is associated with tissue inflammation. Since dopamine treatment of 
brain dead donor rats reduces renal monocyte infiltration, we tested if this treatment affects 
renal function and inflammation in recipients.  
Methods Brain death was induced in F344 rats and was maintained for 6 hrs in all 
experiments. Dopamine was given for 6 (DA 6) or 3 hours (DA 3) from the onset of brain 
death on. Ventilated non brain dead (NBD) and brain dead (BD) animals served as controls. 
Kidneys were transplanted into bilaterally nephrectomized LEW recipients. Serum creatinine 
(s-crea) was measured and leukocyte infiltration was assessed 10 days after transplantation. 
Results One day after transplantation s-crea was significantly reduced in recipients that 
received a renal allograft from dopamine treated BD or from NBD rats compared to BD 
vehicle (P<0.05). 10 days after transplantation, the number of infiltrating monocytes was 
significantly lower in grafts obtained from dopamine treated and from NBD rats (P<0.05). A 
reduced infiltration in these grafts was confirmed by Banff 97 classification. CINC1 and IL-6 
mRNA expression were reduced in DA rats compared to BD controls. No difference for 
MCP-1 and IL-10 were found. 









Although brain death is considered to be an important cause of pre-transplantation allograft 
injury, the majority of renal allografts are still retrieved from deceased donors. Therefore, 
understanding the mechanisms causing tissue injury in BD donors and investigating possible 
strategies to overcome or prevent these harmful processes in BD are essential. Since brain 
death promotes inflammation in end-organs, affects hormone regulation and hemodynamic 
stability, it is generally accepted that this conditions severely influences organ quality [1-3]. 
Brain death seems to be associated with a worse ischemia/reperfusion injury after 
transplantation [4], although in large animals this could not be demonstrated [5, 6]. In the 
sequel of brain death a rapid up-regulation of inflammatory mediators like IL-6 and TNFα 
occurs [7-10]. This might in turn result in the upregulation of an array of genes including 
selectins, fibrinogen and KIM-1 [11]. Brain death is considered to be a risk factor for organ 
dysfunction [12, 13] and may accelerate acute rejection episodes [14-16].  
Because damaging process in organ allografts already occurs during brain death, donor 
treatment might represent a genuine approach to improve organ quality. Several experimental 
studies have emphasized the applicability of this approach and unambiguously demonstrated 
its benefit on transplantation outcome. The use of agents that induce endogenous HO-1 
expression [17] or the use of anti-inflammatory agents [18], i.e. P-selectin glycoprotein ligand 
(sPSGL) or steroids, seems to be promising in this regard.  
In two retrospective clinical studies, Schnuelle et al. [19, 20] demonstrated that dopamine 
treatment of brain dead donors have a beneficial effect on delayed-graft function and long-
term renal allograft survival. The favourable effect of donor dopamine treatment might be 
related to its anti-inflammatory properties, since dopamine inhibits the production of 
chemokines in renal tubular epithelial and endothelial cells [21]. In addition, dopamine 
treatment of brain dead rats reduces monocyte infiltration and also significantly improves 
mean arterial pressure and organ perfusion [22, 23]. Since clinical studies have shown that 
donor dopamine treatment positively affects delayed graft function and acute rejection, the 
present study was conducted to address if dopamine treatment of brain dead donor rats can 
influence early renal function and renal inflammation after transplantation. To this end, we 
harvested renal allograft from brain dead Fisher rats and transplanted these in Lewis 
recipients. Renal function and histology were assessed in both the donor and the recipient. 
 





Inbred male Lewis (LEW, RT11) and Fisher (F344, RT11vr) rats weighing 200 to 250 g were 
obtained from Charles River (Sulzfeld, Germany). Animals were kept under standard 
conditions and fed standard rodent chow and water ad libitum. All procedures were performed 
according to the Guide for the Care and Use of Laboratory Animals published by the National 
Academy of Sciences and were approved by the local authorities (RP Karlsruhe, AZ 35–
9185.81/27/04). 
 
Experimental Protocol  
Before induction of brain death, donor animals were anesthetized with ketamine (Ketanest, 
Pfizer, Karlsruhe, Germany, 100 mg/kg intraperitoneally) and xylazine (Rompun, BayerVital, 
Leverkusen, Germany, 6 mg/kg intraperitoneally) and placed on a heating table to keep their 
body temperature constant. A 3F Fogarty catheter was inserted epidural in an occipital burr 
hole and gradually inflated during 1 minute with 200 µL of saline. The state of brain death 
was verified by the occurrence of autonomic storm, the absence of corneal reflexes and by an 
apnoea test. All animals were mechanically ventilated by a tracheostoma with a rodent 
ventilator (Ugo Basile, Comerio, Italy). Systemic blood pressure (mean arterial pressure 
[MAP], mm HG) was continuously measured (6 hrs) in the donors by a femoral arterial 
catheter (Statham pressure transducer P23Db and a Gould pressure processor, FMI, Ober-
Beerbach, Germany). Anesthetized, non brain-dead ventilated donor animals served as 
controls. Recipients were anesthetized with enflurane (Ethrane; Aca Mueller/Adag Pharma, 
Gottmadingen, Germany). Experiments were performed in the allogeneic Fisher-Lewis rat 
model. Animals were divided into 5 groups. Donor animals were treated intravenously by 
microinjection pumps (CMA/100, CMA/ Microdialysis, Sweden) according to the following 
scheme: 
Group 1: Fisher donor rats were ventilated and treated intravenously with NaCl 0.9% for 6 
hrs (non brain death (NBD) group).  
Group 2: Brain death was induced in Fisher donor rats. BD lasted for 6 hrs; the animals were 
ventilated and treated with NaCl 0.9% (brain death (BD) group). 
Group 3: Brain death was induced in Fisher donor rats. BD lasted for 6 hrs; the animals were 
ventilated and treated with NaCl 0.9% and HES (hydroxy ethyl starch) to normalize blood 
pressure (brain death normotensive (BD-normot) group). 
Group 4: Brain death was induced in Fisher donor rats. BD lasted for 6 hrs; the animals were 
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ventilated and treated for 3 hrs with 10 µg/min/kg dopamine [23] (dopamine treated group 
(DA 3)). 
Group 5: Brain death was induced in Fisher donor rats. BD lasted for 6 hrs; the animals were 
ventilated and treated for 6 hrs with 10 µg/min/kg dopamine (dopamine treated group (DA 
6)).  
Infusion of dopamine and control solutions started at the beginning of brain death induction. 
In each group, the kidney was harvested after 6 hours,  flushed with 1 ml of cold UW solution 
and transplanted in allogeneic bilateral nephrectomized Lewis rats. The transplantation was 
performed as previously published [24-26]. No immunosuppression was administered. Each 
group consisted of a minimum of six animals. 
 
Renal function 
Renal function was assessed both in donors and recipients by serum creatinine. In the 
recipients serum creatinine was measured on days 0, 1, 3, 5, 8 and 10 after transplantation, 
while in the donors serum creatinine was measured before induction of brain death and at the 
end of the brain death period. 
 
Immunohistochemistry 
Renal grafts were harvested 10 days after transplantation. The upper pole of the kidney was 
frozen in liquid nitrogen, and the remaining part fixed in 10% buffered formalin solution. 
Serial sections (4 µm) of paraffin embedded tissue were fixed in 10% neutral buffered 
formalin for immunohistochemical staining. The sections were extensively washed with 
phosphate-buffered saline (PBS) and subsequently treated with 3% hydrogen peroxide. 
Endogenous biotin acivity was blocked using the Avidin blocking kit, (Vector, Burlingame, 
CA). Monocytes and macrophages were detected by ED1 (monoclonal mouse anti-rat, 
(Linaris Biologische Produkte GmbH, Germany) and by major histocompatibility complex 
(MHC) class II expression (F-17–23–2, monoclonal mouse anti-rat, Linaris). Incubations of 
Primary and secondary antibodies were sequentially applied and to the sections for 1 hr. After 
each incubation step the sections were extensively washed with PBS. Standard avidin-biotin 
complex staining was performed according to the manufacturer’s instructions (ABC kit, 
Vector). After addition of 3,3' diaminobenzidine substrate and washing the sections were 
counterstained with hematoxylin. Evaluation of ED1 and MHC class II positive cells was 
performed in a blinded fashion at 400× magnification. At least six animals per group and 20 
fields per section were analysed. 




Paraffin sections were stained with hematoxylin-eosin, periodic acid-Schiff, and trichrome. A 
minimum of 20 microscopic fields per graft were assessed. Histologic grading was performed 
according to the Banff ’97 classification [27]. Sections were blindly evaluated and graded by 
a renal pathologist (R.W.). Histologic evaluation and grading included transplant 
glomerulopathy, tubulointerstitial fibrosis, tubular atrophy, and vasculopathy. The histologic 
grading scale was from 0 to 3 (0=not present, 1=mild alteration, 2=moderate alteration, and 
3=severe alteration). 
 
Histomorphometric analysis  
Hematoxylin-eosin stained sections were used to determine glomerular size.  
The glomerular volume (Vg) was calculated from the mean planar area of glomeruli of which 
the glomerular tuft and the macula densa could be seen. At least ten glomeruli per section 
were evaluated. Mean glomerular area (Ag) was estimated by the surface calculating tool of 
analySIS. Volume was calculated according to the Weibel and Gomez method [28, 29]: 
 
Vg = Ag3/2*ß/d  
 
in which the shape coefficient of the sphere (ß) is 1.38 and the size distribution of the 
glomeruli (d) is 1,01 representing the size assuming a 10% coefficient of variation of the 
caliper diameter. 
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Light cycler polymerase chain reaction 
Grafts from ventilated non BD-, NaCl treated and dopamine treated BD rats were investigated 
10 days after transplantation. Snap-frozen tissue samples were homogenized using a Polytron 
homogenizer (IKA Labortechnik/Fischer Scientific). 500 ng of total RNA was reversed 
transcribed into cDNA according to the manufacturer’s instructions, using the 1st Strand 
cDNA Synthesis Kit. cDNA was diluted in 20 µl DEPC-treated water and stored at -80°C 
until use. Specific DNA standards were generated by PCR amplification of cDNA, 
purification of the amplified products, and quantification by spectrophotometry. Light cycler 
PCR of cDNA specimen and DNA standards were conducted in a total volume of 25 µl, 
containing 2 µl FastStart DNA Master SYBR GreenI, 10 pMol of each forward and reverse 
primer and 2mMgCl2. Primer sequences were as follows: Cytokine Induced Neutrophil 
Chemoattractant 1 (CINC-1) (forward: "AGT TTG AAG GTG ATG CCG C 3", reverse: 
5`GGA CAC CCT TTA GCA TCT TTT G 3`), Interleucin 6 (IL6) (forward: 5` GAT ACC 
ACC CAC AAC AGA CCA G 3', reverse: 5` GCC ATT GCA CAA CTC TTT TCT C 3'), 
Macrophage Chemoattractant Protein 1 (MCP-1) (forward: 5`CAG ATG CAG TTA ATG 
CCC CA 3`, reverse: 5`CCT GCT GCT GGT GAT TCT CTT 3`) and Interleucin 10 (IL10) 
(forward: 5`TAC CTG GTA GAA GTG ATG CCC C 3`, reverse: 5`AAT CGA TGA CAG 
CGT CGC A 3`). The amplification profile consisted of 2 minutes at 50°C and 5 minutes at 
95°C followed by 45 cycles of amplification, each cycle consisting of denaturation at 95°C 
for 15 seconds, annealing for 20 seconds at 55°C and extension for 30 seconds at 72°C. 
Standard curves were generated in all experiments. PCR efficiency was assessed from the 
slopes of the standard curves and was found to be between 90% and 100%. Linearity of the 
assay could be demonstrated by serial dilution of all standards and cDNA. All samples were 
normalized for an equal expression of GAPDH.  
 
Statistical Analysis  
Numerical data are expressed as mean ± standard deviation. For immunohistological 
parameters, renal function, PCR-analysis and histomorphometric analysis statistical analysis 
was performed using the Kruskal-Wallis test with option for multiple comparisons 
(StatsDirect 2.2.8, Aswell, UK). For analysis of the blood pressure data two-way ANOVA 
was applied. For analysis of light microscopy, Fisher’s exact test was used. For survival 
analysis, Kaplan-Meier, Logrank and Wilcoxon tests were applied. A P- value of less than 
0.05 was considered as significant. 




Influence of dopamine on mean arterial pressure and renal function in the donor 
Brain death induced profound hemodynamic alterations, which were characterized by an 
initial increase in mean arterial blood pressure (MAP), followed by sharp decline leading to 
persistent hypotension. Although in non BD animals MAP gradually declined during 6 hrs of 
ventilation, there was a significant difference in MAP observed between BD and NBD in the 
first 3 hrs (Fig 1 A).  
 
Fig 1 A: BD vehicle (open squares) in comparison to NBD group (black line). Although in 
non BD animals MAP gradually declined during 6 hrs of ventilation, there was a significant 
difference in MAP observed between BD and NBD in the first 3 hrs. The results are expressed 
as MAP (mmHg) of at least 4 animals in each group.  
 
 
MAP in BD animals was completely normalized by installation of dopamine during this 
period or by infusion with HES (BD-normot). Cessation of dopamine infusion slightly 
decreased MAP compared to animals that were continuously treated with dopamine over the 
whole brain death period (Fig 1 B, C).  
 




Fig. 1 B: Hemodynamic changes in BD donor rats. MAP was recorded as described in the 
method section. Dopamine treatment during BD (closed circles) significantly improved MAP 
compared to NaCl treated BD rats (DA6 vs BD, P<0.05). After cessation of dopamine 
treatment (DA3, grey triangles) MAP was not different from the NaCl treated BD rats (open 
squares). The results are expressed as MAP (mmHg) of at least 4 animals in each group.  
 
 
Fig. 1 C: BD vehicle (open squares) in comparison to BD normotensive group (closed 
triangle). HES-infusion stabilizised blood pressure during BD. The results are expressed as 
MAP (mmHg) of at least 4 animals in each group.  
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Serum creatinine increased during BD in all donors. However, this was not in a pathological 
range. The rise in serum creatinine was not specific for BD as it also occurred in ventilated 
not BD donors. Serum creatinine was not significantly influenced influenced by dopamine in 
the BD donors. (Fig. 1 D).  
 
Fig. 1 D: Serum creatinine (mg/dl) before and 6 hours after brain death induction in brain 
death donor rats or before and 6 hours after intubation in the living controls (NBD). Serum 
creatinine levels increased during 6 hours in all groups significantly. (NBD, t=0 vs t=6: 
*P<0.05; BD, t=0 vs t=6: $P<0.01; BD-normot, t=0 vs t=6: &P<0.01; DA3, t=0 vs t=6: 
#P<0.01; DA6, t=0 vs T=6: §P<0.01). 
Each group consisted of 5 to 7 animals. Data are shown as means ± standard deviation. 
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Donor dopamine treatment is associated with a better renal function in recipients 
The rise in serum creatinine one day after transplantation was significantly less in dopamine 
treated and NBD groups compared to vehicle treated BD rats (1.7 ± 0.9 vs 0.8 ± 0.4 (DA3) 
and 0.8±0.2 (DA6), vehicle treated vs dopamine treated BD animals P<0.05). Although there 
was also a trend for better renal function at day 3 and 5 after transplantation this did not 
reached statistical significance due to the large standard deviation in the BD group. Serum 
creatinine in recipients which received a graft from dopamine treated brain dead donors did 
not significantly differ from that of recipients receiving a renal allograft from NBD animals 
(0.8 ± 0.5). Recipients receiving a graft from BD donors that were treated with HES showed a 
tendency for a decreased serum creatinine, but this was not statistical significant (1.7± 0.9 vs 
1.0 ± 0.6, BD vs BD-normot, P=NS) (Fig. 2). 
 
Fig. 2 A: Serum creatinine (mg/dl) on day 0, 1, 3, 5, 8 and 10 after transplantation. 
Dopamine treatment in brain dead donors significantly improved renal function in the 
recipients when compared to BD (BD vs DA3 and DA6, *P<0.05). Each group consisted of 5 
to 7 animals. Data are shown as means ± standard deviation. 




Fig. 2 B: The normotensive BD group showed a tendency for reduced serum creatinine, but 




Light microscopic analysis according to the Banff 97 classification  revealed a higher tubulitis 
and interstitial inflammation score in renal allografts obtained from BD animals (BD/BD-
normot. vs NBD: P<0.05, table 1). Tubulitis and interstitial inflammation was reduced in the 
DA3 and DA6 treated groups, although in the latter group this did not reach statistical 
significance (vehicle treated vs. dopamine treated (DA3) BD animals: P<0.05, Table 1).  
 
Table 1: Histologic scores 
according to the Banff`97 
classification of allografts 10 
days after transplantation. 
Living (NBD) or brain death 
(BD) donors treated with 
saline or with HAES 
respectively (BD-norm). In 
addition two groups of brain 
dead donors were treated with 
dopamine over 3 (DA3) and 6 
hours (DA6) after onset of brain death. The results are expressed as number of animals with a 
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particular Banff´97 score; in parentheses, the proportion of animals with this score in each 
group is calculated and expressed as %. NBD and DA3 had significant less mononuclear cell 
interstitial inflammation and tubulitis (P<0.05). i, mononuclear cell interstitial inflammation; 
t, tubulitis; v, intimal arteritis. 
 
 
Donor dopamine treatment is associated with a reduction of monocyte infiltration in the 
recipient’s graft 
In accordance to the Banff classification, the number of ED1 positive monocytes in renal 
allografts obtained from BD animals was significantly higher than in that obtained from NBD 
animals (39 ± 7 vs. 28 ± 5 ED1 positive cells, BD vs. NBD animals, P<0.01) Donor dopamine 
treatment significantly reduced the number of ED1 positive monocytes (39 ± 7 vs. 28 ± 6 






























Fig. 3 A: Analysis of ED-1 positive cells in renal allografts. Living donors (NBD) and brain 
death donors (BD) were treated with saline. Brain death donors of group 4 and 5 were 
treated additionally with dopamine over 3 or 6 hours from the onset of brain death. Renal 
allografts were transplanted into Lewis recipients. 10 days after transplantation the 
transplanted grafts were collected and analyzed. The number of ED1 positive cells was 
reduced in the grafts from DA 3 (28±6) and DA 6 (30±5) donors compared to BD vehicles 
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(39±7) (DA vs BD, P< 0.05) 
The results are expressed as mean number of positive cells per field of view ± standard 
deviation. At least 120 fields of view were analysed comprising 6 to 7 animals per group. 









Fig. 3 B: Representive immunohistological staining for ED1+ cells in renal allografts 
collected 10 days after transplantation. ED1 expression obtained from NDB, BD, DA3 and 
DA 6 is depicted. Original magnification: 400x. 
 
 
Cytokine expression in the grafts 10 days after transplantation 
To investigate if the reduced renal inflammation in allografts obtained from dopamine treated 
BD animals was associated with a change in cytokine expression, IL-6, IL-10, MCP-1 and 
CINC-1 mRNA expression was assessed in these grafts. Although there was a tendency that 
IL-6 mRNA was decreased in renal allografts in the DA3 group, this did not reach statistical 
significance (IL-6/GAPDH ratio: 9 ± 5 vs. 4 ± 2, vehicle vs. dopamine (DA3) treated BD 
animals, P=0.06) (Fig. 4A). Likewise, MCP-1 mRNA expression between the groups was not 
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significant (MCP-1/GAPDH ratio: 2406 ± 210 vs. 2003 ± 726, vehicle vs. dopamine (data not 
shown)). Also the increased IL10 mRNA expression in the dopamine treated group did not 
reach statistical significance (IL10/ GAPDH ratio: 116 ± 25 vs. 131 ± 58, vehicle vs. 
dopamine (data not shown)). In contrast, CINC-1 mRNA expression was significantly 
decreased in the DA3 treated group (CINC-1/GAPDH ratio: 80 ± 25 vs. 34 ± 15, vehicle vs. 
dopamine (DA3) treated BD animals, P<0.05). CINC-1 mRNA expression in this group was 
similar to that of the NBD group (CINC-1/GAPDH ratio: 38 ± 35) (Fig 4B).   
 
Fig. 4 A 
 
Fig. 4 Quantitative PCR-Analysis for IL6 (A) and CINC-1 (B) gene expression in grafts of 
ventilated non BD (NBD), NaCl treated brain death (BD) and dopamine treated brain death 
(DA3) animals 10 days after transplantation. The results are expressed as mean CINC1/S16 
and IL6/S16 ratio ± SD. In each group kidneys from 4 animals were 
analysed. CINC-1: BD vs DA, 80±25 vs 34±15, P<0.05.  
IL6: BD vs DA, 9±5 vs 4±2, P=NS; BD vs NBD, 9±5 vs 4±2, P=NS. 








10 days after transplantation the glomerular volume was significant larger in grafts from BD 
compared to grafts from NBD donors (BD vs NBD: 1.9 ± 0.2 vs. 1.54 ±0.2 µm³, P<0.01). 
Donor dopamine treatment did not significantly influence glomerular volume (vehicle treated 
vs. dopamine treated BD animals: 1.9 ± 0.2 vs. 1.76 ± 0.3 (DA3) and 1.73 ± 0.3 (DA6), Fig. 
5).  




Fig. 5: Enlargement of glomerular volume. Ten days after transplantation glomerular volume 
in grafts from NBD animals was significantly less compared to grafts from BD rats (BD vs 
NBD: P<0.05). 
 




Brain death is considered to be an important donor associated risk factor which influences 
organ quality [13, 15, 30]. Deterioration of organ quality might be related to a number of 
processes that can occur during brain death, e.g. hypotension, reduced organ perfusion, 
hypothermia, coagulopathies and inflammation in end-organs [1] [31, 32]. Since dopamine 
pre-treatment in donors reduces inflammation in donor renal allografts [22, 33], we 
investigated in the present study graft outcome in recipients that received renal allografts from 
dopamine treated brain dead donors. The main findings of this study are the following. Firstly, 
donor dopamine treatment improved mean arterial blood pressure, but it did not significantly 
influence renal function in the donor before harvesting. Secondly, renal function in the 
recipient was significantly better in rats receiving a renal allograft obtained from a dopamine 
treated brain dead donor if compared to the control rats. Thirdly, 10 days after transplantation 
the number of graft infiltrating cells was significantly reduced in the donor dopamine treated 
group. This was reflected by lower Banff 97 tubilitis and interstitial inflammation score.  
 
In brain dead donors serum creatinine was slightly increased at the end of the brain dead 
period. This was however not related to brain death as it was also observed in ventilated non 
brain dead rats. Although dopamine increases renal blood flow, glomerular filtration rate, 
urinary sodium and water excretion [34], serum creatinine did not change in the brain dead 
donors in our study. In comparison to grafts obtained from untreated BD donors, 
renalfunction was significantly better 1 day after transplantation when the grafts were 
obtained from dopamine treated BD or NBD donors. Because renal function recovered in 
time, statistical significance disappeared, but there wasstill a trend for a better renal function 
in these two groups. We have choosen to include a group in which dopamine infusion was 
stopped after 3 hours to investigate if 3 hours of donor dopamine treatment was sufficient to 
influence renal function and inflammation in the recipient. We could already show that 3 
hours of dopamine treatment was able to reduce infiltration of inflammation cells in BD donor 
kidneys significantly [23]. Indeed, 3 hours of dopamine treatment was sufficient to influence 
renal function and inflammation in the recipient beneficial. In the human situation, early renal 
function has an enduring effect on the subsequent course after renal transplantation [35-37] 
and predicts 5 years graft survival [38]. Improvement in early renal function by donor 
dopamine treatment might therefore significantly improve long term graft prognosis [19, 20]. 
It was surprising that some of the beneficial effects were observed for both dopamine 
treatment regimes, e.g. renal function in the recipients, while others, e.g. inflammation, were 
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only seen for 3 hours or 6 hours of dopamine infusion. Nevertheless if both dopamine groups 
were pooled, statistical analysis also revealed that in the dopamine treated groups there was 
significant less inflammation compared to the untreated BD group.  
 
Hypotension might lead to reduced organ perfusion, tissue ischemia, and generation of 
reactive oxygen species (ROS) [13, 39]. Thus, hemodynamic stabilization before organ 
procurement can improve organ quality by limiting ROS mediated organ damage. Moreover, 
hemodynamic stabilization seems to reduce organ inflammation during brain death as was 
previously demonstrated [33] [11-13, 40]. Although it can be argued that improvement in 
blood pressure and organ perfusion largely contribute to the beneficial effect of donor 
dopamine treatment, in the present study we also demonstrate that other strategies to improve 
blood pressure during brain death were less effective or did not influence graft infiltration as 
assessed by serum creatinine and Banff classification respectively. Banff 97 classification 
revealed lower tubulitis and interstitial inflammation scores in the donor dopamine treated 
groups compared to the BD normotensive group. These findings therefore indicate that donor 
dopamine treatment can affect transplantation outcome independently of its hemodynamic 
effect. This is in accordance to the clinical findings of Schnuelle et al [41], demonstrating that 
the favourable effect of donor dopamine treatment was independent of donor blood pressure.  
 
If improved hemodynamics only partially can explain the beneficial effect of donor dopamine 
treatment, then what other factors might be considered? Firstly, dopamine might ameliorate 
ischemia/reperfusion (I/R) injury as we have previously demonstrated [42]. Secondly, 
dopamine treatment reduces monocyte infiltration during brain death and hence reduces the 
number of passenger leukocyte in the graft [22, 33]. These mobile cells migrate out of the 
graft into secondary lymphoid organs where they can initiate an immune response against the 
graft [43]. While amelioration of I/R injury reduces renal inflammation and improves renal 
function, reduction in the number of passenger leukocytes might decrease the response to the 
allogeneic kidney [44].  Because tubulitis is a hallmark for acute interstitial rejection after 
renal transplantation in men, our data indicate that dopamine  given to the donor  may 
influence the process leading to  acute interstitial rejection, as evidenced by a lower Banff 
tubulitis score. 
 
Nevertheless, it remains to be further elucidated how exactly dopamine influences renal 
inflammation per se. Previously, we have shown that dopamine has the propensity to inhibit 
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IL-8 production in renal tubular epithelial cells [21, 45]. In the present study, we now 
demonstrate that CINC-1 expression, a rat homologue for IL-8, is significantly reduced 10 
days after transplantation in the donor dopamine treated group. We also observed a tendency 
for reduced IL6 and MCP-1 expression in these grafts. A reduction in chemokine expression 
might also contribute to a decreased inflammatory response in the transplanted renal allograft.  
 
Glomerular enlargement in renal allografts is associated with inferior graft survival [28] and 
with renal allograft dysfunction [46]. Ten days after transplantation glomerular size was 
significantly larger in grafts obtained from brain dead rats. Donor dopamine treatment 
however did not significantly influence glomerular size in these grafts.  
 
The present study demonstrates that donor dopamine treatment during brain death may 
provide a benefit on graft survival both by improving early renal function after transplantation 
and by reducing renal inflammation. Our data are in concordance to the clinical studies of 
Schnuelle et al [20] who found that donor dopamine usage was associated with improved 
renal function, less acute rejection episodes and improved long term graft survival. These data 
are therefore justifying a prospective randomized multi-centre study on the beneficial effects 
of donor dopamine usage in terms of transplantation outcome. 
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Background In the present study we used the Brown-Norway (BN) to Lewis model as a 
model for acute rejection, to test the hypothesis that dopamine (DA) treatment of BN donors 
significantly reduces the inflammatory response after renal transplantation.  
Methods BN and Lewis rats (Isograft-controls) were treated for 24 hours with DA 
(5µg/kg/min) or NaCl (0.9%) respectively. After 24 hours of cold storage in UW solution, 
renal allografts were orthotopically transplanted into Lewis recipients. All recipients received 
immunosuppression until they were sacrificed. Allografts were harvested 1, 3, 5 and 10 days 
after transplantation and analyzed by light microscopy, immunohistochemistry (CD3, MHC 
class II, ED1, P-selectin and ICAM-1) and by RNase protection assay for cytokine mRNA. 
Results Ten days after transplantation Banff tubulitis scores were significantly lower in DA- 
than in NaCl treated allografts. No significant differences were found in Banff interstitial 
infiltration scores. The numbers of MHC class II + and CD3 + cells were significantly 
decreased in DA treated animals, as assessed by immunohistochemistry. No differences were 
found in the number of ED1 +, P-Selectin +, ICAM-1 + cells. The expression of Ltα -, TNFα -
, IL-1ß - and IL-2 mRNA was significantly reduced in DA treated animals.  
Conclusion Our data indicate that donor DA treatment significantly inhibits tubulitis in renal 
allografts subjected to prolonged cold preservation. A reduced number of infiltrating MHC 
class II +  and CD3+ cells together with decreased cytokine expression could diminish renal 
scarring, reduce allograft immunogenicity and hence improve transplantation outcome. 
 




Organs retrieved from post-mortem donors are subjected to pre-transplantation injury. In 
particular, processes associated with brain death [1], e.g. hemodynamic instability [2] and 
systemic release of cytokines, may damage allografts already before organ retrieval. 
Prolonged cold ischemia and reperfusion injury [3] will cause additional damage, hence 
making the allografts more immunogenic [4]. The adverse effects of brain death and 
prolonged cold preservation on organ quality, might explain why long-term graft survival of 
renal allografts retrieved from living donors is superior to that of post-mortem donors, despite 
better HLA matching of the latter [5].  
Recently, we have demonstrated in two independent studies that donor catecholamine usage 
improves initial renal function after transplantation, reduces the incidence of acute allograft 
rejection episodes and improves transplantation outcome [6, 7]. Although the underlying 
molecular mechanisms remain to be fully delineated, catecholamines inhibit the expression of 
inflammatory molecules such as intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule (VCAM) [8]. As a consequence of cold preservation and reperfusion 
these molecules are strongly upregulated on endothelial cells [9-12]. Moreover, dopamine is 
able to induce the expression of heme oxygenase-1 (HO-1) in renal tubular epithelial and 
endothelial cells [13, 14]. The protective role of HO-1 in ischemia/ reperfusion (I/R) injury 
and transplantation models has unambiguously been demonstrated [15]. We could also show 
that catecholamines can prevent cold preservation injury of endothelial cells in vitro [16] and 
in vivo [17] in a redox dependent manner [16]. 
Acute renal allograft rejection is characterized by the infiltration of mononuclear cells in renal 
tubules, thereby disrupting the tubular basement membrane [18-20]. Recruitment of 
leukocytes involves a complex interplay between a series of molecules expressed on the 
leukocyte and endothelial surface [21, 22]. Chemokines, a large superfamily of structurally 
related cytokines, have been shown to selectively promote the rapid adhesion, chemotaxis, 
and activation of specific leukocyte subpopulations [23, 24]. 
We have previously demonstrated the beneficial effect of donor dopamine (DA) treatment in 
the Fisher to Lewis transplantation model [25]. Although this model is widely used to study 
chronic rejection, the pitfall however, is that transplantation is performed over a minor MHC 
barrier, hardly resembling the clinical situation in which HLA mismatches between donor and 
recipient may occur. 
It is thus far unknown, if donor dopamine pretreatment also has a beneficial effect in a MHC 
discordant donor recipient combination. To address this question, we used in the present study 
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the Brown Norway (BN) to Lewis transplantation model, in which acute rejection is known to 
occur [26]. In particular, we addressed in this model if donor DA pre-treatment can influence 
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MATERIALS AND METHODS  
Animals 
Inbred male Brown Norway (BN, RT1n) and Lewis (LEW, RT11) rats, weighting 200 to 300 
g, were obtained from Harlan-Winkelmann (Borchen, Germany). Animals were kept under 
standard conditions and fed standard rodent chow and water ad libitum. All procedures were 
performed according to the Guide for the Care and Use of Laboratory Animals published by 
the National Academy of Sciences and were approved by the local authorities 
(Regierungspräsidium Karlsruhe AZ: 35-9185.81/166/01). 
 
Surgical procedures and Experimental Protocol 
Surgical procedures in donor rats were performed under general anesthesia with ketamine 
(100 mg/kg body weight administered intraperitoneally) (Ketanest; CP-Pharma, Burgdorf, 
Germany) and xylazine (5 mg/kg body weight administered intraperitoneally) (Rompun; 
Bayer, Leverkusen, Germany). Preconditioning of donor rats was performed using an osmotic 
minipump (Alzet2ML1) implanted subcutaneously in the animal’s back. A catheter attached 
to the pump was placed in the left femoral vein and the pretreatment solution (DA 5 
µg/min/kg or NaCl 0.9%) was administered for 24 hr (mean pumping rate, 10 µl/hr). The 
animals were kept in single cages and had free access to water and chow. The kidneys were 
explanted and briefly flushed with chilled (4°C) University of Wisconsin (UW) solution 
followed by cold preservation for 24 hours at 4°C in UW solution. The renal allografts were 
orthotopically transplanted into Lewis recipients. Recipients were anesthetized with enflurane 
(Ethrane; Aca Mueller/Adag Pharma, Gottmadingen, Germany). A daily injection of 
cyclosporine A (2.5 mg/kg), starting on the day of transplantation, was administered until the 
recipients were sacrificed. Animals were sacrificed at various time points (1, 3, 5 and 10 days 
after transplantation). Hereafter, renal allografts were collected and processed for further 
analysis.  
 
Experimental groups  
The influence of donor DA preconditioning was studied in the Brown Norway - Lewis rat 
model using the following groups:  
Group 1: Allograft-dopamine (ALLO-DA), i.e. Brown Norway donors preconditioned with 
dopamine as described above, the kidneys were transplanted into Lewis recipients.  
Group 2: Allograft-NaCl (ALLO-NACL), i.e. Brown Norway donors treated with NaCl 
0.9%, the kidneys were transplanted into Lewis recipients.  
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In addition, a Lewis to Lewis transplantation was included as isograft control (Group 3), i.e. 
Lewis donors treated with NaCl 0.9%, the kidneys were transplanted into Lewis recipients 
(ISO-NACL). For all groups a minimum of 8 animals were used. The dose of dopamine was 
based on previous studies of Gottmann et al [17].  
 
Histology 
Histological examination was performed by hematoxylin-eosin (HE) staining and light 
microscopy on renal allografts explanted 1, 3, 5 and10 days after transplantation. The tissues 
were fixed in 10% buffered formalin and subsequently embedded in paraffin.  Sections (3-5 
µm) were stained with HE using standard procedures. A minimum of 20 microscopic fields 
per graft were analyzed. Histologic grading was performed according to the Banff ’97 
classification (21) that reported on renal transplant biopsies. Sections were evaluated and 
graded in a blinded fashion by a renal pathologist (R.W.). Histologic evaluation and grading 
included transplant mononuclear cell interstitial inflammation, tubulitis, and intimal arteritis. 
The histologic grading scale was from 0 to 3 (0=not present, 1=mild alteration, 2=moderate 
alteration, and 3=severe alteration). 
 
Immunohistology 
Immunohistology on paraffin sections (3-5µm) was performed using the avidin-biotinylated 
peroxidase immunolabeling method (Vector Laboratories, Inc., Burlingame, CA), with 
monoclonal antibodies directed against monocytes (ED1), MHC class II (F17-23-2) , CD3 
(G4.18) ( Serotec Ltd., Kidlington, England) and ICAM-1(1A29)(BD PharMingen) and with 
polyclonal antibodies directed against P-selectin(M-20)(Santa Cruz Biotechnology, INC.). 
Negative control included omission of primary antibody. The sections were blocked with 10% 
horse serum and incubated overnight with primary antibodies in a dilution of 1:200 (ED1), 
1:100 (MHC II) , 1:50 (CD3), 1:200 (ICAM-1),1:100 (P-Selectin). Hereafter the sections 
were extensively washed followed by incubation for 45 minutes with biotinylated horse–anti-
mouse antibody (1:200). All other procedures were similar as described in the manual of the 
avidin-biotinylated peroxidase immunolabeling kit. Hematoxylin was used to counterstain the 
sections. The results are expressed as Box and Plot graphs. More than 20 fields of view per 
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RNase protection assay  
Total RNA was isolated from iso- and allografts harvested 1, 3 and 5 days after 
transplantation by means of TRIzol Reagent (Invitrogen, Karlsruhe, Germany). RNA was 
precipitated with isopropanol, washed with 70 % ethanol and stored at -80°C until use. RNase 
protection assays were performed with 10µg of RNA according to the manufacturer’s 
instruction (BD Biosciences, Heidelberg, Germany) using the multi-probe template set rCK-1 
and rCK-3. The gels were dried and subjected to autoradiography. RNA transcripts were 
identified by appropriate length of the protected fragments. In each template set, 
housekeeping genes (L32 and GAPDH) were included to control for equal loading. The 




For comparison of means among different groups in immunohistochemistry and RNase 
protection assay, ANOVA with analysis option for multiple comparisons was applied. For 
analysis of light microscopy, Cochran-Armitage Trend test was applied. Data of RNase 
protection assay are shown as means ± SD. Statistical significance was defined as P<0.05.  




Light microscopy  
Five and 10 days after transplantation renal allo- and isografts were analyzed by light 
microscopy. In the Lewis isograft, there was a weak inflammatory response detected at day 5 
(data not shown) and 10 after transplantation (Table 1). This was in large contrast to the BN 
allografts harvested 10 days after transplantation, Banff scores for interstitial infiltration and 
tubulitis were much higher in these allografts. Although there was a tendency that interstitial 
infiltration was slightly decreased in dopamine treated BN allografts (Banff i2: 3/8, Banff i3: 
5/8 compared to Banff i2: 1/8, Banff i3: 7/8 for dopamine vs NaCl treated BN allografts), this 
did not reach statistical significance. Acute rejection, as defined by Banff tubulitis scores, was 
significantly more severe in NaCl than in dopamine treated BN allografs.  In the former 7 out 
of 8 grafts had a Banff t3 score, in the later Banff t3 was not observed. 3 out of 8 grafts 
showed mild tubulitis (Banff t1) and in 5 out of 8 grafts had moderate tubulitis (Banff t2) in 
the dopamine treated group. In general, vasculitis was not observed in this model (Table 1).  
 
BANFF ALLO-DOP 
(n = 8) 
ALLO-NACL 
(n = 8) 
ISO-NACL 
(n = 8) 
i 0 0 (0) 0 (0) 0 (0) 
i 1 0 (0) 0 (0) 0 (0) 
i 2 3 ( 37.5) 1 (12.5) 8 (100) 
i3 5 (62.5) 7 (87.5) 0 (0) 
t 0 0 (0) 0 (0) 0 (0) 
t 1 3 (37.5) 0 (0) 7 (87.5) 
t 2 5 (62.5) 1 (12.5) 1 (12.5) 
t 3 0 (0) 7 (87.5) 0 (0) 
v 0 8 (100) 8 (100) 8 (100) 
v 1 0 (0) 0 (0) 0 (0) 
v 2 0 (0) 0 (0) 0 (0) 
v 3 0 (0) 0 (0) 0 (0) 
 
Table 1 Histologic scores according to the Banff’97 classification of allografts pretreated 
with isotonic saline ( ALLO-NACL, n=8) or dopamine (ALLO-DOP, n=8), or of isografts 
pretreated with isotonic saline (ISO-NACL, n=8) 10 days after transplantation. The results 
are expressed as number of animals with a particular Banff97 score; in parentheses, the 
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proportion of animals with this score in each group is calculated and expressed as %. 
Allografts pretreated with dopamine (ALLO-DOP) had significant less tubulitis (P<0.05). 




We next investigated by means of immunohistochemistry if the mononuclear cell infiltration 
was quantitatively and qualitatively different between dopamine and NaCl pretreated BN 
allografts. 10 days after transplantation the numbers of MHC class II + and CD3+ cells was 
significantly reduced in dopamine compared to NaCl treated BN allografts (Fig1.A). No 
significant difference was found in the number of ED1+ cells between the ALLO-DA and 
ALLO-NACL groups (Fig1. A). Similar results were found when the allografts were collected 
5 days after transplantation (Fig1. B). When renal allografts were collected 1 and 3 days after 
transplantation, no differences were found in the number of infiltrated MHC class II + cells 
between both groups (Fig1. C).  
 
Fig. 1 A 
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Fig. 1 C 
 
Fig. 1: Recruitment of leukocytes in renal allografts. Analysis of the mononuclear cell 
infiltrate was performed by immunohistochemistry for ED1+, MHC class II+ and CD3+ 
cells. BN donors were treated with dopamine (ALLO-DA) or NaCl (ALLO-NACL) as 
described. Renal allografts and isografts (ISO-NACL) were transplanted into Lewis recipient. 
Ten (A) and five (B) days after transplantation the transplanted grafts were collected and 
analyzed. The expression of MHC class II+ cells in allo- and isografts was also assessed at 
earlier time-points (C). The results are expressed as Boxplot graphs. More than 20 fields of 
view per section were evaluated at 400x magnification. Statistical difference in mean number 
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Three, 5 and 10 days after transplantation, the number of infiltrated ED1+, MHC class II+ and 
CD3+ cells was significantly lower in the Lewis isografts than in the BN allografts. A 
representative staining for MHC class II and CD3 in the ALLO-DA and ALLO-NACL groups 
is depicted in Fig 2. No statistically significant difference of P-Selectin and ICAM-1 
expression was observed between the ALLO-DA and ALLO-NACL group (data not shown)  
 
Fig. 2: Representative immunohistological staining for MHC class II+ and CD3+ cells in 
renal allografts collected 10 days after transplantation. MHC class II expression (A and B) 
and CD3 expression (C and D) obtained from NaCl (A and C) and dopamine (B and  D) 
treated BN donors is depicted. Original magnification: 400x.  
 
 
Cytokine mRNA expression  
To test if cytokine mRNA expression was also changed in dopamine treated BN allografts, we 
performed RNAse protection assays.  Renal iso- and allografts were harvested 1, 3 and 5 days 
after transplantation. The expression of TGFβ1, 2 and 3 increased in time but was not 
different between dopamine and NaCl treated allografts (data not shown). Similarly the 
mRNA expression of IL-1β, IL-2, LTα and TNFα increased over time (Fig 3). This was more 
pronounced in the ALLO-NACL group for all of these cytokines. Five days after 
transplantation IL-1β, IL-2, LTα and TNFα mRNA were significantly higher in the ALLO-
NACL group than in the ALLO-DA group.  




Fig. 3 A 
 
Fig. 3 B  
 
Fig. 3: Analysis of cytokine mRNA expression in renal allo and isografts. RNase protection 
assay was performed as described in the materials and method section. Statistical significant 
differences between the ALLO-DA and ALLO-NACL groups were found for IL-1β, (A), IL-2 
(B), Ltα (C) and TNFα (D). A total of 4 different RNA preparations in each group were 
performed. Reproducibility of the RPA was tested 3 times using the same RNA preparation 
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and was found to be highly reproducible. The results are expressed as relative cytokine mRNA 




Fig. 3 C 
 
Fig. 3 D 
 
 




In the present study we addressed the question if donor dopamine pretreatment influences the 
inflammatory response in transplanted renal allografts subjected to prolonged cold storage. 
This was studied in the MHC discordant BN to Lewis transplantation model, in which acute 
rejection is known to occur [26]. The major findings of this study are summarized as follows. 
First, donor dopamine treatment significantly reduced the severity of acute rejection as 
indicated by lower Banff tubulitis scores. Second, donor dopamine treatment significantly 
reduced the number of infiltrating MHC class II + and CD3 + cells, analyzed 5 and 10 days 
after transplantation. Third, donor dopamine treatment significantly reduced LTα-, TNFα-, 
IL1β and IL2 mRNA expression in transplanted renal allografts. These data confirm and 
extend our previous findings in the Fischer to Lewis transplantation model. 
There is ample evidence that prolonged cold storage of solid organ allografts is associated 
with poor transplantation outcome [27-30]. Several explanations might account for this 
association. In vitro studies using cultured endothelial and tubular epithelial cells have 
demonstrated that prolonged cold storage results in severe cell damage [31, 32]. Similar 
findings have also been shown for renal allografts subjected to hypothermic preservation [33]. 
Delayed graft function might occur as a consequence of tubular damage and contributes to the 
development of chronic rejection and late graft loss [6, 7]. In addition, vascular damage might 
result in impairment of the endothelial barrier function and hence form tissue edema, capillary 
occlusion and secondary ischemia [34-36]. Moreover, cold induced vascular damage may also 
promote leukocyte adherence as has been suggested by the studies of Clavien et al [37, 38]. 
Cytoprotection during cold preservation is therefore of utmost importance. Previously, we 
have shown that dopamine is able to protect endothelial and tubular cells against cold 
preservation injury [11]. The cytoprotective effect of dopamine might thus underlie, at least 
partially, the beneficial effect of donor dopamine treatment in the BN to Lewis model.  
Apart from its direct protective role against cold preservation injury, dopamine is able to 
induce HO-1 in endothelial and tubular cells [13].Via HO-1 catalyzed degradation of heme 
into bilirubin and carbon monoxide, HO-1 is believed to convey protection against I/R injury 
[15, 39]. Tullius et al showed that donor pretreatment with cobalt protoporphyrin 6-24 h 
before organ harvesting up-regulates HO-1 in the grafts and prevents both short-term and 
long-term I/R injury in renal allografts [40]. The mechanism by which HO-1 modulates 
inflammation is, however, not yet completely understood. It has been postulated that this 
might be mediated by down-regulation of adhesion molecules [41-43] and by the production 
of the anti-inflammatory cytokine IL-10 [44]. Although we have previously demonstrated, 
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that DA treatment inhibits the expression of ICAM-1 and VCAM on endothelial cells [11], it 
remains to be established if this underlies the reduction of infiltrated mononuclear cells found 
in transplanted renal allografts obtained from DA treated donors. No mRNA expression for 
IL-10 was observed in renal iso - and allografts (data not shown).  
Although we have previously demonstrated that DA treatment of Fischer rats with brain death 
resulted in upregulation of HO-1 [45], in the present study we did not observe HO-1 induction 
in cold preserved renal allografts (data not shown).This discrepancy might be explained by 
the fact that in the former study no cold preservation was performed. Cold preservation might 
cause proteolysis and might affect RNA stability [16]. We speculate therefore that HO-1 was 
not critically involved in the protective effect of DA treatment found in this study.  
Cold preservation and I/R injury are known to be associated with inflammation. In the present 
study we show that donor dopamine pretreatment of BN donors reduces LTα, TNFα, IL-1ß 
and IL-2, mRNA expression in the renal allografts after transplantation. These cytokines 
participate in immune activation and thus may perpetuate renal inflammation and renal 
scarring. Monocytes and T-cells both produce significant amounts of TNFα which, in turn, 
up-regulates adhesion molecules on endothelium [46-48], hence further promoting renal 
inflammation in this model. A reduced expression of IL-2 in dopamine treated BN allografts 
might be due to the reduced number of infiltrated CD3 + cells in these grafts. Acute rejection 
is mediated by T-cells that recognize and destroy tubular cells in an allo-antigen dependent 
fashion [18-20, 49, 50]. Interestingly, the severity of tubulitis, as defined by the Banff’97 
classification, was significantly decreased in DA treated allografts. This is in accordance with 
the clinical studies of Schnuelle et al [7] from our group who found that donor DA usage was 
associated with less acute rejection episodes. 
In conclusion our results suggest that pre-treatment of organ donors with dopamine is a 
meaningful pre-conditioning strategy, as it reduces tubulitis. A clinical prospective 
randomized study to investigate if donor pretreatment with dopamine reduces acute rejection 
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Background Carbon monoxide releasing molecules (CORMs) are a novel class of 
compounds that can deliver CO to tissues in a controllable fashion. Here, we investigated the 
beneficial effect of CORM-3 on cold preservation-induced injury in vitro and its influence 
on vascular function and on neo-intima formation after aorta transplantation. 
Methods Abdominal aortas from Lewis rats were cold preserved in UW with or without 
CORM-3. Hereafter, whole mount staining for CD31, acetylcholine mediated vasorelaxation 
and transplantation in syngenic rats were performed.   
Results During cold preservation CORM-3 protected human umbilical vein endothelial cells 
(HUVEC) against necrosis and prevented denudation and intercellular gap formation in 
isolated rat abdominal aortas. Cold-preservation resulted in a profound loss of acetylcholine-
mediated vasorelaxation of aorta segments, which was restored when CORM-3 was added 
during preservation. Vasorelaxation in response to the NO-donor SNP was not changed by 
cold preservation and not influenced by CORM-3. Cold preservation of aortic isografts in 
UW for 24 hrs resulted in a significant increase in fibrotic adventitial remodeling and neo-
intima formation two months after transplantation compared with isografts that were not 
subjected to cold preservation. Presence of CORM-3 during cold preservation significantly 
reduced fibrotic adventitial remodeling and neo-intima formation.  
Conclusions Our study demonstrates that addition of CORM-3 to the UW preservation 
solution prevents endothelial damage, thereby limiting vascular loss of function directly after 
cold preservation. Because CORM-3 also prevents intimal hyperplasia, our findings might 
offer better approaches for organ preservation in order to limit transplant loss resulting from 
chronic allograft vasculopathy.   
  




Allocation of organ allografts has become possible by adequate improvements in organ 
preservation. In solid organ transplantation, static cold storage is the most widely used 
modality for preserving cadaveric organs prior to transplantation. However, with increasing 
cold ischemia time, organ quality and function are deteriorating as a consequence of a series 
of events such as oxidative stress, intracellular iron release and calcium overload [1-3]. Cold 
preservation injury is a major cause of pre-tranplantation injury of allografts and is 
significantly associated with initial organ non-function and late transplant loss [4-7]. 
Chronic transplant vasculopathy remains a leading cause for chronic organ loss after 
transplantation [8, 9](8, 9) and is characterized by a prominent vascular remodeling in which 
the luminal areas of arteries become obliterated due to occlusive intimal hyperplasia. 
Although the etiology of intimal hyperplasia is not well delineated, pre-transplantation injury 
is recognised as an important cause for this complication. In addition, as donor allogeneic 
endothelial cells of the graft’s vasculature are under continuous attack of the recipient’s 
immune system, an imbalance between damage and repair might contribute to intimal 
hyperplasie [10]. Participation of migrating smooth muscle cells and proliferation of 
recruited progenitor cells in neo-intima formation have been well documented in primarily 
experimental models of transplant vasculopathy [11, 12].  
Carbon monoxide (CO), an endogenous by-product of heme catalysis by heme oxygenase 
(HO), has a diversity of cell biological functions, including cGMP-mediated vasorelaxation 
[13, 14], inhibition of cell proliferation [15, 16], inhibition of apoptosis [17] and suppression 
of inflammation [18]. Based on these effects it is not surprising that CO has the propensity to 
protect different organs against ischemia and reperfusion injury [19-23]. It has been 
postulated that the mechanism by which CO mediates organ protection is, amongst others, 
via the induction of HO-1 and activation of the p38 MAPK signalling pathway [13, 17, 18]. 
In most organ transplantation studies involving CO, delivery of CO was performed by 
ventilation [19, 21, 22]. As a novel approach to deliver CO, Motterlini et al has reported on a 
new class of compounds, termed CO-releasing molecules (CORMs), which are able to 
release CO in a controllable manner under physiological conditions [24]. In particular, the 
fully water-soluble CORM-3 (tricarbonylchloro(glyconato)ruthenium(II)) and CORM-A1 
(sodium boranocarbonate), can be potentially used as additives in preservation solutions [23, 
25]. 
Because endothelial cell injury is a prominent feature of cold ischemia (26), strategies to 
mitigate cold preservation injury might be a beneficial approach to limit intimal hyperplasia. 
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In the present study we employed in vitro and in vivo models to test the hypothesis that addition 
of CORM-3 to the preservation solution protects vascular endothelial cells from damage, and 
hence better preserves vascular function during cold storage. In addition, we hypothesize that a 
reduction in endothelial cell damage will significantly decrease neo-intima formation. To study 
the effect of CORM-3 on neo-intima formation developing as a result of solely cold 
preservation-induced endothelial damage and not alloantigen-driven immunity, a syngeneic 
Lewis-to-Lewis aortic transplant model was used.  
 
  





Endothelial cell growth medium MedKIT, Phenol-red free medium (Promocell, Heidelberg, 
Germany), PBS (Invitrogen, Karlsruhe, Germany), Fetal bovine serum (FBS) Gold (PAA 
laboratories GmbH, Pasching, Austria), Tripsin/EDTA solution, DMSO, TritonX-100, 
tricarbonyldichlororuthenium(II) dimer ([Ru(CO)3Cl2]2), glycine, sodium ethoxide,  
tetrahydrofuran, acetylcholine (Ach), sodium nitroprusside (SNP), 1H-[1, 2, 4]oxadiazolo[4, 
3-alpha]quinoxalin-1-one (ODQ)  (Sigma, St. Louis, MO), Bovine Serum Albumin 
(SERVA, Heidelberg, Germany), 37% formaldehyde (Mallinckrodt Baker, Deventer, 
Holland). 
 
Synthesis of tricarbonylchloro(glycinato)ruthenium(II) 
Tricarbonylchloro(glycinato)ruthenium(II) ([Ru(CO)3Cl(glycinate)]) was synthesized from a 
commercially available compound, tricarbonyldichlororuthenium(II) dimer ([Ru(CO)3Cl2]2). 
Briefly, [Ru(CO)3Cl2]2 (0.5 g) and glycine (0.151 g) were placed under nitrogen in a round-
bottomed flask. Methanol (291 ml) and sodium ethoxide (0.132 g) were added and the 
reaction was allowed to continue under stirring for 18 hrs at room temperature. The solvent 
was then removed under pressure and the yellow residue re-dissolved in tetrahydrofuran 
(THF). The yellow solution was evaporated down to give a pale yellow solid (yield 92-96%) 
and was aliquoted and stored in closed vials at room temperature. For each experiment 
CORM-3 was dissolved freshly in PBS. 
 
Cell culture and CORM-3 treatment  
Human umbilical vein endothelial cells (HUVECs) were isolated from fresh umbilical cords 
and cultured as described previously [2]. The cells were seeded in 24-well plates in basal 
endothelial medium supplemented with 10% FBS and essential growth factors until they 
formed a confluent monolayer. Cells were then stored for 24 hrs at 4oC in UW solution in the 
presence or absence of different concentrations CORM-3. In some experiments cells were 
pre-treated with different concentrations CORM-3 for 6 hrs prior to cold preservation. 
Thereafter the cells were washed two times with PBS and stored for 24 hrs at 4°C in UW 
solution. Directly after cold preservation cell damage was assessed by measuring lactate 
dehydrogenase (LDH) (Roche Diagnostics, Mannheim, Germany) activity in the 
supernatants as recommended by the manufacturer. Only HUVECs from passage 2 to 6 were 
used in this study. 




Inbred male Lewis rats weighing 250 to 300g were obtained from Charles River (Sulzfeld, 
Germany). Animals were kept under standard conditions and fed standard rodent chow and 
water ad libitum. All procedures were performed according to the Guide for the Care and 
Use of Laboratory Animals published by the National Academy of Sciences and were 
approved by the local authorities (RP Karlsruhe, AZ 35–9185.81/91/07).  
 
Vascular function 
Abdominal aortas were explanted from Lewis rat, and either directly used for subsequent 
experiments or stored for 24hrs at 4oC in UW solution in the presence or absence of 50µM 
CORM-3. Vascular function measurement was performed according to previous description 
by Witte et al (27). Briefly, the aortas were prepared and cleaned from peri-adventitial fat 
and surrounding connective tissues, cut transversely into 2-mm width rings and mounted on 
stainless steel hooks in individual organ baths containing Krebs-Henseleit solution (NaCl 
119mM, KCl 3mM, MgCl2 1.2mM, CaCl2 1.5mM, NaH2PO4 1.2mM, NaHCO3 20mM, 
Glucose 10mM) at 37 ºC and aerated with 75% N2, 20% O2 and 5% CO2. The aortic rings 
were placed under a resting tension of 15mN and equilibrated for 60 minutes. During this 
period, tension was periodically adjusted to the desired level and the Krebs-Henseleit 
solution was changed regularly. The aortic rings were challenged by increasing 
concentration of KCl (20mM, 30mM, 40mM, 50mM, 80mM and 124mM) in Krebs solution 
in which NaCl was substituted by KCl to keep osmolarity constant. The maximal contraction 
forces to potassium chloride were determined according to the responsive curves. Aortic 
rings were washed until resting tension was obtained again. KCl 50mM was used to pre-
contract the aortic rings until a stable plateau was reached. Concentration response curves 
were constructed by cumulatively adding acetylcholine (Ach, 10-9-10-4 M) or sodium 
nitroprusside (SNP, 10-9-10-5 M) to elicit the endothelium-dependent (Ach) or endothelium-
independent (SNP) relaxations. The data were monitored and analysed using the LabView-
based software previously developed in our lab. 
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Whole mount aorta staining 
To study the effect of cold preservation with or without CORM-3 on endothelial integrity, 
freshly isolated or cold preserved aortas were transversely cut into 3-4 mm segments and 
fixed at room temperature for 2hrs in freshly prepared 4% formaldehyde. After fixation, the 
segments were washed three times with PBS for 1hr. Subsequently, the segments were 
incubated for 20 min in PBS containing 1% BSA, 0.5% Triton and 5% rabbit serum, 
followed by extensively washing with PBS. The segments were incubated overnight at 4oC 
with a purified mouse anti-rat CD31 antibody (BD Pharmingen, Heidelberg, Germany) 
diluted in PBS. After washing, rabbit anti-mouse Texas-red conjugated IgG was added for 
2hrs. Nuclei were visualized by addition of TOTO3 10 min before mounting. Finally, the 
aorta segments were longitudinally cut into halves and mounted onto glass slides in 50% 
glycerol/PBS, with the luminal side up. Fluorescence was analysed by confocal microscopy 




Aorta transplantation was performed in the syngeneic Lewis-to-Lewis strain combination. 
All animals received ketamine and xylazine (100 and 6 mg/kg i.p., respectively) as an 
anesthetic agent. A 1.5 cm long segment of the descending abdominal aorta was removed, 
thoroughly flushed with UW-solution, and either directly transplanted or subjected to 24 hrs 
of cold preservation in UW solution. Aortas were preserved in UW solution at 4°C either in 
the presence or absence of 50µM of CORM-3. Aortas were orthotopically transplanted in 
between the renal arteries and bifurcation. The cranial anastomosis was made as close to the 
renal arteries as technically possible to minimize diameter difference. End-to-end 
anastomoses were performed using 9-0 nylon suture. Total warm ischemic time in the 
recipient was consistently ~30 minutes. Grafts were harvested 2 months after transplantation 
and then processed for histological analysis as described below.  
 
Quantification of intimal hyperplasia 
Two months after transplantation, aorta grafts from each groups (n=5) were harvested, fixed 
in 4% formaldehyde and mounted in paraffin. Sections were cut (5 µm) from at least 4 
different segments of the graft, deparaffinized according to standard methods and stained 
with hematoxylin/eosin.  
The degree of intimal hyperplasia was assessed by morphometric analysis and expressed as 
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mean ratio of the intima surface (µm2) / intima + media surface (µm2) in different sections 
and segments of the transplanted aorta.  
 
Statistical analysis 
Data are presented as mean ± SD or mean ± SEM for the indicated number of separate 
experiments. All analyses were based on more than three independent experiments. 
Differences between groups were determined by Student’s t test. A p-value of less than 0.05 
was considered statistically significant.  
 
 




CORM-3 protects endothelial cells against cold preservation damage 
Addition of CORM-3 to the preservation solution protected endothelial cells against cold 
preservation damage in all HUVEC cell lines tested (n=5). The protective effect of CORM-3 
was detected over a wide concentration range of CORM-3, with maximal inhibition already 
occurring at 16 µM (Figure 1A, black circles). To test if the protective effect of CORM-3 
was dependent on the release of CO, similar concentrations of degassed CORM-3 were 
tested in parallel experiments. In contrast to CORM-3, degassed CORM-3 did not inhibit 
LDH release during cold preservation (CORM-3 vs. degassed CORM3, p<0.01) (Figure 1A, 
filled squares). We also investigated if CORM-3 pre-treatment of HUVEC, followed by cold 
preservation in the absence of CORM-3, was equally effective as addition of CORM-3 only 
during cold preservation. Pre-treatment was less effective compared to treatment during cold 
preservation, as significant higher concentrations of CORM-3 were required for protection 
(Figure 1A, open triangles). The protective effect of CORM-3 was largely independent of 
cGMP, since inhibition of guanylate cyclase (GC) by ODQ only marginally, though 
significantly, inhibited the protective effect of CORM-3 on cold preservation-induced 
endothelial damage (Figure 1B). Similar results were observed with higher concentrations of 


























degassed CORM-3 in CP
 
Fig. 1 A 
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Fig.1 CORM-3 treatment renders vascular endothelial cells resistance to hypothermia-
induced cell damage. (Fig. 1 A) Different concentrations of CORM-3 were either added to 
HUVECs during cold preservation (filled circles) or HUVECs were pre-treated for 6 hrs 
with similar concentrations of CORM-3 before cold preservation was started (open 
triangles). A degassed solution of CORM-3 (filled squares) tested in the same concentration 
range was used to demonstrate that the effect was mediated by CO release. (Fig. 1 B) 
HUVECs were pre-treated for 1 hr with 50µM of ODQ or left untreated. Hereafter the cells 
were subjected to 24 hrs of cold preservation in the presence or absence of 50µM of CORM-
3. ODQ was also present during cold preservation in the pre-treated group. Directly after 
cold storage cell damage was assessed by LDH-release in the supernatants. All experimental 
conditions were performed in triplicate. The results of a representative experiment are 
expressed as mean ± SD. A total of 5 experiments were performed. (* p<0.01)  
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CORM-3 maintains vascular function after cold preservation ex vivo 
We next assessed if also the endothelium in aorta segments were damaged during cold 
preservation and to what extent this was prevented by the addition of CORM-3 to the 
preservation solution. The endothelium in aorta segments that were stored for 24 hrs at 4oC 
was dramatically changed compared with freshly isolated, no cold preserved aorta’s. After 
cold preservation, endothelial cells displayed an irregular morphology with large 
intercellular gaps between the cells and in the majority of cells nuclear condensation and 
fragmentation occurred (Figure 2, left panel). In contrast, when CORM-3 was added during 
cold preservation cell morphology, CD31 expression and nuclear appearance (Figure 2, 
middle panel) was similar to that observed in freshly isolated aorta’s that were not subjected 
to cold preservation (Figure 2, right panel).  
 
Fig. 2: Influence of CORM-3 on endothelial integrity in aorta segments subjected to cold 
preservation. Whole mount staining for CD31 (red) was performed as described in the 
Material and Method section. Nuclear staining is depicted in blue. Note that in the aorta 
segments subjected to cold preservation in the absence of CORM-3, endothelial cell 
morphology was irregular with intercellular gaps appearing between adjacent endothelial 
cells. Also in the majority cells nuclear condensation and fragmentation was observed (left 
panel). In contrast, aorta segments to which 50 µM of CORM-3 was added during cold 
preservation (middle panel) appeared to be similar to freshly isolated aorta segments not 
subjected to cold preservation (right panel). Original magnification: 200x.                    
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Since endothelial NO production plays a critical role in vasorelaxation (27, 28), we 
subsequently tested if this response was impaired by cold preservation. Endothelial 
dysfunction was defined as a reduction in maximal relaxation in response to acetylcholine. 
After 24hrs of cold preservation, vascular function was markedly impaired, as indicated by a 
significant reduction in maximal relaxation compared to freshly isolated aortas (aortas with 
cold preservation vs freshly isolated aortas: 24.6± 10.7% vs 54.1± 2.6%, p<0.01). When 
CORM-3 (50µM) was added during cold preservation, endothelial function was significantly 
improved, reaching a maximal relaxation of 43.4±7.6% (cold preservation-CORM-3 vs cold 
preservation, p<0.05) (Figure 3A). In contrast to the endothelium-dependent vasorelaxation 
response, the endothelium-independent response was not affected by cold preservation. 
Addition of the NO donor sodium nitroprusside (SNP) to the organ bath resulted in a dose-
dependent vasorelaxation. No significant differences between the two treatment groups and 
freshly isolated aorta’s were observed (Figure 3B), indicating that, unlike endothelial cell 

































































Fig. 3 A                                                                     Fig .3 B 
Fig. 3: Administration of CORM-3 during cold preservation improves vascular function. 
Isolated abdominal rat aortas were subjected to cold preservation (CP) for 24 hrs in the 
presence (CP-CORM-3, black circles) or absence (CP, open circles) of 50µM of CORM-3. 
Naïve aortas without cold preservation (black diamonds) were included as control. (A) 
Endothelial function was analysed by endothelium-dependent relaxation in response to 
cumulative acetylcholine concentrations (10-9-10-4 M). (B) Smooth muscle cell function was 
demonstrated by endothelium-independent relaxation in response to cumulative sodium 
nitroprusside concentrations (10-9-10-5 M).  
Five animals were included in each group and 16-18 aortic segments of each group were 
analysed. The results were expressed as mean maximal relaxation ± SEM at indicated 
concentration Ach or SNP. (*p<0.05, CP-CORM-3 vs CP).  





CORM-3 suppresses intimal hyperplasia after transplantation 
To demonstrate the influence of cold preservation on vascular remodeling, we performed 
abdominal aorta transplantations in the syngeneic Lewis-to-Lewis rat strain combination. 
Before transplantation, donor aorta grafts were stored for 24 hrs at 4˚C in UW solution with 
or without 50µM CORM-3. When the aortas were harvested two months after 
transplantation, macroscopic inspection consistently revealed massive amounts of fibrous 
tissue surrounding transplants that were preserved at 4°C in the absence of CORM-3 (Figure 
4A, middle panel). In contrast, grafts that were preserved in the presence of CORM-3 did not 
display any signs of adventitial fibrous remodeling (Figure 4A, right panel) resembling the 
naïve aorta of non-transplanted animals (Figure 4A, left panel).  
 
Fig. 4 A 
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Histological analysis revealed that two months after transplantation neo-intima formation 
was marginal in the Lewis-to-Lewis model when no cold preservation was performed (Fig. 
4B, picture to the left). Cold preservation significantly aggravated neo-intima formation 
when the aortas were preserved at 4°C in the absence of CORM-3 (Figure 4B, middle panel), 
while addition of CORM-3 to the preservation solution obviously attenuated neo-intima 
formation (Figure 4B, right panel).  
 
Fig. 4 B 
 
 
Quantitative analyses using computerized morphometry (i.e. determination of the ratio of 
intima surface / media + intimal surface) in different sections and segments of the graft 
revealed that the degree of intimal hyperplasia was significantly reduced in CORM-3- 
treated aorta grafts (cold preservation-CORM-3 vs cold preservation, 0.12±0.01 vs 
0.45±0.04, p<0.01) (Figure 4C).  




Fig. 4 C 
Fig. 4: Addition of CORM-3 during cold preservation inhibits vascular remodeling. (A) 
Syngeneic aorta transplantations were performed as described in the Material and Method 
section. The aortas were subjected to 24 hrs of cold preservation in the absence (CP) or 
presence (CP-CORM-3) of 50µM CORM-3. Two months after transplantation the grafts 
were harvested and macroscopically examined. Note the presence of fibrous tissue 
surrounding the graft (arrow) in the aortas subjected to cold preservation in the absence of 
CORM-3 (middle panel). This was not observed when 50 µM of CORM-3 was added during 
cold preservation (right panel). For comparison an aorta from a naïve non-transplanted rat 
is also depicted (left panel). (B) After macroscopic examination, the grafts were harvested 
and tissue sections were analysed by light microscopy using H&E staining. Representative 
photographs of transplanted grafts not subjected to cold preservation (No CP), subjected to 
cold preservation in the absence (CP) or presence of 50 µM of CORM-3 (CP-CORM-3) are 
depicted. Intimal hyperplasia is shown as the tissue in between the black arrows. Original 
magnification: 200x. (C) Quantitative analysis of intimal hyperplasia. Grafts from group CP 
and CP-CORM-3 were analysed by means of quantitative computerized morphometry. 
Grafts from the No-CP group were not analysed because intima thickening was only 
marginally present and only at the site of anastomosis. The degree of hyperplasia was 
assessed as described in the Materials and Method section. The results are expressed as 
mean ratio [intima surface (µm2) / intima + media surface (µm2)] ± SEM of 5 different 
sections for each group and with n=6 animals in each group. (*p<0.01).  






Chronic allograft vasculopathy (CAV) is a leading cause for late allograft loss after organ 
transplantation [5, 6, 10, 11]. Both prolonged cold ischemia time and immune-mediated 
mechanisms are believed to contribute to CAV. A characteristic finding in CAV is intimal 
hyperplasia, arising from the migration and proliferation of smooth muscle cells (SMC) 
culminating in the formation of an occlusive neo-intima. In the present study we 
hypothesized that prevention of endothelial damage during cold preservation can 
significantly ameliorate intimal hyperplasia. We therefore first analysed if addition of 
CORM-3 to UW preservation solution can protect in vitro cultured HUVECs and aorta 
endothelium from cold preservation injury. Secondly, we assessed to what extent cold 
preservation affects endothelial function, defined as vasorelaxation in response to 
acetylcholine. Finally we addressed if prevention of vascular injury by addition of CORM-3 
during cold preservation reduces intimal hyperplasia after transplantation. To exclude 
alloimmune-mediated mechanisms in the development of intimal hyperplasia, these latter in 
vivo studies were performed in the syngeneic Lewis-to-Lewis aorta transplant model. The 
main findings of our study are the following: CORM-3 protects in vitro cultured HUVECs as 
well as aorta endothelium against cold preservation-induced damage. Cold preservation 
causes impaired endothelial function reflected by a diminished endothelium-dependent but 
not -independent vasorelaxation response. Addition of CORM-3 during cold preservation 
improves vascular function and limits intimal hyperplasia after transplantation. 
 
The finding that CO beneficially affects intimal hyperplasia in an aorta transplantation model 
is in itself not novel as this has already been demonstrated by Otterbein et al [26]. However, 
in their model the recipients were treated, as opposed to our study in which only the graft 
was treated during cold preservation. Moreover recipient treatment was performed by means 
of CO inhalation over the whole observation period, starting directly after transplantation. In 
addition they did not perform cold preservation of the allograft. This is not trivial because 
our data indicate that cold preservation severely damages endothelium in vitro as well as in 
aorta grafts before transplantation. Based on their data it is therefore unclear if CO treatment 
of the recipient is able to prevent intimal hyperplasia in the face of pre-existing vascular 
injury. Our study clearly shows that prevention of endothelial injury during cold preservation 
is very efficacious in limiting intimal hyperplasia in a syngeneic aortic transplant model. We 
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are however aware that a syngeneic donor – recipient combination is not reflecting the 
clinical practice of organ transplantation and that ongoing alloimmune-mediated vascular 
damage is of importance for the development of intimal hyperplasia. Nevertheless, this study 
emphasizes the pivotal role of cold preservation damage on vascular remodeling, and 
suggests that if CO treatment would be implemented in transplantation medicine, it should 
be preferably already start during cold preservation. 
 
Indeed, several studies have shown that application of donor CO treatment can ameliorate 
chronic allograft nephropathy [27] and improve islet allograft survival [28]. In all of these 
studies, however, cold preservation was not performed. Although our data indicate that pre-
treatment with CORM-3 followed by cold preservation in the absence of CORM-3 was to 
some extent protective, much higher concentrations of CORM-3 were required to achieve 
protection. Hence, the beneficial effect of donor CO conditioning might be partly lost upon 
prolonged cold preservation. Addition of CORM-3 to the preservation solution has also been 
studied in heart grafts, but they were not transplanted [25]. After ex vivo reperfusion of these 
grafts, a significant improvement in systolic and diastolic function as well as coronary flow 
was found. Our own data with aorta grafts also show functional improvement after cold 
preservation when CORM-3 was added to the preservation solution. The role of cGMP in 
functional improvement by CORM-3 was not assessed in our study, although in vitro 
experiments revealed that the protective effect of CORM-3 on LDH-release by HUVECs 
was only marginally influenced in the presence of a guanylate cyclase inhibitor.  
 
Vascular remodeling following cold preservation and transplantation was not only restricted 
to intimal hyperplasia, but also the amount of fibrous tissue surrounding the graft was clearly 
increased. Intimal hyperplasia and expansion of the fibrous tissue were both attenuated when 
cold preservation was performed in the presence of CORM-3. This might be related to the 
inhibitory effect of CO on the proliferation of smooth muscle cell [29] and fibroblasts [30]. 
However, as ongoing inflammation might amplify smooth muscle cell proliferation and since 
CO has anti-inflammatory properties, inhibition of inflammation can not be completely 
excluded. Specific immunohistochemisty for various leukocyte subsets was not performed 
since microscopical analysis of H&E stained sections did not reveal a significant amount of 
inflammatory cells in both the CORM-3 treated and non-treated grafts.    
 
In conclusion, our study demonstrates that endothelial damage during cold preservation is an 
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eligible condition for intimal hyperplasia after transplantation and that it can occur 
independently of an anti-donor immune response. Since chronic allograft vasculopathy 
remains a major cause for transplant loss, prevention of vascular injury before organ 
implantation is of utmost importance. This objective can simply be achieved by addition of 
CORM-3 to the preservation solution. Further studies are nevertheless warranted to assess 
the efficacy of this approach for transplantation outcome in vascularized allogeneic solid 
organs.    
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There is general consensus that amongst the renal replacement modalities, renal transplantation is 
the most desirable therapy for patients with end-stage renal failure, as it not only significantly 
improves quality of life but also reduces mortality risk compared to patients on dialysis [1]. Yet, 
the increasing number of patients on the waiting list and the relative stable supply of donors will 
continue to enlarge the negative balance between organ donors and recipients in the coming 
years. Therefore more and more donors that do not fulfil the optimal criteria for organ donation 
are now being used to increase the potential donor pool. The caveat however is, that with the use 
of renal allografts from marginal donors there is in general a higher frequency for delayed graft 
function observed, which might translate in a poorer long-term graft survival [2]. Because 
marginal donors to a large extent will continue to contribute to the donor pool, new concepts are 
warranted to limit organ damage before transplantation and to maintain organ quality.  
 
Brain death - and cold storage associated injury are the leading causes for pre-transplant 
deterioration of organ quality. Inasmuch as brain death can lead to hemodynamic instability [3] 
and promotes a proinflammatory state of the graft [4-7], optimal donor management is of critical 
importance to the success of transplantation. 
 
Static cold storage is routinely used to make organ allocation possible. Extended cold ischemia 
time however affects graft function and graft survival negatively [8-10]. Also static cold storage, 
which was developed in the area of optimal donors, might not be ideal anymore when facing a 
qualitative change of deceased donors. 
 
The studies presented in this thesis were aimed to understand how brain death and cold storage, 
either alone or in combination, influence organ quality or function after transplantation. 
Moreover, attempts were made to reduce pre-transplantation injury through donor or organ pre-
conditioning.  
 
Although there is clear evidence that brain death induces an inflammatory response in a number 
of organs [4-6, 11, 12], little is known about the mechanism by which this is mediated. Because 
vagus nerve activity ceases after brain injury [13, 14], impairment of the cholinergic 
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inflammatory reflex might be a possible explanation for the inflammatory response in end-
organs. Using an animal model we tested in Chapter 2 the hypothesis that brain death induced 
inflammation correlates with autonomic neurological dysfunction and that vagus nerve 
stimulation could attenuate the pro-inflammatory state of organs in brain-dead donors. 
We could demonstrate that heart rate variability (HRV) decreased in brain-dead animals, 
suggesting a decreased vagal tone [15, 16]. In affymetrix chip analysis we could confirm with 
Koodstaal et al. [17, 18] that a number of pro-inflammatory genes are upregulated in the small 
intestine of brain-dead animals. Beyond it we could show that stimulation of the vagus nerve 
could normalize the expression of these genes. Also a number of pro-inflammatory genes, e.g. 
chemokines, adhesion molecules and signalling molecules, which were not influenced by brain 
death, were modulated by vagus nerve stimulation. Systemically we observed a significant 
increase of serum TNFα during the course of brain death, but not in brain-dead animals receiving 
vagus nerve stimulation. Using qPCR we could show that some of the changes in gene expression 
during brain death and intervention were also observed in other organs such as heart, kidney and 
liver. Most interestingly, renal function was clearly better when allografts obtained from brain-
dead animals receiving vagus nerve stimulation were transplanted in syngeneic recipients, 
compared to allografts from brain-dead animals that did not receive vagus nerve stimulation. 
Hence we conclude in Chapter 2 that impairment of the cholinergic inflammatory reflex, at least 
partly, might underlie brain death induced inflammation. 
 
Although static cold storage is the most widely used modality for preserving organs from 
deceased donors, it is also a major cause for pre-transplantation injury of grafts [9, 19-21]. In 
Chapter 3 we addressed to what extent brain death and cold ischemia have a synergistic effect 
on organ damage and tissue inflammation after renal transplantation in rats. We could show that 
cold preservation increases DNA damage in renal tissue before implantation. This is in line with 
other groups showing that prolonged cold ischemia increases apoptosis and necrosis in renal 
tubular cells [22-24]. Salahudeen also reported that prolonged preservation of cadaveric kidneys 
is a significant predictor for graft loss [19, 22]. Our study indicates that brain death augments 
DNA damage when grafts are subsequently subjected to prolonged cold preservation. Brain death 
can lead to hemodynamic instability and therefore to hypoperfusion in the kidney. This may in 
turn make the renal tissue more prone to cold ischemic damage. Ten days after transplantation 
renal inflammation was significantly higher in grafts that were subjected to cold preservation. 
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Brain death aggravated renal inflammation; particularly vasculitis was significantly more severe 
in transplanted grafts from brain-dead animals that were exposed to cold preservation compared 
to cold preserved grafts from the living donors. Sanchez-Fructuoso et al [25] also found that brain 
death is a risk factor for acute vascular rejection, but the role of cold ischemia was not assessed in 
their study. The findings of Simpkins et al [26] suggest that cold ischemia time is not a risk factor 
for acute interstitial rejection when grafts are obtained from living donors. This is not surprising 
because cold ischemia time of grafts from living donors is in general short and transplantation 
outcome is much better compared to organs retrieved from deceased donors. Because cold 
ischemia time didn't exceed 8 hours in the study of Simpkins, while in our study a cold ischemia 
time of study 24 hours was applied, this may explain the different findings between both studies. 
Brain death was associated with papillary necrosis in transplanted grafts, which might be related 
to hypoperfusion of the renal tissue during the state of brain death. Subsequently ischemic 
damage could occur, resulting in papillary necrosis [27, 28]. With exception of VEGF and IL-10 
no significant differences in mRNA expression for cytokines or growth factors in renal tissue 
were found between the groups. VEGF was strongly up-regulated in grafts from brain-dead 
animals compared to grafts from living donors. Since VEGF is up-regulated by hypoxia in a 
variety of organs [29-31], the increased expression might be related to tissue ischemia. Ten days 
after transplantation IL10 expression was still increased in grafts from brain-dead donor rats, 
probably as a response to renal inflammation. In conclusion we demonstrate in Chapter 3 that 
brain death amplifies tissue damage before and after transplantation when renal allografts are 
subjected to prolonged cold ischemia. This once more stresses the importance of minimizing cold 
ischemia time in grafts from deceased donors in order to prevent aggravation of graft injury and 
hence to improve transplantation outcome. 
 
Patients with irreversible brain injury are frequently treated on the intensive care unit with 
catecholamines to stabilize blood pressure [32-35]. Interestingly, the use of catecholamines on 
potential donors significantly influences transplantation outcome [36, 37]. In brain death models 
dopamine application not only improves mean arterial pressure, but also reduces mononuclear 
cell infiltration in the kidney [38]. In Chapter 4 we tested the hypothesis that the anti-
inflammatory effect of dopamine is independent of blood pressure stabilisation. We investigated 
the involvement of α- and β-adrenergic- as well as dopaminergic receptors in this regard.  
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As mentioned above, hypotension during brain death may subsequently lead to hypoperfusion of 
organs, tissue ischemia and consequently to generation of reactive oxygen species [12, 39]. We 
have recently demonstrated in an animal model, that dopamine treatment during brain death 
improves renal perfusion [38]. A correlation between hemodynamic stabilisation and reduced 
renal inflammation has also been demonstrated by other groups [11, 12, 40, 41]. Therefore blood 
pressure stabilization to physiological values seems to be auspicious in preventing tissue injury in 
BD donors before organ procurement. Dopamine applied in a clinically relevant dosage also 
exerts beneficial effects on renal inflammation independently from hemodynamic stabilisation. 
We could show that 24 hours of dopamine pre-treatment (stopping directly before brain death 
induction) reduced monocyte infiltration, although mean arterial pressure was not influenced 
during brain death. Moreover D-receptor antagonists abrogated the anti-inflammatory effect of 
dopamine without changing its blood pressure stabilising properties, whereas application of a D-
receptor agonist reduced monocyte infiltration, but it did not improve mean arterial pressure 
during brain death. Hence dopamine seems to have a direct anti-inflammatory effect mediated via 
D-receptor stimulation.  
In BD animals renal HO-1 was significantly upregulated. Dopamine and the D-receptor agonist 
pergolide abrogated the upregulation of HO-1. The findings on HO-1 seems to be in conflict with 
previous in vitro data reported by our group, showing that HO-1 expression was upregulated by 
dopamine [42]. Since HO-1 expression is upregulated during cellular stress, e.g. ischemia, it is 
conceivable that up-regulation of HO-1 during brain death was related to cellular stress through 
hemodynamic disturbances, hypothermia and coagulopathy [3]. If dopamine reduces cellular 
stress than up-regulation of HO-1 will accordingly not occur. It also must be emphasized that up-
regulation of HO-1 in vitro only occurred at relative high dopamine concentration and was 
clearly dependent on the pro-oxidative properties of dopamine [42]. In vivo these concentrations 
were not reached. In conclusion, we demonstrate in Chapter 4 that hemodynamic stabilisation is 
beneficial to limit BD induced inflammation. Nevertheless, the anti-inflammatory effect of 
dopamine involves more than blood pressure stabilisation. D-receptor stimulation and even non-
receptor mediated effects of dopamine might collectively contribute to the anti-inflammatory 
effect of dopamine in brain dead donors. 
 
Since dopamine treatment reduces the inflammatory response in brain-dead donor animals [38, 
43], we addressed in Chapter 5 if dopamine treatment of brain-dead donor rats can influence 
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early renal function and renal inflammation after transplantation. A main finding of this study is 
that donor dopamine treatment improved renal function in the recipients independently of 
changes of renal function in the donors. In the human transplantation situation, early renal 
function has a beneficial effect on transplantation outcome [8, 44, 45] and predicts 5 years graft 
survival [46]. Improvement in early renal function by donor dopamine treatment might therefore 
significantly improve long term graft prognosis [36, 37]. Ten days after transplantation the 
number of graft infiltrating cells was significantly reduced in the donor dopamine treated group. 
This was reflected by lower Banff 97 tubilitis and interstitial inflammation score. Because 
tubulitis is a hallmark for acute interstitial rejection after renal transplantation in men, our data 
indicate that donor dopamine treatment may influence the process leading to acute interstitial 
rejection. Our findings suggest that dopamine treatment reduces monocyte infiltration during 
brain death and hence reduces the number of passenger leukocyte in the graft [38, 43]. These 
mobile cells migrate out of the graft into secondary lymphoid organs where they can initiate an 
immune response against the graft [47]. A significant reduction in CINC-1 expression, a rat 
homologue for IL-8, might also contribute to a decreased inflammatory response in the 
transplanted renal allograft. Because dopamine also ameliorates ischemia/reperfusion injury [48] 
this could contribute to a reduced inflammation and an improvement of renal function. In 
conclusion we demonstrate in Chapter 5 that donor dopamine treatment during brain death may 
provide a benefit on graft survival both by improving early renal function after transplantation 
and by reducing renal inflammation.  
Donor dopamine treatment has a beneficial effect on transplantation outcome in the Fisher to 
Lewis model. In this model however, donor and recipient only differ in minor histocompatibility 
antigens [49], while in men renal transplantation is in the majority of cases performed across 
major histocompatibility complex barriers. In Chapter 6 we used the MHC discordant Brown 
Norway to Lewis transplantation model, a model in which acute rejection is known to occur [50], 
to address if donor dopamine treatment is also effective in this combination, even when allografts 
are subjected to prolonged cold preservation. One major finding of this study was that donor 
dopamine treatment significantly reduced the severity of acute rejection. This was indicated by 
lower Banff tubulitis scores.  
Cold preservation and ischemia reperfusion injury are known to be associated with inflammation 
[51-54]. We could show that donor dopamine pre-treatment of Brown Norway donors reduces 
LTα, TNFα, IL-1ß and IL-2, mRNA expression in the renal allografts after transplantation. These 
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cytokines might modulate inflammation stimulating monocytes, T-cell proliferation and by 
increasing the expression of adhesion molecules on the endothelium [55-57]. In our study donor 
dopamine treatment significantly reduced the number of infiltrating MHC class II + and CD3 + 
cells, analyzed 5 and 10 days after transplantation. A reduction of IL-2 expression in dopamine 
treated grafts might be due to the reduced number of infiltrated CD3 + cells in the transplanted 
kidneys. Acute rejection is mediated by T-cells that recognize and destroy tubular cells in an allo-
antigen dependent fashion [58-62]. The severity of tubulitis was significantly decreased in 
dopamine treated allografts. This is in accordance with the clinical studies of Schnuelle et al [37] 
who found that donor dopamine usage was associated with less acute rejection episodes. Hence 
we demonstrate in Chapter 6 that donor dopamine treatment improves transplantation outcome 
even when transplantation is performed in MHC discordant donor recipient combinations.  
 
With regard to protection against cold storage induced damage, we also investigated a 
compound belonging to the class of CO-Releasing Molecules (CORM). Apart from its anti-
inflammatory effects [63], [64, 65], CO might protect the endothelium by virtue of its iron 
binding properties. Iron chelators, e.g. defferoxamine, are known to be protective against 
preservation injury [66]. Because cold preservation time is a risk factor for chronic allograft 
vasculopathy [67] it is of utmost importance to protect the endothelium during cold 
preservation. A characteristic hallmark for chronic allograft vasculopathy, a leading cause for 
chronic organ loss after transplantation [36, 68], is intima hyperplasia often leading to vascular 
obliteration. In Chapter 7, we investigated the beneficial effect of CORM-3 on cold 
preservation injury in HUVECs and its influence on vascular remodelling and vascular function 
in a syngeneic rat aorta transplantation model. We could show that CORM-3 protected 
endothelial cells against cold preservation injury via liberation of CO. Cold storage induced 
endothelial denudation and intercellular gap formation in isolated abdominal aortas of rats, 
while this was prevented when CORM-3 was added to the preservation solution. Vascular 
function was significantly impaired after 24 hrs of cold ischemia. This was mediated by 
impairment of endothelial NO production, since vessel relaxation by addition of the NO donor 
SNP was not affected after cold ischemia. Two months after aorta transplantation, intima 
hyperplasia was detected in all grafts, which were subjected to 24 hrs of cold preservation. 
Addition of CORM-3 to UW-solution significantly inhibited intima hyperplasia. In conclusion, 
we demonstrate in Chapter 7 that endothelial damage during cold preservation is an eligible 
Chapter 8 – General Discussion 
 
 168 
condition for intima hyperplasia after transplantation even in the absence of an anti-donor 
immune response. Addition of CORM-3 to UW-solution prevents endothelial damage, 
maintains vascular function and limits intima hyperplasia. Further studies are nevertheless 
warranted to assess the efficacy of this approach for transplantation outcome in vascularized 
allogeneic solid organs. 
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Conclusions and Future Perspectives 
As it is know generally acknowledged that kidney transplants from poorly matched unrelated 
living donors show a better graft survival compared to that from well matched deceased donors 
[69], the concept of reducing pre-transplantation tissue injury as a mean to improve long-term 
allograft survival has received more appreciation in recent years. Both donor brain death and cold 
preservation are major causes of pre-transplantation injury, and hence represent genuine targets 
for the development of new strategies in donor management and organ preservation. 
The studies presented in this thesis not only give more insights on the impact of allo-antigen 
independent factors, i.e. brain death and cold preservation, on transplantation outcome, but also 
show how their negative influence can effectively be diminished by donor pre-conditioning and / 
or changes in cold preservation. The main lessons that should be learned from these studies are 
the following. First, brain death induced inflammation might be linked to impairment of the 
cholinergic inflammatory reflex, a finding that has previously not been recognized. Second, 
donor dopamine pre-conditioning is very effective to improve transplantation outcome. It reduces 
inflammation during brain death, possibly by improving hemodynamics but also because of its 
direct anti-inflammatory effect. Moreover, dopamine pre-treatment seems to protect the allograft 
against cold preservation injury. This is also found in a recently finished prospective randomized 
clinical study on donor dopamine usage, demonstrating that the salutary effect of dopamine on 
delayed graft function is more pronounced when cold ischemia time is long (Schnülle et al, 
unpublished data). Third, brain death and cold preservation are synergistic, i.e. they aggravate 
tissue damage before and after transplantation. Fourth, protection of the endothelium during cold 
preservation might reduce chronic allograft vasculopathy. This could be achieved by 
implementation of CO in preservation solutions.  
 
The main question that I would like to address now is what are the clinical implications of our 
findings and what are the future perspectives for transplantation research.  
Impairment of the vagus nerve has been described in brain-injured patients [13, 14], it is therefore 
conceivable that vagus nerve stimulation during brain death would have a beneficial effect on the 
inflammatory response in end-organs. Although it is tempting to suggest that vagus nerve 
stimulation should be performed in deceased donors, our data are still preliminary and should be 
confirmed in allo-transplantation models. Yet, vagus nerve stimulation already has shown to be 
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an effective activator of the anti-inflammatory pathway in several in vivo models [70-72]. The 
issue of timing and duration of vagus nerve stimulation in the brain death model also needs to be 
addressed.  
 
Our study once more stresses the importance of minimizing cold ischemia time in grafts from 
deceased donors. However, for logistical reasons this can not always be achieved. New strategies 
in donor management and/or organ procurement aimed to minimize pre-transplant injury are 
therefore warranted. Promising prospects might be donor pre-conditioning [36, 37, 68] and 
hypothermic machine perfusion [73, 74]  
 
One of the beneficial effects of donor dopamine usage is clearly related to protection against cold 
preservation injury. This effect is however not receptor mediated and independent of dopamine’s 
blood pressure stabilising properties. Recently we have developed a new dopamine derivative, 
i.e. n-octanoyl-dopamine (NOD) that is devoid of hemodynamic action and shows in vitro a 40 x 
higher efficacy in its protective effect. Due to the fatty acid attached to the amine side chain, 
NOD is highly hydrophobic, making its clinical application difficult. This problem can be 
overcome by dissolving NOD in so called semi-fluorinated alkanes (SFA) and using emulsion 
hereof for intravenous application. The advantage of SFA emulsions is not only that they can be 
used as drug delivery system, but that they can also be used as oxygen carriers or carriers for 
carbon monoxide. Therefore SFA emulsions might represent a new technological platform, which 
has a potential use in donor management for systemic delivery of protective compounds to organ 
allografts. In addition, SFA emulsions might be used for other technologies of organ 
preservation, i.e. hypo- or normothermic machine perfusion, to deliver oxygen to the allograft.  
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